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Background. Maternal thyroid hormone supply is crucial for fetal neurodevelopment, 
particularly during the first 20 weeks of gestation when the fetus cannot synthesize sufficient 
levels of thyroid hormones. Previous studies of maternal thyroid function and child ADHD or 
executive function have yielded inconsistent results. A number of factors that may modify the 
association between maternal thyroid function and fetal neurodevelopment have been 
understudied. First, variants in deiodinase-encoding genes may impact the nature of the 
association between maternal thyroid function and ADHD because they may alter thyroid 
hormone concentrations in the placenta or in the fetal cerebral cortex. Second, maternal dietary 
and selenium intake are crucial for both thyroid hormone synthesis and conversion. Third, fetal 
sex may impact maternal thyroid function and fetal deiodinase activity.  
Methods. We estimated the association of maternal thyroid function biomarkers at 17 
weeks’ gestation with preschool ADHD and with measures of preschool executive function at 3.5 
years. We also assessed effect measure modification by three sets of variables: (1) maternal SNPs 
in deiodinase-encoding genes DIO1 and DIO2 (rs2235544 and rs225014) and one child SNP in 
DIO2 (rs225014), (2) maternal iodine and selenium intake, and (3) child sex. We used a nested 
sub-study of preschool ADHD within the Norwegian Mother and Child Cohort (MoBa) (for the 
ADHD outcome: N=260 ADHD cases + N=549 representative controls; for the executive 
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function outcomes: N=342). 
Results. A one-standard deviation increase in maternal free thyroxine index (fT4i) was 
associated with a 0.10 standard deviation unit increase in parent-rated inhibition (95%CI: 0.01, 
0.19), a 0.13 standard deviation unit increase in teacher-rated inhibition (95%CI: 0.01, 0.24), 
and a 0.13 standard deviation unit increase in parent-rated working memory (95%CI: 0.04, 
0.22). We did not detect any main effects of maternal thyroid function on preschool ADHD. Nor 
did we detect any clear patterns of effect measure modification by maternal or child deiodinase-
encoding gene variants, maternal nutrient intake, or child sex.   
Conclusions. Maternal thyroxine may be uniquely important for fetal 
neurodevelopment. Although we did not detect a modifying effect of SNPs in deiodinase-
encoding genes, more research is warranted given the biological importance of deiodinases in 
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CHAPTER 1. INTRODUCTION AND SPECIFIC AIMS 
1.1 Attention Deficit Hyperactivity Disorder (ADHD) 
Attention Deficit Hyperactivity Disorder (ADHD) is the most commonly diagnosed 
childhood neurodevelopmental disorder, affecting approximately 136 million children and 
adolescents worldwide (prevalence: 5.6%).1,2 The symptoms of ADHD may present during the 
preschool period, and may act as early indicators of the disorder. However, few studies have 
investigated preschool ADHD symptoms. ADHD is characterized by inattention, hyperactivity, 
and impulsivity,3 and is associated with significant distress and pervasive social and academic 
impairment.4 Although often perceived as a childhood disorder, ADHD can persist into 
adulthood when it is associated with higher risks for incarceration, employment difficulties, and 
substance use disorders.5–7 At the societal level, ADHD creates a significant financial burden. In 
2014, the estimated lifetime ADHD-related total costs per individual was approximately 13,000 
to 19,000 US dollars.8 The significant personal and societal impact of this disorder underscores 
the importance of understanding its risk factors and etiology, with the goal of eventually 
developing effective preventative measures. 
ADHD Risk Factors. The etiology of ADHD is poorly understood, though evidence 
suggests that it is a heterogenous disorder that can result from varied combinations of genetic 
and environmental factors.9 Risk factors for ADHD include smoking and alcohol consumption 
during pregnancy, prenatal ADHD, paracetamol (acetaminophen) use during pregnancy, young 
maternal age, maternal depression and anxiety, high maternal BMI, and child male, among 
others (Table 1, below). Evidence for the aforementioned risk factors varies, and it is unclear 
whether each risk factor causally contributes to the etiology of ADHD. The heritability estimates 
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of ADHD are high (70-90%),10,11 indicating a strong genetic contribution. Nonetheless, 
substantial variation in the disorder may be attributable to nongenetic (environmental) risk 
factors and their interplay with genetic risk factors.12 Characterizing causal pathways to ADHD 
is crucial because some pathways, in theory, may be preventable. The aim of this dissertation 
was to investigate one hypothesized nongenetic pathway to ADHD: the influence of maternal 
thyroid hormones during gestation on fetal brain development.  
 
Table 1. Risk factors for Attention-Deficit Hyperactivity Disorder  
Established risk 
factors 
Prenatal • Maternal smoking during pregnancy
13–15  
• Severe maternal psychosocial stress or depression13,16  
Genetic / Social  • Male sex
13–15  






• Multiple pregnancy complications16  
• Maternal thyroid dysfunction18,19 
• Prenatal exposure to alcohol20 
• Maternal illicit drug use during pregnancy13 
Genetic • Variants in genes regulating dopamine and serotonin 
function21,22 
Sociodemographic 
• Low maternal and paternal education14 
• Low income13 
Birth outcome • Preterm birth
23 
• Low birth weight24 
Developmental / 
Environmental 
• Poor quality/quantity of stimulation and support in child’s 
home environment13 
• Child diet25 
 
Stability of ADHD. Current diagnostic guidelines for ADHD recommend assessing the 
disorder between 4-18 years of age.2 This recommendation is partly due to the fact that before 
the age of 4, it is challenging to assess children’s behavior in multiple settings such as at home 
and at school (a key aspect of the ADHD diagnosis). A possible side-effect of this 
recommendation, however, is that the preschool ADHD phenotype has been understudied. 
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There are both clinical and etiologic motivations for investigating ADHD in preschool. Clinically, 
earlier interventions for ADHD have been efficacious,26–28 and may reduce later symptom load 
and resulting impairments. Although the DSM guidelines are better suited for children who have 
begun school, rating scales for preschool ADHD have been validated.29 Etiologically, the extent 
to which preschool ADHD and later childhood ADHD share common causes is unclear. 
Investigating the pathways contributing to both preschool and later ADHD might help uncover 
both shared and unique causes.   
The prevalence of ADHD generally declines with age; however, the pattern of decline 
differs across symptoms. Specifically, hyperactivity and impulsivity show somewhat rapid drops 
in symptom severity with age, whereas symptoms of inattention persist—or decline more 
gradually—with age.30 In a longitudinal study of ADHD diagnosis from preschool into 
childhood, Lahey and colleagues found that although the ADHD diagnosis proportion declined, 
most children who were diagnosed with ADHD in preschool continued to have this diagnosis 
into childhood.31 However, among those who retained their diagnosis of ADHD, there was much 
variability in the specific subtype (predominantly inattentive, predominantly 
impulsive/hyperactive, and combined) as the children aged. In addition to symptom domain, 
child age and the method of assessing ADHD both affect the stability of ADHD. For example, 
there was a stronger association between ADHD symptoms at 4-6.11 years and 5-7.11 years than 
between ADHD symptoms at 3-5.11 years and 4-6.11 years, suggesting that ADHD diagnoses 
have higher stability at older ages.32 With respect to measurement systems, a DSM-IV diagnostic 
interview combined with maternal ratings of child behaviors better predicts later ADHD than 
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1.2 Executive Function 
Executive function refers to a set of cognitive capacities that enable goal-directed and 
self-regulatory behavior.35 Processes that make up executive function include planning, 
attentional flexibility, impulse control, and working memory.36,37 Impulse control (i.e. 
inhibition) refers to the ability to override a prepotent response with a more appropriate one.35 
Working memory is defined as the ability to hold and manipulate information in mind when it is 
no longer perceptually available.36,37 Impairments in executive function have been associated 
with an increased risk of addiction, conduct disorder, difficulties maintaining employment, and 
poor physical health (e.g. overeating and obesity).38–41 
Developmental timeline and stability of executive function. The processes of 
executive function undergo substantial development during the preschool years,36,42 and the 
development of executive function continues into early adulthood (Figure 1). The developmental 
trajectories of executive function processes are heterogeneous (Figure 1). Simple working 
memory (holding representations in mind in the absence of stimuli) emerges earlier than 
response inhibition.43 Whereas working memory shows a more linear development—with 
gradual ameliorations with age—inhibition demonstrates a sudden increased capacity during the 
preschool years.43 The neural underpinnings of executive function processes also follow 
somewhat distinct developmental changes.43,44 Despite the fact that executive function continues 
to develop into adulthood—and the fact that the separate processes develop at different rates—
individual differences in executive function are fairly stable across the lifespan.45,46  
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Figure 1. “Development of skills underlying executive components. Darker 
areas reflect periods of increased growth. SHIFT = shifting; ATT = attention; 
R = response set; RI = response inhibition; WM = working memory.” 
Reprinted from Psychological Bulletin, Volume 134(1), “Executive function 
in preschoolers: A review using an integrative framework”, by Garon and 
colleagues (2008);43 permission from the American Psychological 
Association is not required for the reproduction of a maximum of three 
figures or tables from a journal article or book chapter. 
 
 
Predictors of Executive Function. Research on predictors of executive function has 
largely focused on the home environment: child executive function has been associated with 
parenting behaviors, early-life poverty, marital status, and parental psychological distress.47–51 
Additional maternal predictors of executive function include smoking during pregnancy, anxiety 
during pregnancy, and maternal executive function.52–54 Child predictors of executive function 
include birth weight, preterm birth, language abilities and temperament.51,55,56 Neural predictors 
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of executive function include frontal brain activity as measured by EEG50 and white matter 
abnormalities.56 Maternal thyroid function, which affects fetal neurodevelopment may also 
predict executive function, though findings have been mixed.57–59 Finally, twin studies suggest 
that executive function is among the most heritable psychological traits; however, high 
heritability does not negate the effect of the environment at the individual level.12  
 
1.3 Executive Function and ADHD  
Impaired executive function processes is a key feature of ADHD.60 Indeed, a meta-
analysis of 83 studies found that children and adolescents with ADHD had significantly 
impaired executive function relative to those without ADHD.61 Furthermore, training meant to 
improve working memory (a component of executive function) has been associated with reduced 
ADHD symptoms.62 Just as executive function is comprised of a set of heterogeneous processes 
with divergent developmental trajectories, so too is ADHD.63 For example, ADHD symptoms of 
hyperactivity and impulsivity decrease in severity with age, whereas ADHD symptoms of 
inattention are more persistent with age.30 That being said, evidence suggests that deficits in 
executive function do not fully account for the etiology of ADHD, and the executive function 
deficits that can be a part of ADHD vary greatly across children.61 This is all to say that, although 
ADHD and executive function measures may be related, they are far from redundant.  
 
1.4 Etiology of ADHD and Causal Pathways Contributing to Executive 
Function 
ADHD is a heterogeneous disorder that likely arises via multiple etiologic pathways.64 
Similarly, multiple and varied underlying mechanisms likely contribute to the development and 
ongoing support of executive function processes. The nature of these etiologic paths and 
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underlying mechanisms, however, is poorly understood.  
One proposed mechanism—which is the focus of this dissertation—is that disrupted 
neurodevelopment during early gestation contributes to ADHD and to impaired executive 
function. Indeed, those with ADHD are more likely to have neurodevelopmental anomalies, 
including smaller brain volumes and protracted brain development trajectories,65 suggesting 
that insults to brain development may at least in part underlie symptoms. Executive function 
has been associated with frontal brain activity as measured by EEG,50 and impairments of 
executive function has been associated with white matter abnormalities.56 Although the neural 
underpinnings of ADHD and of executive function are still unclear, these findings imply that 
early-emerging neural structures and functions may be important.  
Early gestation, in particular the first half of gestation (during which neurons begin to 
proliferate, migrate, become myelinated, and form synapses), is a sensitive window for 
neurodevelopment. Insults during this time can have lasting effects. Thyroid hormones, which I 
discuss in more detail in section 1.5, regulate the expression of genes that influence neural 
migration, differentiation, myelination, and synaptogenesis.66,67 An excess or a dearth of thyroid 
hormones during the prenatal period can thus have important effects on neurodevelopment, 
discussed further in section 2.1.  
 
1.5 Thyroid function mechanisms 
Thyroid hormone synthesis and conversion in euthyroid individuals. The 
pituitary gland releases thyroid stimulating hormone (TSH) into the bloodstream, through 
which it travels to the thyroid gland and binds to TSH receptors (Figure 2). The binding of TSH 
to its receptor prompts the synthesis of thyroid hormones triiodothyronine (T3) and thyroxine 
(T4) (Figure 2). The synthesis of these thyroid hormones may be inhibited by the presence of 
thyroid peroxidase antibodies (TPOAb) (Figure 3). Synthesized thyroid hormones are released 
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into the bloodstream. Most (~99%) of the circulating thyroid hormones are ‘bound’—that is, 
bound to binding proteins like thyroxin-binding globulin.68 The remaining thyroid hormones 
are referred to as free T3 (fT3) and free T4 (fT4). These thyroid hormones travel throughout the 
body in the bloodstream, affecting the development and function of many tissues and systems, 
including the brain. Of T3 and T4, T3 is the biologically more active thyroid hormone. TSH, T4, 
and T3 constitute a negative feedback loop whereby higher levels of T4 and T3 suppress TSH 
activity (Figure 3).  
Circulating T3 and T4 can be taken up by cells, wherein they are converted to other 
thyroid hormones by deiodinases (Figures 2, 3). Specifically, T4 is converted within cells to the 
biologically active T3 by deiodinases types 1 and 2 (D1, D2, referred to as ‘activating 
deiodinases’). T4 and T3 may also be ‘deactivated’ (I.e. converted to rT3 or T2, respectively) by 
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Figure 2. Overview of thyroid hormone action. TSH, thyroid 
stimulating hormone; T4, thyroxine; T3, triiodothyronine; D1/D2, 
deiodinases types 1 and 2. 
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Figure 3. Negative feedback loops regulating the synthesis of 
thyroid hormones.   
 
Thyroid function during pregnancy. Upon implantation, the conceptus releases 
human chorionic gonadotropin (hCG), which is structurally similar to TSH.69 Human chorionic 
gonadotropin binds to TSH receptors on the pituitary gland, leading to increased levels of T3 
and T4, and decreased levels of TSH, particularly during the first trimester.69 As a result, 
maternal T4 production increases by approximately 50% relative to the general population.69 
Because of changes in thyroid hormone levels during pregnancy, reference ranges for classifying 
thyroid hormone disorders are not as clear, though several large studies have computed 
gestation time-specific reference ranges.70–73 Table 2 describes the reference-ranges among non-
pregnant adults as well as trimester-specific reference ranges for a number of thyroid function 
biomarkers.  
Thyroid function is typically tested by measuring TSH and/or fT4 immunoassay on 
serum samples, and thyroid disorders are classified according to each biomarker’s reference 
range (Tables 2, 3). However, immunoassay of unbound thyroid hormones (e.g. fT4) during 
pregnancy may yield inaccurate measures due to a number of pregnancy-related changes: 
elevated thyroxine binding globulin concentrations, increased total thyroid hormone levels, 
lower levels of albumin in the blood, and interference from circulating hCG.74–76 The gold 
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standard measure of free thyroid hormones, which uses equilibrium dialysis as the first step, can 
most accurately detect pregnancy-related changes in free thyroid hormone levels.77 However, 
this gold standard measure of free thyroid hormones is costly.75 An alternative validated method 
is to compute indices of fT3 and fT4 using TT3, TT4, and T3 uptake.76 
 
 























1.2 – 2.9 1.25 – 2.72 1.43 – 3.16 1.40 – 3.16 
Serum fT4 Isotopic 
Equilbrium Dialysisc 
(pmol/L) 
13 – 39 10.53 – 18.28 9.53 – 15.68 8.63 – 13.61 
Serum fT3 Isotopic 
Equilbrium Dialysisc 
(pmol/L) 





Unclear if reference range is different among pregnant 
women; more research is needed. 
a Depends on population and laboratory, but approximate values are listed here.  
b Radioimmunoassay, chemiluminometric assay, or another immunoassay.  
c Gold standard measure of free thyroid hormones, not frequently used due to cost and availability.  
d Based on multiple other papers.  
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Table 3. Prevalence of thyroid disorders during pregnancy   
Thyroid Disorder Description 
Prevalence Among  
Pregnant Women 
Overt Hypothyroidism Elevated TSH and suppressed fT4 0.5% 80,81 
Subclinical Hypothyroidism Elevated TSH with normal fT4 2.0-3.0% 80,81 
Hypothyroxinemia Normal TSH and low fT4 1.3% 82 
Hyperthyroidism Suppressed TSH and elevated fT4 and/or fT3 0.1-0.4% 80,81 
 
Maternal-fetal thyroid hormone transference. During early prenatal 
development, the fetus cannot synthesize its own thyroid hormones.83 Until approximately the 
20th week of gestation, the fetus must rely on the mother’s thyroid hormone supply, which can 
cross to the fetus (Figure 4).84 Of T3 and T4, mostly maternal T4 crosses to the fetus.85 In the 
fetus, maternally-supplied T4 can be converted to T3 by fetal deiodinase type 2, which is active 
in the fetal cerebral cortex as early as 7 weeks’ gestation.86 In addition to deiodinase type 2, 
deiodinase type 3 (the ‘deactivating’ deiodinase) is reliably detected in fetal tissues.86,87  
Prenatal neural development and maternal thyroid hormones. In the fetal 
cerebral cortex, T3 (converted from maternally-supplied T4) can bind to receptors in the nuclei 
of cells to affect the expression of genes that regulate neurodevelopmental processes, including 
neural proliferation, migration, synaptogenesis, myelination, and dendrification (Figure 4).88,89 
The first 20 weeks of gestation is an important window for fetal neurodevelopment because 
most neural migration and proliferation takes place during this period (Figure 4).90 At 5 weeks’ 
gestation, synapses begin to form, continuing into term.89 Thus, during the first half of 
gestation, sufficient levels of maternal thyroid hormones are crucial for healthy fetal 
neurodevelopment. Section 2.1 discusses more evidence for the association between maternal 
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Figure 4. “Relationship between thyroid hormone action and development 
of the brain. In the first trimester of pregnancy early neuronal proliferation 
and migration is dependent on maternal thyroxine (T4). In foetal tissues, 
inactivating type 3 deiodinase (D3) enzyme expression falls and 
development of the thyroid gland commences. By the end of the first 
trimester, development of the hypothalamic-pituitary axis has occurred and 
a surge in thyroid-stimulating hormone (TSH) secretion results in the onset 
of foetal thyroid hormone production, expression of the activating type 2 
iodothyronine deiodinase enzyme (D2) and increasing occupation of 
thyroid hormone receptors (TRs) by 3,5,3¢-L-triiodothyronine (T3). 
Continuing development of the brain in the second and third trimesters 
relies increasingly on T4 produced by both the foetus and mother. 
Continued post-natal development is entirely dependent on neonatal 
thyroid hormone production. Apo-TR, unliganded unoccupied thyroid 
hormone receptor.” Reprinted from the Journal of Neuroendocrinology, 
Volume 20(6), “Neurodevelopmental and Neurophysiological Actions of 
Thyroid Hormone”, by Williams and colleagues (2008),89 reprinted under 
the terms of the Creative Common Attribution License (CC BY).  
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1.6 Factors Modifying the Biological Impact of Maternal Thyroid Function 
Maternal and fetal deiodinases. Deiodinase type 1 (located in cell plasma 
membranes) and deiodinase type 2 (located in the endoplasmic reticulum of cells) both mainly 
convert T4 to the more biologically active thyroid hormone T3. Deiodinase type 1 is expressed in 
the liver, kidney, gut, lungs, thyroid, pituitary,78,91 and possibly the placenta.88 There is minimal 
evidence that deiodinase type 1 is expressed in the fetus sufficiently early in gestation to 
influence the effect of maternal thyroid function on fetal neurodevelopment. Deiodinase type 2 
is expressed in the pituitary, brain, brown adipose tissue, adrenal, liver, thyroid, heart, skeletal 
muscle,78,91 as well as in maternal uterine decidual cells92 and in the fetal cerebral cortex.86,87 
Deiodinases modify the local intracellular levels of thyroid hormones, affecting the 
concentration of T3 that is available to influence gene expression within cells.83,93,94 In this way, 
deiodinases modify the association between circulating levels of thyroid hormones and their 
biological impact: intracellular T3 availability can vary somewhat independently from T3 levels 
circulating in the bloodstream. That being said, T3 produced by deiodinases can be released 
back into circulation.93 In fact, the main source of circulating T3 comes from local conversion of 
T4 to T3 by deiodinases, and not synthesis in the thyroid hormone gland.94 
Therefore, deiodinase activity in the maternal liver, for example, would not be expected 
to modify the association between circulating maternal thyroid function biomarkers and fetal 
neurodevelopment because deiodinases in the liver would directly affect maternal circulating 
thyroid function biomarkers. In other words, maternal thyroid function biomarker levels would 
be an intermediate variable on the path from maternal deiodinase activity and fetal 
neurodevelopment. However, maternal deiodinases in the placenta—which consists of both 
maternal and fetal cells and is a place of maternal-fetal transfer—could possibly alter the supply 
of maternal thyroid hormones that reach the fetus, independent of circulating maternal levels. 
Maternal deiodinase type 2 is expressed in maternal uterine decidual cells, which form the 
maternal portion of the placenta.92 The presence of deiodinase type 1 in the placenta is 
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debated.95 
Deiodinase type 2 and deiodinase type 3 (the deactivating deiodinase) are expressed in 
the fetus, with deiodinase type 2 expression occurring in the fetal cerebral cortex as early as 7 
weeks’ gestation.86,87 Mostly maternal T4 is transferred to the fetus, where it can be converted to 
the more biologically active T3 by fetal deiodinase type 2.85 Thus, fetal deiodinase type 2 may 
modify the association between circulating maternal thyroid function biomarkers and fetal 
neurodevelopment.  
Maternal Iodine and Selenium Intake. Nutritional elements iodine and selenium 
influence the synthesis of thyroid hormones in the thyroid gland as well as the conversion of 
thyroid hormones by deiodinases. Iodine can be found in small amounts in natural sources such 
as seafood, water, and some vegetables, whereas selenium can be found in fish, eggs, meat, 
mushroom, and cereals.96 The selenium level in crops is partly dependent on soil content, which 
varies geographically and seasonally.97 
Iodine deficiency is the most common preventable cause of neurocognitive deficits 
worldwide.98 To combat the adverse outcomes associated with iodine deficiency, many countries 
(including Norway) fortify table salt.99 Yet, even in countries with universal salt iodization, 
iodine insufficiency persists, and iodine deficiency remains the most common cause of 
endocrine disorders.100 Women who are pregnant are at a higher risk of iodine deficiency for 
three main reasons.69 First, there is an increased synthesis of T3 and T4 during pregnancy 
(particularly during the first trimester), and iodine is required for this synthesis. Second, the 
renal clearance of iodine is greater in pregnant women compared to those who are not pregnant. 
Third, some of the maternal iodine supply is transferred to the fetus.69 Because of these reasons, 
pregnant women require approximately 50% more iodine than those who are not pregnant.69  
Iodine deficiency alters thyroid hormone synthesis and conversion. When iodine levels 
are insufficient, the thyroid gland synthesizes relatively more T3 and less T4, leading to 
hypothyroidism.101 Furthermore, in iodine deficient states, the expression of deiodinase type 2 is 
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up-regulated (and deiodinase type 3 is downregulated) in the central nervous sytem.102 This 
altered regulation would have the effect of converting more T4 to the more biologically active 
T3.  
Selenium is a constituent of deiodinase enzymes, making it essential for the local 
conversion of thyroid hormones.98 Like iodine, selenium requirements increase during 
pregnancy, with 60 µg/day intake recommended for women who are pregnant.103 Selenium 
supplementation is associated with reduced thyroid peroxidase antibodies, allowing for more 
thyroid hormone synthesis.104–106 Selenium supplementation is also associated with increased 
deiodinase activity leading to higher levels of T3,107 while selenium deficiency is associated with 
increased T4 and decreased T3 levels. Whereas iodine deficiency has been recognized as an 
important preventable threat to fetal and child development, selenium deficiency is relatively 
understudied.  
Fetal/Child Sex. There are a number of mechanisms that might lead to sex-related 
differences in maternal thyroid function’s effect on neurodevelopment. First, as early as 3 weeks 
post-fertilization, maternal serum human chorionic gonadotropin (hCG) levels are higher in 
pregnant women carrying female than male fetuses.108 Because hCG is structurally similar to 
TSH and thus also stimulates thyroid hormone synthesis, the sexually dimorphic levels of hCG 
may differentially alter the balance of maternal TSH, T4, and T3 by fetal sex. Second, animal 
research has demonstrated that sex hormones can affect deiodinase activity.109 Different 
deiodinase activity in male versus female fetuses could lead to different local T3 availability to 
male versus female fetuses, modifying the association between maternal thyroid function and 
fetal neurodevelopment. 
Attention deficit disorder is more commonly diagnosed in male children, and the most 
frequently subtype of ADHD diagnosis varies by sex: male children are more likely to be 
diagnosed with the hyperactive/inattentive subtype whereas female children are more likely to 
be diagnosed with the inattention subtype.13–15 Part of this this sex difference may be due to 
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cultural norms and expectations regarding the behavior of male and female children. However, 
part of this difference may also reflect biological mechanisms such as the interaction of hCG, sex 




Specific Aims. To contribute to the growing body of research probing the etiologic role 
of maternal thyroid hormones in the development of ADHD, this dissertation had two 
overarching aims:  
Aim 1. Estimate the association between maternal thyroid function biomarkers at 17 
weeks’ gestation and clinically diagnosed ADHD at 3.5 years.  
Aim 2. Estimate the association between maternal thyroid function biomarkers at 17 
weeks’ gestation and measures of executive function at 3.5 years. 
 
To further characterize the nature of the associations described in Aims 1 and 2, this 
dissertation had the following effect-measure modification sub-aims:  
Sub-aims 1a & 2a. Assess whether maternal dietary intake of iodine and selenium are 
effect measure modifiers of the associations described in Aims 1 and 2.  
Sub-aims 1b & 2b. Assess whether maternal and child genotypes on select SNPs related 
to thyroid hormone synthesis and conversion are effect measure modifiers of the associations 
described in Aims 1 and 2.  
Sub-aims 1c & 2c. Assess whether child sex is an effect-measure modifier of the 
associations described in Aims 1 and 2.  
 





CHAPTER 2. CRITICAL LITERATURE REVIEW 
2.1 Evidence for the effect of thyroid hormones on neurodevelopment  
In a recent systematic review, Moog and colleagues (2017) reviewed both human and 
animal literature to explore the effect of maternal thyroid hormones on neurodevelopment from 
a functional (cognitive) and morphological perspective.68 Based on animal research–which 
permits more experimental control as well as direct observation of brain development–Moog 
and colleagues concluded that thyroid hormone levels have widespread effects on neural 
proliferation, neural migration, neural differentiation, myelination, and synaptogenesis.68 
Although the ability to directly assess brain development and structure in human participants is 
ethically limited, the authors also concluded that human maternal thyroid function is associated 
with child neurodevelopment (based on cognitive and psychomotor assessments, as well as 
clinical diagnoses of disorders like Autism Spectrum Disorder and ADHD).68  
Thyroid hormones exert their effect on neurodevelopment via the regulation of relevant 
genes. For example, T3 regulates the expression of reelin during brain development, which is a 
glycoprotein that is important for neural migration.110 Similarly, developmental hypothyroidism 
is associated with decreased expression of two neurotrophic factors that regulate neural 
differentiation: Brain-Derived Neurotrophic Factor (BDNF) and Neurotrophic Factor-3 (NT-
3).111 Morphologically, hypothyroidism is associated with poorer developed dendrites (less 
arborization and fewer synapses).68 
Based on their review, Moog and colleagues noted that the adverse effects of aberrant 
maternal thyroid hormones are greater during early pregnancy compared to later pregnancy,68,85 
which is consistent with the fact that the fetus is unable to synthesize its own thyroid hormones 
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until approximately mid-gestation. Their systematic review suggested that even mild disruptions 
in maternal thyroid hormones can have significant effects on prenatal brain development.68 
These results imply that the first half of gestation is an important window for healthy maternal 
thyroid function, and that even small (e.g., sub-clinical) variation in thyroid hormones may 
affect prenatal neurodevelopment. 
2.2 Evidence for the association between maternal thyroid function and 
ADHD and executive function  
Along with collaborators (Gro D. Villanger, Heidi Aase, Thea S. Skogheim, Matthew P. 
Longnecker, R. Thomas Zoeller, Ted Reichborn-Kjennerud, Gun P. Knudsen, Pål Zeiner, and 
Stephanie M. Engel), I have written a systematic review of studies investigating the association 
between maternal or neonatal thyroid function and ADHD or related behaviors (which includes 
some executive function outcomes).57 We reviewed a number of databases (Embase, Pubmed, 
Cinahl, PsycInfo, ERIC, Medline, Scopus, and Web of Science) for English language articles 
published or available online ahead of print as of April 2018. We combined search terms for 
maternal or child thyroid hormones and related clinical conditions with search terms for ADHD 
and related outcomes. In the original search, we identified 730 non-duplicated articles to review, 
669 of which were excluded after title/abstract review. After full-text review of the remaining 61, 
38 additional articles were excluded, leaving 23 eligible studies. After two updates, 5 additional 
studies were added, for a total of 28 eligible studies. Of the 28 studies reviewed, 16 dealt 
specifically with maternal thyroid function and ADHD or related outcomes in their children. 
Overall, the 16 studies suggest an association between maternal thyroid function and ADHD and 
related behaviors; however, there are a number of limitations in the extant literature, which are 
discussed below. The results of the systematic review are summarized in Tables 4-6.  
First, few studies estimated the effect of a given thyroid dysfunction or biomarker. The 
most commonly studied maternal thyroid dysfunction was hypothyroxinemia: 6 studies 
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reported estimates of association between maternal hypothyroxinemia and ADHD or related 
outcomes. However, each of these 6 studies used a different outcome measure, including ADHD 
prescription, ADHD diagnosis, and different parent- or teacher-completed inventories (Tables 4, 
5). Nonetheless, we conducted a meta-analysis of 4 of the 6 studies (two were excluded due to 
insufficient information), and found that across the 4 studies, maternal hypothyroxinemia was 
associated with increased odds of ADHD or related symptoms (OR=1.54, 95%CI: 1.02, 20.33). 
No other maternal thyroid classifications included a sufficient number of similar estimates to 
analyze. 
Like maternal hypothyroxinemia, there was some evidence of an association between 
maternal hypothyroidism and ADHD and related outcomes: three of five studies reported that 
the disorder was associated with inattention, distractibility, impaired working memory, or 
ADHD prescriptions (Table 5). Even fewer studies estimated the effects of other maternal 
thyroid dysfunctions, including hyperthyroidism, making it not possible to draw conclusions 
across the studies.  
Evidence of an association between maternal thyroid function biomarkers and ADHD or 
related symptoms was either mixed or minimal. Thyroid stimulating hormone (TSH) was the 
most commonly studied biomarker, but all five studies reported different effects of TSH (though 
all effects were relatively small or null). No studies investigated the association between 
maternal TT3 or fT3 and ADHD or related outcomes. In summary, given the large number of 
maternal thyroid exposure by child outcome combinations in the extant literature, it is difficult 
to draw conclusions about the association between maternal thyroid function and child ADHD 
or related symptoms. 
Second, all but one of the reviewed studies of maternal hypothyroxinemia (and of 
maternal fT4) used immunoassay to assess fT4. Recent studies have demonstrated that 
immunoassay is not as accurate a measure of fT4 during pregnancy, in part because of 
interference from circulating human chorionic gonadotropin.74,75 The gold standard method, 
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which involves equilibrium dialysis as the first step, better detects pregnancy-related changes in 
fT4, but is costly.75 The fT4 index, based on T3-uptake and TT4, is a more accurate alternative 
than immunoassay fT4 (see section 4.5 for more description).76 
Third, only half (8 of 16) of the reviewed studies adjusted for maternal smoking. Based 
on the literature, maternal smoking is both a well-established risk factor for ADHD and is 
consistently associated with thyroid hormone function,13–15,112 and thus should be at least 
considered as a potential confounder in analyses. Although recent evidence has demonstrated 
that smoking is not a direct confounder in this context,77 it is nonetheless on an important 
confounding path between maternal thyroid function and ADHD.  
Fourth, only two studies investigated ADHD-related outcomes in preschool, both of 
which found that maternal thyroid hormone biomarkers (specifically, TPOAb and TSH) were 
significantly associated with offspring ADHD outcomes.113,114 Most studies investigated ADHD-
related outcomes in childhood, which is consistent with the current recommendation that 
ADHD be diagnosed between 4 and 18 years.2 The phenotype of early ADHD has been 
understudied, and as a result, children younger than 4 with ADHD may go undiagnosed. It is 
important for more research to focus on the preschool ADHD phenotype, both from an etiologic 
standpoint (it is unclear whether preschool and later ADHD reflect the same underlying 
disorder) and from an intervention standpoint (earlier interventions might be more effective 
than later inventions for reducing symptom severity). 
Fifth, despite the importance of iodine intake for thyroid synthesis and function and for 
brain development, only one study in this systematic review evaluated the role of iodine in 
thyroid function (and no studies investigated the role of selenium). Vermiglio and colleagues 
assessed children born to mothers from moderately iodine deficient versus sufficient regions, 
and found that ADHD was more common in the moderately iodine deficient region.115 However, 
this study included only 27 participants. Two other studies did assess iodine, but did not 
evaluate the interaction of iodine and thyroid hormones.116 
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Sixth, only 3 of the 16 studies presented separate estimates for male and female children. 
However, not only does ADHD present different in boys than in girls, trajectories of brain 
development and executive function development differ by sex, and fetal sex may also influence 
maternal thyroid function (see sections 1.6 and 2.3 for more details). 
Finally, none of the 16 studies investigated how deiodinase-encoding genes might affect 
the association between maternal thyroid function and child neurodevelopment. However, 
deiodinases may alter availability of thyroid hormones to the fetus, which could in turn impact 
neurodevelopment (see sections 1.6 and 2.3 for more details).  
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Table 4. Studies of maternal thyroid hormones or dysfunction and offspring ADHD or related behaviors 
(pre-publication version of tables in Drover and colleagues57) 
First Author, Year 
Country 
Study Design (Sample 
Size) 








Case-cohort (Ncases = 
1143, Ncontrols = 7624)  
TSH and fT4 measured using 
automated immunoassay (median of 9 
weeks’ gestation, range 5-19 weeks) 
2+ filled prescriptions for 
ADHD medication based on 
National Registers (median 
age of 8.4 yrs)  
5, 8, 10, 12, 15, 





(Ntotal = 857014) 
Maternal hyperthyroidism or 
hypothyroidism based on hospital 
diagnosis or prescription (diagnosed 
before or after birth)  
ICD-10 diagnosis of ADHD, 
dispensed prescription of 
ADHD medication (3-18 yrs)  
2, 8, 9, 10, 11, 
12, 26, 45, 46 
Chevrier, 2011119 
USA 
Prospective birth cohort 
(Ntotal = 287) 
TSH and TT4 measured using 
immunochemiluminometric assay; fT4 
measured by direct equilibrium dialysis 
then radioimmunoassay (26.9 ±3.4 
weeks gestation) 
McCarthy memory tests, Child 
Behavior Checklist completed 
by mothers, Conner’s Kiddie 
Continuous Performance Test 
(5 yrs) 
1, 3, 8, 10, 19, 
21, 23, 26, 35, 
36, 37, 38, 39, 
40, 41, 47 
Endendijk, 2017120 
The Netherlands 
Prospective birth cohort 
(Ntotal = 442) 
Serum TSH, fT4, and TPOAb 
measured by immunoassay (12, 24, 
and 36 weeks’ gestation) 
Child Behavior Checklist 
completed by mothers and 
fathers (23-60 mos) 
1, 5, 8, 12, 13, 
14, 15, 18, 22, 
27, 33, 32, 42, 




prospective cohort (Ntotal 
Maternal hypothyroxinemia based on 
immunoassay TSH (<18 weeks 
Child Behavior Checklist filled 
out by parents (6 yrs) 
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prospective cohort (Ntotal 
= 3139) 
Maternal TPOAb based on 
immunoassay (7.9 - 17.9 weeks 
gestation) 
Child Behavior Checklist filled 
out by parents (3 yrs) 







prospective cohort (Ntotal 
= 3736) 
Maternal TSH based on immunoassay 
(13.5±1.7 weeks gestation) 
Child Behavior Checklist filled 
out by parents (1.5, 3 yrs) 
1, 2, 5, 8, 13, 
14, 15, 16, 17, 
18, 19, 33, 42 
Haddow, 1999122 
USA 
Prospective cohort (Ntotal 
= 186) 
Maternal hypothyroidism based on 
TSH and fT4 immunoassay (second 
trimester gestation) 
Conners’ Continuous 
Performance Test, WISC-III 






control (Ncases = 47 944, 
Ncontrols = 2 274 713) 
Maternal hyperthyroidism or 
hypothyroidism based on medical 
registry diagnoses (Before or during 
pregnancy)  
ADHD medication prescription 
(3+ yrs)  





Cohort selected based 
on maternal thyroid 
hormone status (Ntotal = 
192) 
Maternal thyroid dysfunction based on 
serum TSH and TPOAb immunoassay 
(first trimester) 
WISC-III freedom from 












prospective cohort (Ntotal 
= 3873)  
Maternal hypothyroxinemia or 
subclinical hypothyroidism based on 
TSH and fT4 immunoassay (13.6 1.9 
weeks gestation) 
Conners’ Parent Rating Scale–
Revised Short Form (8 yrs) 
2, 5, 8, 11, 12, 
14, 15, 16, 18, 





prospective cohort (Ntotal 
= 2000) 
Maternal hypothyroxinemia based on 
TSH and fT4 immunoassay (Median: 
12.9 weeks gestation) 
Strengths and Difficulties 
Questionnaire (5.1 0.2 years) 
5, 14, 15, 18, 





prospective cohort (Ntotal 
= 4357 to 4370 
depending on analysis) 
Maternal thyroid dysfunction based on 
TSH, fT4, and TPOAb immunoassay 
(10.7 2.8 weeks gestation) 
The Strengths and 
Weaknesses of ADHD 
Symptoms and Normal 
Behavior filled out by parents 
(16 yrs)  





prospective cohort (Ntotal 
= 5131)  
Maternal hypothyroxinemia based on 
TSH and fT4 immunoassay, and TSH 
levels using immunoassay 
(10.7 2.8 weeks gestation) 
Rutter B2 Scale –Finnish 
version filled out by parents (8 
yrs) 




Cohort selected based 
on maternal thyroid 
hormone status (Ntotal = 
44) 
Maternal hypothyroidism based on 
medical records of diagnoses (during 
pregnancy) 
Behavioral Rating Inventory of 
Executive Function filled out 




Cohort selected based 
on geographic region 
(Ntotal = 27)  
Maternal hypothyroxinemia based on 
TSH and fT4 immunoassay (5-10, 11-
14, 18-20 weeks gestation) 
Clinical observation and 
diagnosis for ADHD, 
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IV-TR items (8-10 yrs) 
Key for adjustment set: 1 = gestational age at birth; 2 = child sex; 3 = SES indices; 4 = child intellectual disability; 5 = parental education; 6 = 
school term; 7 = evaluator psychologist; 8 = maternal age; 9 = maternal origin; 10 = maternal residence; 11 = maternal marital status; 12 = 
maternal parity; 13 = birth weight; 14 = ethnicity; 15 = maternal smoking; 16 = time of thyroid sampling during pregnancy; 17 = mode of birth 
delivery; 18 = maternal psychopathology; 19 = child apgar score; 20 = maternal weight/BMI; 21 = number of children in family; 22 = maternal 
breastfeeding; 23 = comorbid diagnoses; 24 = concomitant medication treatments; 25 = maternal bipolar subtype; 26 = income; 27 = alcohol use; 
28 = protein intake; 29 = prenatal corticosteroids; 30 = bilirubin; 31 = sepsis; 32 = congenital anomalies; 33 = maternal use of thyroid medications; 
34 = maternal hypertension; 35 = country of birth;  36 = diet quality index; 37 = home density and/or family structure; 38 = season of assessment; 
39 = delivery complications; 40 = maternal vocabulary; 41 = child hospitalization; 42 = child age at testing; 43 = maternal diabetes I; 44 = assisted 
reproductive technology (e.g. hormone stimulation); 45 = multiple births; 46 = year of birth/birthday; 47 = maternal language. 
Abbreviations: ADHD = Attention Deficit Hyperactivity Disorder, DSM = Diagnostic and Statistical Manual of Mental Disorders, fT4 = Free 
thyroxine, ICD = International Classification of Diseases, mos = months, TPOAb = Thyroid peroxidase antibodies, TSH = Thyroid stimulating 
hormone, WISC = Wechsler Intelligence Scale for Children, yrs = years.  
a The adjustment set includes variables that were statistically controlled for in analyses included in this review, or were assessed as potential 
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Table 5. Estimated associations between maternal thyroid disorders and offspring ADHD or related behaviors  
(pre-publication version of tables in Drover and colleagues57)  
Exposure Outcome (Time) Estimate 
Hypothyroxinemia    
 Andersen 2018117 ADHD prescription (8.4 yrs median) HRoverall = 1.46 (1.04, 2.06) 
  HRboys = 1.16 (0.76, 1.77) 
  HRgirls = 2.28 (1.21, 4.29) 
 Oostenbroek, 2017125 Teacher SDQ hyperactivity/inattention (5 yrs) ORft4<10th %tile = 1.47 (0.99, 2.20) 
  ORft4<5th %tile = 1.70 (1.01, 2.86) 
 Parent SDQ hyperactivity/inattention (5 yrs) ORft4<10th %tile = 0.85 (0.50, 1.46) 
  ORft4<5th %tile = 0.78 (0.36, 1.66) 
 Modesto 201519 CPRS ADHD symptoms (8 yrs) β = 0.07 (0.003, 0.14) 
 Vermiglio 2004115 DSM-IV ADHD diagnosis (8-10 yrs) χ2 = 2.34, p = .001 
 Ghassabian 2014121 CBCL ADHD symptoms (6 yrs) β = 0.12 (-0.04, 0.27), p = 0.14 
 Päkkilä 2014127 RB2 inattention & hyperactivity (8 yrs) ORboys = 0.61 (0.18, 2.03) 
 RB2 inattention & hyperactivity (8 yrs) No exposed girls with combined symptoms estimate 
Hypothyroidism   
 Andersen 2018117 ADHD prescription (8.4 yrs median) HR = 1.05 (0.77, 1.43) 
 Instanes 2016123 ADHD prescription (3+ yrs) OR = 1.2 (1, 1.4) 
 Samadi 2015128 BRIEF impaired working memory (9-14 yrs) MD = 6.84, p = 0.067a 
 Haddow 1999122 CPT distractibility (7-9 yrs) MD = -3, p = 0.08 
 CPT impaired sustained attention (7-9 yrs) OR = 3 (1, 5) 
Overt Hypothyroidism   
 Andersen 2018117 ADHD prescription (8.4 yrs median) HR = 0.98 (0.44, 2.20) 
Subclinical Hypothyroidism  
 Andersen 2018117 ADHD prescription (8.4 yrs median) HR = 1.06 (0.76, 1.48) 
 Modesto 201519 CPRS ADHD symptoms (8 yrs) β = -0.01 (-0.07, 0.05) 
Thyroid dysfunction   
 Komendova, 2018124 WISC-III freedom from distractibility (6-9 yrs) MD = 0.38 (-4.76, 5.52) 
 Päkkilä 2015126 SWAN ADHD symptoms (16 yrs) NS 
Hyperthyroidism   
 Andersen 2018117 ADHD prescription (8.4 yrs median) HR = 1.11 (0.79, 1.57) 
 Instanes 2016123 ADHD prescription (3+ years) OR = 1.2 (0.9, 1.5) 
 Andersen 2014118 ICD-10 ADHD prescription/diagnosis (3-18 yrs) NS based on figure 3 
Overt Hyperthyroidism    
 Andersen 2018117 ADHD prescription (8.4 yrs median) HR = 0.93 (0.53, 1.62) 
Subclinical Hyperthyroidism  
 Andersen 2018117 ADHD prescription (8.4 yrs median) HR = 1.24 (0.81, 1.90) 
Abbreviations: ADHD = Attention Deficit Hyperactivity Disorder, DSM = Diagnostic and Statistical 
Manual of Mental Disorders, BRIEF = Behavioral Rating Inventory of Executive Function, CPRS = 
Conner’s Parent Rating Scale – Revised, CPT = Conners Continuous Performance Test, mos = months, 
ICD = International Classification of Diseases, MD = Mean Difference, NR = Not Reported, NS = Not 
significant, RB2 = Rutter B2 Scale – Finnish Version, SDQ = Strengths and Difficulties Questionnaire, 
SWAN = Strengths and Weaknesses of ADHD Symptoms and Normal Behavior, WISC = Wechsler 
Intelligence Scale for Children, yrs = years, %tile = Percentile.  
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Table 6. Estimated associations between maternal thyroid hormone biomarkers and offspring ADHD 
or related behaviors (pre-publication version of tables in Drover and colleagues57) 
Exposure  Outcome (Time) Estimate 
Lower fT4   
 Oostenbroek 
2017125 
↑Teacher SDQ hyperactivity/inattention (5 
yrs) 
OR = 0.95 (0.85, 1.05) 
 Parent SDQ hyperactivity/inattention (5 
yrs) 
OR = 1.01 (0.90, 1.13) 
 Chevrier 
2011119 
↑ CBCL attention problems (5 yrs) β = -0.10 (-2.03, 1.82) 
 ↓ KCPT attention problems (5 yrs) β = 7.52 (-4.86, 19.91) 
Higher fT4   
 Andersen 
2018117 






CBCL attention deficit/hyperactivity (3 yrs) OR = 1.77 (1.15, 2.72) 
Higher TSH   
 Endendijk, 
2017120 
CBCL attention problems (23-60 mos) rboys(df=224) = 0.21, 
p<.01 
  rgirls NR, not significant 
 Oostenbroek 
2017125 
Teacher SDQ hyperactivity/inattention (5 
yrs) 
OR = 1.02 (0.96, 1.09) 
 Parent SDQ hyperactivity/inattention (5 
yrs) 
OR = 1.01 (0.92, 1.11) 
 Päkkilä 
2014127 
RB2 inattention & hyperactivity (5 years) ORboys = 1.17 (1.00, 
1.36) 
  ORgirls = 1.39 (1.07, 1.80) 
 Chevrier 
2011119 
↑ CBCL attention (5 yrs)  β = -0.65 (-1.26, -0.04) 
 ↑ KCPT attention (5 yrs) β = -0.75 (-4.61, 3.12) 
 Ghassabian 
2011113 
CBCL attention deficit/hyperactivity (1.5-3 
yrs) 
βSD of TSH = 0.08 (0.01, 
0.15) 
Higher TT4   
 Chevrier 
2011119 
CBCL attention problems (5 yrs) β = 0.00 (-0.27, 0.28) 
 ↑ KCPT attention problems (5 yrs) β = 0.09 (-1.70, 1.87) 
Abbreviations: ADHD = Attention Deficit Hyperactivity Disorder, CBCL = Child Behavior Checklist, 
mos = months, KCPT = Conners Kiddie Continuous Performance Test, RB2 = Rutter B2 Scale – 
Finnish Version, SDQ = Strengths and Difficulties Questionnaire, yrs = years 
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2.3 Evidence for potential modifying effects 
Evidence for the role of deiodinase-encoding genes in the maternal-fetal 
thyroid function. Deiodinase type 1 and deiodinase type 2 are encoded by the genes DIO1 and 
DIO2, respectively. Variants in these genes have been associated with fT4 levels and the fT3/fT4 
ratio in adults.129–133 Among adults, variants in these genes have also been associated with 
psychological well-being and heavy alcohol consumption.134,135 Among children, a SNP in DIO2 
(rs225014) was associated with intellectual disability in an iodine-deficient region.136 To date; 
however, no study has investigated whether these SNPs affect the association between maternal 
thyroid function and fetal neurodevelopment.  
Table 7 summarizes relevant literature on the association between a number of SNP 
variants in DIO1 (rs2235544) and DIO2 (rs225011, rs225012, and rs225014) and thyroid 
function or cognitive/behavioral outcomes. The A allele of SNP rs2235544 in DIO1 is associated 
with a less active deiodinase type 1, leading to less conversion of T4 to T3 and thus higher serum 
concentrations of fT4.131,132 Because deiodinase type 1 is particularly important in responding to 
hypothyroidism,137 I hypothesized that among children of mothers with the AA genotype of 
rs2235544, lower maternal thyroid hormone levels (characteristic of hypothyroidism) would be 
associated with worse executive function and a higher odds of ADHD. 
The C allele of rs225014 (DIO2) is associated with a less active deiodinase type 2, leading 
to less conversion of T4 to T3; however, this SNP has not been associated with fT3 or fT4 levels. 
This may be because deiodinase type 2 is located in the cell’s endoplasmic reticulum and thus 
takes longer to affect circulating thyroid hormone levels than deiodinase type 1, which is located 
in the cell’s plasma membrane.93 That being said, changes in conversion rate would nonetheless 
affect the intracellular availability of T3. Given that deiodinase type 2 in the fetal cerebral cortex 
provides most of the biologically active T3 to support fetal neurodevelopment, a slow conversion 
rate could negatively impact neurodevelopment. This negative impact would be exacerbated if 
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the mother additionally supplied a lower amount of T4 to convert. Thus, I predicted that in 
children with the C allele of rs225014 (DIO2), lower maternal T4 or fT4i would be associated 
with worse executive function or a higher odds of ADHD. My prediction for the role of maternal 
SNP rs225014 was similar, considering the potential importance of deiodinase type 2 in 
maternal placental cells. 
The SNPs rs225012 and rs225011 (DIO2) have been relatively less studied, however they 
are highly linked with rs225014 (Table 7).  
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• Associated with fT4 levels in a meta-analysis129,130,138 
o A allele associated with higher fT4 levels131  
• Associated with circulating ft3/ft4 ratio132,133 
o C allele is associated with a higher fT3/ft4 ratio, which suggests that this allele leads to 
more active D1 (converting t3 to t4)132,133 






• Not associated with serum thyroid parameters in one study139 
• Not associated with ft3/ft4 ratio in some studies133,140 
• TT genotype correlated with higher D2 activity141 
• Associated with heavy alcohol consumption, bipolar disorder, and psychological well-being on T4 
therapy134,135,142  







• Not associated with ft3/ft4 ratio133 







• Not associated with ft3/ft4 ratio133 
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Evidence for nutritional factors. The importance of iodine for neurodevelopment 
and cognitive function is underscored by the fact that iodine deficiency is the most common 
preventable cause of neurocognitive deficits worldwide,98 and iodine deficiency during 
pregnancy has been associated with cognitive impairments in offspring, including impairments 
in executive function.143–145 However, the role of mild to moderate iodine deficiency in 
neurodevelopment is less studied.143 Maternal iodine intake during pregnancy has been 
associated with maternal thyroid function. In a study of the Norwegian Mother and Child Cohort 
(MoBa), Abel and colleagues found that mild to moderate iodine deficiency in pregnant women 
was associated with fT4 and fT3 levels, though the effect sizes were small.146 There is mixed 
evidence for an association between iodine levels during pregnancy and offspring cognitive 
function. Whereas one study found no association between urinary iodine and child cognitive 
function at 4 years,147 another study found that low maternal iodine was associated with worse 
working memory and inhibition.143 The latter study conducted an effect measure modification 
similar to that in this dissertation, but found that maternal thyroid function did not modify the 
association between maternal iodine intake and child executive function.143  
The role of selenium in cognitive function is less studied than iodine; however, there is 
evidence in support of selenium’s importance in thyroid function.148 Recent studies have found 
that maternal urinary selenium levels during pregnancy were positively associated with 
cognitive function in their 4 year old children,147 and that maternal selenium intake during 
pregnancy was positively associated with better child psychomotor and language development at 
1.5 years.103 However, to my knowledge, no studies have investigated whether selenium modifies 
the association between maternal thyroid function and offspring neurodevelopment.  
Evidence for child sex. Recent evidence suggests that fetal sex can influence the effect 
of maternal thyroid function on child ADHD or executive function.117,120,127 However, the 
direction of effects in these three studies have been inconsistent, with one study reporting 
stronger associations in boys than in girls,120 and the other two studies reporting stronger 
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associations in girls than in boys.117,127 The role of child sex as a modifier of the association 
between maternal thyroid function and child outcomes is a burgeoning area of research. A 
recent study found that maternal exposure to phthalates (which are endocrine disruptors) was 
differentially associated with birthweight depending on child sex.149 Another study found that 
child sex did not modify the association between maternal hypothyroxinemia and child IQ.121 
Clearly, the role of child sex in the association between maternal thyroid function and offspring 
outcomes requires further investigation.    
 





CHAPTER 3. INNOVATION 
The papers in this dissertation were the first studies of maternal thyroid function and 
ADHD or executive function to incorporate potential genetic modifiers. And, in investigating the 
modifying effects of maternal and child variants in the deiodinase-encoding genes DIO1 and 
DIO2, this is the first study to consider the role of maternal and fetal thyroid hormone 
conversion in fetal neurodevelopment. Although genetic variants in deiodinase-encoding genes 
provide an incomplete picture of thyroid hormone conversion (it does not reflect gene 
expression or tissue-specific activity), previous studies have found that variants in DIO1 and 
DIO2 are associated with circulating thyroid hormone levels as well as outcomes including well-
being and intellectual disability (Table 7).  
Second, this dissertation includes the first studies of maternal thyroid function and 
ADHD or executive function to investigate effect measure modification by maternal nutritional 
factors (specifically dietary iodine and dietary selenium intake). Whereas some previous studies 
assessed the association between maternal thyroid function and ADHD in an iodine-deficit 
region,115 no study has assessed the interaction between iodine (or selenium) and maternal 
thyroid function. Iodine and selenium both are crucial in thyroid hormone synthesis and 
conversion. Furthermore, dietary intake of these nutrients is theoretically modifiable, providing 
a potential mechanism that could reduce the severity of ADHD or executive function 
impairments.  
Third, whereas all but one119 previous study of maternal thyroid function and ADHD or 
executive function used a flawed measure of maternal fT4, this dissertation used a validated 
index that accurately estimates fT4 during pregnancy. Specifically, most previous studies have 
used immunoassay to measure fT4; however, pregnancy-related changes in thyroid function, 
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lower levels of albumin in blood, as well as interference from hCG, make immunoassay an 
inaccurate measure of free thyroid hormones during gestation.74 Instead of immunoassay, this 
dissertation used an index to estimate free thyroid hormones that was validated against the gold 
standard measure.76  
Fourth, this dissertation included multiple outcome assessments, which each may reflect 
different aspects of ADHD or executive function. Specifically, the studies in this dissertation 
included a clinical assessment of ADHD, performance-based measures of working memory, 
inhibition, and impulsivity, and inventory measures of working memory, inhibition, and 
emotional control (completed by parents and teachers). This suite of outcome measures allows 
this dissertation to contribute to discussions about the clinical value of Research Domain 
Criteria (RDoC), the dissociation between parent- and teacher-rated executive function, and 
whether performance-based and inventory measures of executive function tap into the same 
construct. Most previous studies of maternal thyroid function and ADHD or executive function 
have included only one outcome measure. 
 





CHAPTER 4. METHODS 
4.1 Overview of Study  
 This dissertation used data from a study of ADHD nested within the Norwegian Mother 
and Child Cohort (MoBa) to assess the association between maternal thyroid function at 17 
weeks’ gestation and multiple child outcomes at 3.5 years, including clinically-assessed ADHD 
and continuous measures of executive function. In addition, this dissertation assessed effect 
measure modification by maternal and child variants in deiodinase-encoding genes (DIO1, 
DIO2), maternal nutrient intake (iodine and selenium), and child sex. The first paper (which 
constitutes Chapter 5 of this dissertation) investigates these questions with preschool ADHD as 
the outcome. The second paper (which constitutes Chapter 7 of this dissertation) investigates 
these questions with continuous measures of executive function as the outcomes. This chapter 
(Chapter 4) is not a comprehensive summary of the methods; rather, it presents some additional 
details about the study population, validation studies supporting the variables used in this 
dissertation, as well as additional details not included in the papers (e.g. a discussion of the 
directed acyclic graph and the a priori power analyses). Table 8 below summarizes the 
distinctions between papers 1 and 2. 
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Table 8. Summary of paper 1 and paper 2  





260 children with ADHD  
549 representative controls 
342 children who were clinically evaluated 
and their mothers 
Exposure 
Maternal thyroid function biomarkers at 17 
weeks’ gestation 
Maternal thyroid function biomarkers at 17 
weeks’ gestation 
Outcome Clinical preschool ADHD 
Performance-based and inventory 
measures of executive function 
Potential 
modifiers 
Included in paper (Chapter 5):  
Maternal SNP rs225014 in DIO2 
Maternal SNP in rs2235544 in DIO1 
Child SNP in rs225014 in DIO2 
 
Included in supporting analyses (Chapter 
6): 
Maternal dietary iodine intake 
Maternal dietary selenium intake 
Child sex 
Included in paper (Chapter 7): 
Maternal SNP rs225014 in DIO2 
Maternal SNP in rs2235544 in DIO1 
Child SNP in rs225014 in DIO2 
 
Included in supporting analyses (Chapter 
8): 
Maternal dietary iodine intake 
Maternal dietary selenium intake 
Child sex 
 
4.2 Study Population 
The Norwegian Mother and Child Birth Cohort (MoBa). MoBa is a population-
based longitudinal prospective birth cohort that consists of over 100,000 pregnancies with 
births spanning October 1999 – July 2009. Mothers living in Norway were invited to participate 
in MoBa prior to their first routine ultrasound during pregnancy (between 17-18 weeks’ 
gestation). Of the 277,702 pregnancies invited, 41% participated in the MoBa study.150 Retention 
in the MoBa was high: 91-95% completed the 3 prenatal questionnaires, 79-88% provided 
maternal, child, or paternal blood samples, and 62% completed a questionnaire when their child 
was 3 years old.151   
The ADHD sub-study. Nested within MoBa is the ADHD sub-study, which has a case-
cohort design. The main goal of the ADHD sub-study is to investigate the role of maternal 
exposures to toxicants (mainly organophosphates) and preschool ADHD, with maternal thyroid 
hormones as the mediators of this relationship.  
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Figure 5 depicts how the ADHD sub-study is nested within the overall MoBa cohort. The 
ADHD sub-study began in 2008, and invited mothers from the MoBa cohort who had given 
birth to their index children April 2004 onwards, had completed the 3-year screening 
questionnaire (the Child Behavior Checklist), had available biospecimen, and were within a 1-
hour flight of Oslo, Norway. Of the overall MoBa cohort, 16,577 mother/child pairs met these 
criteria. Of the 16,577 mothers, all potential ADHD cases (N = 2062) were identified based on a 
pre-screening scale that was included in the 3-year questionnaire. Also invited was a random 
sample of those identified as potential non-cases based on the screening questionnaire (N = 
264) Of those invited to the clinical assessment, 870 mother/child pairs participated in the 
clinical evaluation. In addition to those who participated in the clinical assessment, the ADHD 
sub-study included already collected data from a random sample of 549 dyads from the overall 
MoBa cohort.  
The first of the dissertation uses those included in the ADHD case-cohort study, whereas 
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Figure 5. Overview of sampling frame. 
 
Comparison of the ADHD Sub-study to the overall MoBa population and the 
general Norwegian population. A recent study compared MoBa maternal characteristics to 
the general Norwegian population and found that although prevalence estimates of exposures 
and outcomes were slightly biased in the MoBa cohort, estimates of eight different exposure-
outcome associations were not biased.152 The exposure-outcome associations that Nilsen and 
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colleagues investigated included: prenatal smoking and low birthweight, prenatal smoking and 
placental abruption, prenatal smoking and stillbirth, offspring low birthweight and neonatal 
death, chronic hypertension and gestational diabetes, maternal vitamin use and placental 
abruption, parity and preeclampsia, and marital status and preterm birth.152 
Table 9 includes the distribution of maternal characteristics reported by Nilsen et al.152 
along with the distribution in the data that were used for this dissertation. The distribution of 
maternal characteristics in the ADHD sub-study is similar to that of the overall MoBa cohort, 
which bodes well for estimates of exposure-outcome associations. One exception is maternal 
smoking, although this difference is likely due to the study design: the ADHD sub-study was a 
case-cohort study, which means that mothers of children with ADHD are over-represented in 
our study sample. Because maternal smoking is related to offspring ADHD, the proportion of 
mothers that report smoking is likely to be higher in the overall study sample.  
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Table 9. Distribution of maternal characteristics in the Norwegian population, in the Norwegian Mother 
and Child Birth Cohort (MoBa), and among mothers of children clinically evaluated for the ADHD sub-
study and those who were randomly selected (N = 914; the random sample overlapped with the clinically 
evaluated sample). Frequencies of missing are not presented here. Data for the Norwegian population 










Maternal age at delivery 
  
 <25  67 707 (17.0) 8734 (11.9) 86 (9.5) 
 25-34 266 171 (66.7) 52 638 (71.5) 653 (71.8) 
 >34 64 961 (16.3) 12 207 (16.6) 171 (18.8) 
Marital status  
   
 Single 25 547 (6.4) 2599 (3.5) 34 (3.9) 
 Cohabiting 172 287 (43.2) 33 930 (46.1) 417 (47.3) 
 Married 195 944 (49.1) 36 732 (49.9) 430 (48.8) 
Parity 
   
 0 162 983 (40.9) 31 763 (43.2) 446 (49.0) 
 1 142 211 (35.7) 26 486 (36.0) 317 (34.8) 
 2 65 770 (16.5) 11 840 (16.1) 120 (13.2) 
 >2 27 885 (7.0) 3490 (4.7) 27 (3.0) 
Smoking 
   
 Unknown 60 254 (15.1) 9512 (12.9) 
 
 No 295 618 (74.1) 59 548 (80.9) 694 (78.9) 
  Yes 42 977 (10.8) 4519 (6.1) 186 (21.1) 
 
 
4.3 Study Timeline 
 
Figure 6 presents a timeline of the MoBa and ADHD sub-study.  
 
Figure 6. Study timeline 
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4.4 Measurement of maternal nutrient intake  
 Because maternal nutrient intake was not included in the main dissertation papers, I 
describe the measurement of maternal nutritional factors here. Nutritional factors—specifically 
maternal dietary iodine and selenium intake—were measured as part of a semi-quantitative food 
frequency questionnaire that mothers completed at approximately 22 weeks’ gestation.153 
Women were asked to report the frequency with which they consumed a number of different 
food items since becoming pregnant (e.g. by reporting the number of servings per day, per week, 
or per month, or by reporting the frequency with which they consumed a given food item). 
Additionally, women reported changes in their diet since becoming pregnant, use of dietary 
supplements, the number of times each week they ate different types of meals (e.g. breakfast, 
morning snack, lunch, etc.), as well as a broad classifications or diet profiles (e.g. omnivore, 
vegetarian, vegan, etc). In total, the questionnaire included 340 questions grouped into 40 
overarching questions, which addressed the consumption of 255 food items and 13 different 
dietary supplements. 
4.5 Validation and reliability information about select variables 
Maternal Thyroid function assessment. Although clinical measures of thyroid 
hormone biomarkers typically use serum, a recent validation study demonstrated that thyroid 
hormone biomarker measurements from plasma and serum are very highly correlated. Villanger 
and colleagues (2017)76 conducted a pilot study to assess three main aspects of thyroid hormone 
measures: (1) The validity of plasma measures as compared to assays using serum, (2) the effect 
of multiple freeze-thaw cycles on thyroid hormone concentrations, and (3) the validity of 
calculated indices of free thyroid hormones. To assess these three questions, Villanger and 
colleagues (2017) collected a 25mL blood sample from 17 women in their third trimester of 
pregnancy. These samples were spun within one hour of collection and were separated into one 
1.5 mL aliquot of serum and five 1.5 mL aliquots of plasma. The serum aliquot was handled and 
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analyzed using gold standard methods: it was frozen immediately and then fT3 was measured 
using equilibrium dialysis followed by high-performance liquid chromatographytandem mass 
spectrometry. The five aliquots of plasma were each subjected to different handling procedures: 
(1) Frozen immediately (”Silver standard”), (2) Kept for 24 hours at room temperature, (3) Kept 
for 24 hours at room temperature, and then frozen and thawed once, (4) Kept for 48 hours at 
room temperature, and (4) Kept for 48 hours at room temperature, and then frozen and thawed 
once. Immunoassay was used to measure thyroid hormone biomarkers (TT3, TT4, TSH, T3 
uptake, TPOAb) in both the serum and the plasma samples. 
Villanger and colleagues found very high correlations between serum and plasma 
measures of TT4, TT3, TSH, TPOAb, T3, and fT3 and fT4 indexes (Table 10).76 These results 
demonstrate the validity of using plasma assays for thyroid hormone biomarker 
measurements.76  
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Table 10. A partial reproduction of Table 1 (“Comparing Serum and Optimal Treated Plasma from 17 
Pregnant Women (Only 14 Women Had Thyroxine Peroxidase Antibody Above Detection) Using 
Spearman’s Rank Correlation and Wilcoxon Signed-rank test”) from Epidemiology, Volume 20(3), “Effects 
of Sample Handling and Analytical Procedures on Thyroid Hormone Concentrations in Pregnant 
Women’s Plasma”, by Villanger and colleagues’ (2017). Reprinted with permission from Wolters Kluwer 
Health, Inc.  
Thyroid variable Serum vs. Plasma 
Spearman’s Rho (Rs) (95% CI: Lower, Upper) 
Total thyroxine, TT4 0.97 (0.84, 1.00) 
Total triiodothyronine, TT3 0.99 (0.93, 1.00) 
Thyroid stimulating hormone, TSH  1.00 (0.96, 1.00) 
Thyroxine peroxidase antibody, TPOAb 0.94 (0.78, 0.99) 
T3 uptake 0.98 (0.95, 1.00)a 
Free T4 index, fT4i 0.97 (0.84, 1.00) 
Free T3 index, fT3i  0.99 (0.95, 1.00)b 
a “Difference plasma versus serum (Wilcoxon signed-rank test; 95% CI: -1.0000, -0.9999).” 
b “Difference plasma versus serum (Wilcoxon signed-rank test; 95% CI: -7.0, -1.5).”  
 
Furthermore, Villanger and colleagues found no effect of freeze-thaw cycles on thyroid 
hormone concentrations, but did find a positive effect of storage time on TT3 concentrations. 
Specifically, they found that TT3 concentrations increased by approximately 1.35 ng/dL per each 
24 hour period of storage. Finally, the correlation between gold-standard measured fT4 in 
serum and the calculated fT4 index was high (r = 0.81, 95% CI: 0.52, 0.94), validating the use of 
the free thyroid hormone indices. These indices (see equations 1) were used in both papers of 
this dissertation 
 




Equations 1. Computed index for free thyroxine (fT4i) and free triiodothyronine (fT3i).141  
 
Validity and reliability of executive function measures. Table 11 presents a 
summary of the validity and reliability of the continuous executive function measures used in 
paper 2 (Chapter 7).  
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Table 11. Validity and reliability of executive function measures 
Test Description Used to 
assess… 










completed by a 
caregiver to assess 
child’s executive 
function ability (e.g., 
there are a number 
of items to measure 
ability to control 
impulses, shift 
attention, hold 
information in mind, 
and other 
components of 






• Most subscales have high 
(.80 to .89) to very high 
(.90+) test-retest reliability 
coefficients.154 
• There is minimal research 
on concurrent validity with 
behavioral tests of 





• A standardized 
battery of tests 
including behavioral 
assessments that 
assess verbal and 
nonverbal IQ across 




• By 30 months of age (6 
months younger than the 
children in the proposed 
dissertation), this test 
demonstrates concurrent 
validity when compared to 
other measures of 
cognitive and language 
development.155 
 





reward or a delayed 
but larger reward.   
Inhibition • Delay of Gratification 
tasks show moderate 
correlations with other 














• The statute test (measure 
of attention) has high 
(.83) test re-test 
reliability.158 
• Moderate to high 
correlations with tests of 
related constructs 
(memory, executive 
function) suggests good 
concurrent validity.158  
 
 
Validity of nutritional measures. A recent validation study compared the MoBa 
food frequency questionnaire to a 4-day weighed food diary as well as to biomarkers in urine 
and plasma.159 This study found that compared to the 4-day weighed food diary, the MoBa food 
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frequency questionnaire correctly classified dietary selenium intake for 64% of participants and 
dietary iodine intake for 67% of participants.159 Compared to urinary iodine secretion, the MoBa 
food frequency questionnaire correctly classified dietary iodine intake for 63% of participants.159 
The authors concluded that the food frequency questionnaire in MoBa is a valid tool for 
classifying participants’ nutrient intake in to low and high categories.  
 
4.6 Potential Adjustment Set and the Directed Acyclic Graph  
We created a directed acyclic graph (DAG) based on the extant literature of maternal 
thyroid function and child ADHD (or executive function) (Figure 7). There is much uncertainty 
surrounding the etiologic paths contributing to ADHD and supporting the development of 
executive function, hence most of the paths in the DAG represent best guesses based on past 
research.  
Here, I will highlight a number of key variables in the DAG to provide some context for 
its construction. First, maternal ADHD is associated with offspring ADHD,160–162 as well as a 
number of risk factors for both maternal thyroid dysfunction and offspring ADHD, including 
maternal education,163,164 smoking during pregnancy,165,166 alcohol use during pregnancy,167–169 
age at child birth,170 and BMI.171–176 Maternal symptoms of ADHD is thus a key variable for 
understanding the structure of causal and non-causal paths between maternal thyroid function 
and offspring ADHD or executive function (maternal executive function is also predictive of 
child executive function). 
Second, maternal smoking is a well-established risk factor for ADHD and other cognitive 
impairments (such as impaired executive function); however, evidence suggests that its effect is 
not direct. Therefore, the DAG includes mediating paths from smoking to ADHD through pre-
eclampsia,177,178 and low birthweight,179,180  as well as non-causal backdoor paths through 
maternal ADHD,165,166 maternal age at child birth,170 and maternal education.163,164 
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Third, the nature of the association between maternal BMI and maternal thyroid 
function is unclear. However, based on past evidence, it is hypothesized that the association 
between maternal BMI and maternal thyroid function is in part due to non-causal backdoor 
paths through diet quality and maternal ADHD.171–176  
From this DAG, we selected all potential covariates as initial adjustment factors. For 
parsimony, we then subsequently eliminated covariates that did not meaningfully contribute to 
the model.181 The full set of potential adjustment factors included: maternal self-reported 
ADHD, diabetes before or during pregnancy, history of major depression, dietary iodine intake, 
dietary selenium intake, smoking during pregnancy, maternal age at time of birth, education, 
and child sex. After eliminating covariates that did not meaningfully contribute to the model, the 
final adjustment set (for both overarching specific aims) included: maternal smoking, age, 
history of major depression, and maternal self-reported ADHD, and child sex.  
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We selected covariates based on a directed acyclic graph (DAG) and subsequently 
eliminated covariates that did not contribute meaningfully to the model for parsimony.51 We 
identified the following set of potential adjustment factors based on our DAG: maternal self-
reported ADHD, diabetes before or during pregnancy, history of major depression, dietary 
iodine intake, dietary selenium intake, smoking during pregnancy, age, and education, and child 
sex. The final covariate adjustment set included: maternal smoking, age, history of major 
depression, and maternal self-reported ADHD, and child sex. Maternal iodine and selenium 
intake were estimated from the food frequency questionnaire (22 weeks’ gestation). Maternal 
depression was measured at 17 weeks’ gestation using 8 items from the Lifetime History of 
Major Depression scale that assessed self-reported symptoms in line with DSM-III criteria.52 In 
the MoBa questionnaire completed when their children were three years old, mothers’ 
symptoms of ADHD were ascertained using six items from the Adult ADHD Self-Report Scale, 
based on DSM-IV criteria.53 Maternal smoking, maternal age, maternal diabetes, maternal pre-
pregnancy body mass index (BMI), and child sex were based on both self-report and on MBRN 
records.   
 
4.7 A priori power analyses 
A priori power to detect main effect of Aim 1. The epi.ccsize function in the epiR 
R package estimates the power to detect the main effect in a case-control study.182 Given that the 
ADHD sub-study has a case-control design, this function is well-suited for estimating the power 
to detect effects in this dissertation. The predictor in this power analysis was dichotomized 
thyroid hormone levels (the epiR package did not have options for alternative functional forms). 
The outcome in the power analysis was clinical preschool ADHD status (case/control). 
Descriptions of the function as well as the rationale are described in Table 12, and the results of 
the power analysis are in Table 13.   
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Table 12. Inputs to epi.ccsize function in the epiR R package for estimating the power to detect the 
effect on clinical ADHD. The form of the function call is: epi.ccsize(OR, p0, n, power, r = 1, rho = 0, 
design = 1, sided.test = 2, conf.level = 0.95, method = "unmatched", fleiss = FALSE). 
 
Parameter Description of Parameter from 
Documentation182 
Input Rationale  
OR scalar, the expected study odds 
ratio. 
1.2 – 1.6 • Varied to investigate the power 
to detect a main effect of 
OR=1.2 to 1.6. 
p0 scalar, the prevalence of 
exposure amongst the controls 
0.5 • This assumes dichotomizing 
thyroid hormones into high/low 
at the median. 
n scalar, the total number of 
subjects in the study (i.e. the 
number of cases plus the number 
of controls). 
872 • Total number of cases and 
controls, including random 
sample.  
 
power scalar, the required study power. Unspecified • Left unspecified to estimate 
power  
r scalar, the number in the control 
group divided by the number in 
the case group. 
(530+82)/260 • The number of controls 
(including the random sample) 
over the number of cases. 
rho scalar, the correlation between 
case and control exposures for 
matched pairs. This argument is 
ignored when method = 
"unmatched" 
NA • Not applicable because the 
design is unmatched.  
 
design scalar, the design effect 1 • Default value.  
 
sided.test use a one- or two-sided test? Use 
a two-sided test if you wish to 
evaluate whether or not the odds 
of exposure in cases is greater 
than or less than the controls. 
Use a one-sided test to evaluate 
whether or not the odds of 
exposure in cases is greater than 
the controls. 
2 • Conduct a 2-sided test. 
conf.level scalar, the level of confidence in 
the computed result 
0.95 • Based on 95% confidence 
intervals, or an alpha of 0.05. 
method  a character string defining the 
method to be used. Options are 
unmatched or matched. 
“unmatched” • The case-control design of the 
ADHD sub-study is unmatched. 
fleiss logical, indicating whether or not 
the Fleiss correction should be 
applied. This argument is ignored 
when method = "matched". 
F • Decided not to apply the Fsleiss 
correction to be more consistent 
with other the other power 
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Table 13. Estimated power to detect the main effect of thyroid hormones on ADHD using the epi.ccsize 
function in the epiR R package with thyroid hormones dichotomized at the median. 
 
Parameter Inputs Function Output 





A priori power to detect the gene by thyroid hormone interaction in aim 1. 
The powerGE function in the powerGWASinteraction R package estimates the power to detect 
gene by environment interaction effects in a case-control design. The environmental factor in 
this power analysis was dichotomized thyroid hormone levels; powerGE does not have an option 
for alternative functional forms. The genetic factor is a single SNP. The outcome of the power 
analysis is clinical preschool ADHD status (i.e. case or control). Table 14 describes the inputs to 
this function in detail, as well as provides the rationale for the chosen input. The estimated 
power to detect effects is summarized in Table 15. 
 
Table 14. Inputs to powerGE function in the powerGWASinteraction R package for estimating the power 
to detect the Gene by Environment (thyroid hormone) interaction. The form of the function call is:  
powerGE(n, power, model, caco, alpha, alpha1, maintain.alpha) 
Parameter Description of Parameter from 
Documentation183  
Input Rationale  
n Sample size: combined number of 
cases and controls. Note: exactly 
one of n and power should be 
specified 
872 • Total number of cases and 
controls, including random 
sample.  
 
power Power: targeted power. Note: 




• Left unspecified to estimate 
power 
model List specifying the genetic model. 
This list contains the following 
objects: 
  
 prev Prevalence of the outcome in the 
population. Note that for case-
only and empirical Bayes 
estimators to be valid, the 
prevalence needs to be low. 
0.05 • Estimated prevalence of ADHD 
is approximately 5% 
 pGene Probability that a binary SNP is 1 
(i.e. not the minor allele frequency 
for a three level SNP). 
0.3 – 0.5 • There are two alleles for each 
SNP of interest, with a 
probability ranging from 0.3 to 
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0.5.  
 pEnv Frequency of the binary 
environmental variable. 
0.5 • This assumes dichotomizing 
thyroid hormones into high/low 
at the median.  
 orGE Odds ratio between the binary 
SNP and binary environmental 
variable. 
1.2 • Assuming a small association 
between thyroid hormones and 
the genes of interest.  
 beta.LOR Vector of length three with the 
odds ratios of the genetic, 
environmental, and GxE 







• The genes are not expected to 
have a main effect. The 
environment (thyroid hormones) 
are assumed here to have a 
small effect (OR=1.2).  
• The effect of the interaction is 
varied from OR = 1.2 to 1.6 to 
estimate power. 
 nSNP Number of SNPs (genes) being 
tested 
1 • SNPs will be tested individually.  
• Power is slightly reduced if 
multiple SNPs are tested 
together.  
caco Fraction of the sample that are 
cases (default = 0.5). 
260/872 • There are 260 cases in the 
sample.  
 
alpha Overall (family-wise) Type 1 error 
(default = 0.05). 
0.05 • Standard alpha value.  
• Power is increased slightly if 
this value is less conservative 
(e.g., alpha = 0.1). 
 
alpha1 Significance level at which testing 
during the first stage (screening) 
takes place. If alpha1 = 1, there is 
no screening. 
NA • Not applicable because the 
analysis will not screen SNPs 
before assessing interaction.  
 
maintain.alpa1 Some combinations of screening 
and GxE testing methods do not 
maintain the proper Type 1 error. 
Default is True: combinations that 
do not maintain the Type 1 error 
are not computed. If 
maintain.alpha is False all 
combinations are computed. 
NA • Not applicable because the 
analysis will not screen SNPs 
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Table 15. Estimated power to detect the Gene by Environment interaction effect using the powerGE 
function in the powerGWASinteraction R package. 
Parameter Inputs Function Output 
pGene beta.LOR GxE Effect Estimated Power 
0.3 1.2 8.7% 
 1.4 18.1% 
 1.6 30.8% 
0.4 1.2 9.2% 
 1.4 19.7% 
 1.6 33.6% 
0.5 1.2 9.4% 
 1.4 20.0% 
 1.6 33.9% 
 
A priori power to detect main effect in aim 2. Finally, the pwr.f2.test function in 
the pwr R package estimates the power to detect main effects in a multivariate linear regression. 
The function was not designed for a case-control study. However, because this dissertation used 
inverse probability of sampling weights to weight back to the cohort eligible for the ADHD sub-
study, this particular power analysis need not consider the case-control design. This power 
analysis takes into consideration the number of predictors (i.e. the number of variables in the 
adjustment set as well as the thyroid hormone variable) and the sample size. The outcome of the 
power analysis was a single score on a continuous variable (e.g., one of the dimensional 
behavioral tasks). The variables were all modelled linearly; there is no option for alternative 
functional forms. The description of the inputs and the rationale for the choice of input for the 
functions is detailed in Table 16. The results of the power analysis are presented in Table 17. 
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Table 16. Inputs to pwr.f2.test function in the pwr R package for estimating the power to detect the effect 
on the dimensional data. The form of the function command is:  
pwr.f2.test(u = NULL, v = NULL, f2 = NULL, sig.level = 0.05, power = NULL). 
Parameter Description of Parameter 
from Documentation184 
Input Rationale  
u degrees of freedom for 
numerator 
6 • This is based on a model with a single 
thyroid hormone term and 5 
adjustment factors (3 of the 5 minimally 
sufficient adjustment sets have 5 
variables). 
v degrees of freedom for 
denominator 
335 • Only those who completed the clinical 
evaluation have dimensional data, so 
the degrees of freedom for the 
denominator is (260 + 82) – 6 – 1 = 
335. 
f2 effect size 0.02 – 0.35 • An f2 value of 0.02 indicates a small 
effect, and a value of 0.35 indicates a 
large effect size.  
sig.level Significance level (Type I 
error probability) 
0.05 • Standard alpha value.  
• Power is increased slightly if this value 
is less conservative (e.g., alpha = 0.1). 
 
power Power of test (1 minus Type 
II error probability) 
NULL • Left unspecified to estimate power. 
 
Table 17. Estimated power to detect the main effect of thyroid hormones on dimensional data using the 
epi.ccsize function in the epiR R package. 
Parameter Inputs Function Output 
f2 Estimated Power 
Small (0.02) 45 
Med (0.15) 99.9 
Large (0.35) >99.9 
 





CHAPTER 5. PAPER 1: MATERNAL THYROID FUNCTION AND 
PRESCHOOL ADHD IN THE NORWEGIAN MOTHER AND CHILD COHORT 
STUDY: EFFECT MEASURE MODIFICATION BY DEIODINASE-ENCODING 
GENE VARIANTS? 
 
Note: Tables and figures for this chapter are in sections 5.6-5.8. 
5.1 Chapter 5 Overview 
There is mixed evidence for an association between maternal thyroid function and child 
Attention Deficit Hyperactivity Disorder (ADHD). Maternal thyroid hormone supply is crucial 
for fetal neurodevelopment, particularly during the first 20 weeks of gestation when the fetus 
cannot synthesize sufficient levels of thyroid hormones. Variants in deiodinase-encoding genes 
may impact the nature of the association between maternal thyroid function and ADHD because 
they are required to deliver maternal thyroid hormone to the fetus. Deiodinases have not been 
previously examined in the context of human fetal neurodevelopment and may clarify an 
association between thyroid hormone and ADHD if one exists.  
We conducted a case-cohort study of preschool ADHD, drawing data from a sub-study of 
ADHD nested within the Norwegian Mother and Child Birth Cohort (MoBa) as well as a random 
sample of representative controls from MoBa, yielding 260 cases and 549 controls. We 
estimated the association between multiple biomarkers of maternal thyroid function at 17 weeks’ 
gestation and the odds of ADHD as classified by a diagnostic interview based on DSM-IV-TR 
criteria. We assessed effect measure modification of these associations by two maternal SNPs 
(DIO1: rs2235544; DIO2: rs225014) and by one child SNPs (DIO2: rs225014). 
Associations between maternal thyroid function biomarkers and child ADHD were 
mostly near-null and were imprecise. We furthermore did not find evidence of effect measure 
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modification by maternal or child SNPs.  
This is the first study to assess whether maternal and child gene variants in genes 
encoding deiodinase enzymes modify the association between maternal thyroid function 
biomarkers and ADHD. Although we did not find evidence of modification, this paper presents 
biological hypotheses that may direct investigations in future studies. 
 
5.2 Introduction  
 
Attention deficit hyperactivity disorder (ADHD) is the most commonly diagnosed 
childhood neurodevelopmental disorder, with an estimated worldwide prevalence of 5.6% 
among children and adolescents.1 In preschool-aged children, the symptoms of ADHD—
hyperactivity, inattention, and impulsivity—can present and may be early neurodevelopmental 
indicators of the disorder.185 Across the lifespan, ADHD is associated with adverse outcomes 
including social and academic impairments, employment difficulties, and incarceration.5,6,186 
The causes of ADHD are unknown but are likely multifactorial and include both 
environmental and genetic components (heritability estimates are high: 70-90%10,11). A number 
of factors have been associated with ADHD, though the extent to which the risk factors reflect 
causal pathways is unclear. Such factors include maternal exposures or experiences during 
pregnancy (smoking, alcohol consumption, paracetamol use, depression and anxiety), general 
maternal health and demographic features (young maternal age, high pre-pregnancy BMI), as 
well as child male sex.13–15,187–189 One risk factor with a plausible causal biological mechanism is 
maternal thyroid function: recent systematic reviews have reported some evidence for an 
association between maternal thyroid dysfunction (most notably maternal hypothyroxinemia) 
and ADHD, or symptoms thereof.57,58,190 However, only two studies have assessed maternal 
thyroid function and ADHD symptoms exclusively in the preschool period.113,114 The relationship 
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between maternal thyroid function and offspring neurodevelopment is of interest because it is, 
in theory, amenable to clinical intervention. Mechanisms underlying the role of maternal 
thyroid function in fetal neurodevelopment and the etiology of ADHD require further 
elaboration, which is the aim of this study.  
In the fetal brain, thyroid hormones bind to receptors in the nuclei of cells, affecting the 
expression of genes that regulate neurodevelopment.88 Because the fetus does not synthesize 
sufficient thyroid hormones until mid-gestation, it relies on the maternal thyroid hormone 
supply to support neurodevelopment.83,84 Triiodothyronine (T3) in the human fetal cortex is 
derived from maternal thyroxine (T4), which crosses more freely to the fetus than T3.85 There is 
evidence that deiodinase type 2—which converts T4 to the more active T3—is present in the 
placenta and fetal cerebral cortex as early as 7 weeks’ gestation.86,87 Because the fetus does not 
synthesize sufficient quantities of its own thyroid hormones until later in gestation, the 
conversion of maternally-supplied T4 to T3 by deiodinases within the fetal cerebral cortex, is a 
crucial contributor to fetal neurodevelopment. Furthermore, the activity of fetal deiodinase 2 
has the potential to modify associations between circulating maternal thyroid hormones and 
their biological impact on the fetus by altering the local fetal availability of T3.191 
Maternal deiodinases may also play an important role in modifying associations between 
circulating maternal thyroid hormone levels and neurocognitive deficits or disorders, like 
ADHD. Circulating concentrations of thyroid hormones can differ from intracellular thyroid 
hormone concentrations due in part to the activity of deiodinases; moreover, maternal 
deiodinase activity exhibits tissue specificity, and varies by gestational age.93,192,193 Maternal 
deiodinases type 2 (and type 3) is expressed in the decidual cells of the uterus, which form the 
maternal part of the placenta.92 The presence of maternal deiodinases in the placenta provide a 
pathway through which maternal deiodinases may influence the supply of maternal thyroid 
hormones to the fetus, independent of maternal circulating circulating thyroid hormone 
concentrations. The role of maternal deiodinase type 1 is less clear, as the presence of this 
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deiodinase in the placenta is still debated.95  
The genes DIO1 and DIO2 encode deiodinase types 1 and 2, respectively. The C allele of 
the DIO1 SNP rs2235544 (which is an intron variant located at 1:53909897) is associated with a 
more active deiodinase type 1 and consequently with a higher fT3/fT4 ratio compared to the A 
allele.132,133 The TT genotype of the DIO2 SNP rs225014 (T92A, a missense variant located at 
14:80203237) is associated with a more active deiodinase type 2,141 though it has not been found 
to be related to the fT3/fT4 ratio.133,140 Both rs2235544 and T92A have also been associated with 
cognitive and behavioral outcomes that are frequently comorbid with adult ADHD, including 
heavy alcohol consumption and bipolar disorder.134,135,194 Among children, T92A was associated 
with intellectual disability among children in an iodine-deficient region,195 demonstrating its 
potential role in neurocognitive outcomes. To our knowledge, no study to date has examined 
how maternal or child variants in these SNPs affects the association between maternal thyroid 
function during pregnancy and any neurobehavioral outcomes (including child ADHD). 
During gestation, maternal thyroid hormone concentrations, maternal thyroid hormone 
conversion, and fetal conversion of maternally-supplied thyroid hormones each may impact 
fetal thyroid hormone supply and thus neurodevelopment. The present study is a first step at 
disentangling the effects of these separate pathways. We investigated the association between 
biomarkers of maternal thyroid function at 17 weeks’ gestation and diagnostic classifications of 
ADHD symptoms in preschool children who were 3.5 years old on average. To indirectly 
characterize the role of maternal and fetal thyroid hormone conversion in this relationship, we 
evaluated effect measure modification by maternal SNPs in DIO1, and DIO2, as well as by child 
SNPs in DIO2. We addressed these questions using a case-cohort study of preschool ADHD 
nested within the longitudinal prospective Norwegian Mother and Child Birth Cohort (MoBa). 
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5.3 Methods 
Study population. The Norwegian Mother and Child Cohort Study (MoBa) is an 
ongoing prospective population-based cohort study of Norwegian-speaking women that is 
conducted by the Norwegian Institute of Public Health (41% participation rate).196 The current 
paper is a nested case-cohort study of ADHD, using data from a clinical sub-study of ADHD (to 
act as cases) as well as data from a random sample of those eligible for the ADHD sub-study (to 
act as controls).  
The clinical sub-study of ADHD oversampled children with high scores on ADHD 
symptoms, using data from the MoBa questionnaire that was administered to mothers at child 
age 3 years.197 The questionnaire included 11 items about ADHD, including six items from the 
Child Behavior Checklist/1.5-5198 and five items from the DSM-IV-TR criteria for ADHD.185 
Children with scores  90th percentile on these 11 items (n = 2798) were invited to participate, 
along with randomly selected children (n = 654) (Figure 8). In total, about 35% agreed to 
participate in the ADHD sub-study, and from 2007 to 2011, 1195 children (mean age: 3.5 years, 
age range: 3.1 – 3.8 years) took part in a 1-day clinical assessment including diagnostic 
interviews with parents (with few exceptions, mothers) (Figure 8).  
Because the present study investigated maternal thyroid function biomarkers measured 
in maternal urine samples, the sample was restricted to the 870 children whose mothers had 
available urine samples (Figure 1). Of the 870 children, those who were classified as having 
ADHD according to DSM-IV-TR criteria or as having subthreshold symptoms of ADHD 
(diagnostic procedure described below) were included as the cases in this case-cohort design (n 
= 260) (Figure 8).  
The controls in this study were a random sample of 549 children from those who were 
eligible for the ADHD sub-study (those with completed 3-year MoBa questionnaires, who were 
born between April 2004-January 2008, and who lived within a direct flight of Oslo) and whose 
mothers had available urine samples (Figure 8). These controls were randomly selected 
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independent of their scores on the 3-year MoBa questionnaire, and theoretically represent the 
exposure distribution among those eligible for the ADHD sub-study.    
Maternal thyroid function assessment. Blood samples were collected as part of 
MoBa during the first ultrasound appointment (typically 17-18 weeks’ gestation). Two 7ml 
ethylenediamine tetraacetic acid (EDTA) tubes (Becton-Dickinson (BD), Plymouth, UK) of 
blood were drawn, one of which was spun to pull off plasma, and then was shipped overnight at 
room temperature to a central biospecimen processing lab.199 Most samples arrived at the 
biobank the day after collection, and were stored in 1ml cryovials at -80°C.199,200 
For thyroid function biomarker analysis, the samples were shipped frozen on dry ice to 
ARUP Laboratories in Salt Lake City, Utah. Plasma TSH, total T3 (TT3), and total T4 (TT4) were 
estimated using a quantitative chemiluminescent immunoassay on a Roche Cobas e602 blood 
analyzer.201 We additionally computed an indirect measure of plasma free T4 (fT4i) and fT3 
(fT3i) using T3-uptake and TT4 or TT3, respectively.76 Validity of our thyroid function 
measurements and their sensitivity to biospecimen handling procedures within birth cohort 
studies such as MoBa have been previously reported.76 
Diagnostic interview and classification. Diagnostic assessments of the children 
were based on the Preschool Age Psychiatric Assessment (PAPA) interviews with their 
parents.202 In the ADHD study, only symptoms lasting  3 months were counted as present. 
Trained graduate psychology students conducted the interviews under supervision by a child 
psychologist or psychiatrist.  
As an inter-rater reliability check, we had a separate rater who was blind to the parent 
and teacher screen ratings rescore audiotapes of 79 randomly selected assessment interviews. 
The average intra-class correlations (ICCs) were .97 for HI symptoms, .99 for IA symptoms, and 
.98 for the total number of ADHD symptoms. 
Diagnostic classification was based on parent reports in the PAPA interview, which is 
designed for evaluating children aged 2-6 years of age, and is well-validated for use with 
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preschoolers.203,204. Preschool ADHD was defined by the presence of 6 or more symptoms with 
evidence of impairment that met the criteria for the predominantly hyperactive/impulsive, 
predominantly inattentive or combined presentation of ADHD (as defined by the DSM-IV-TR) 
and were reported by parents to be pervasive across at least two settings. Subthreshold 
preschool ADHD was defined as either the presence of 6 or more symptoms as described above, 
but without clear evidence of impairment, or as 3-5 symptoms with evidence of impairment. Of 
the 260 cases in the present study, 114 were classified as having preschool ADHD, and 146 were 
classified as having subthreshold preschool ADHD. The ADHD classifications/diagnoses defined 
by the PAPA are not equivalent to clinical ADHD diagnoses, which would require a broader 
assessment including multiple sources of information and informants. However, for simplicity, 
we hereafter refer this group of 260 children as ‘cases’ or as those with ‘preschool ADHD’.    
Genotyping. Blood samples for DNA extraction were collected at approximately 17 
weeks’ gestation from the mother and from infant cord blood at delivery. DNA from blood was 
extracted using FlexiGene, and candidate SNPs were measured using Sequenom IPLEX. We 
considered 2 maternal SNPs (rs2235544 in DIO1 and rs225014, or T92A, in DIO2) and 1 child 
SNP (T92A in DIO2). Child SNPs in DIO1 were not considered because there is little evidence 
that DIO1 is expressed early enough in gestation to influence the effect of maternal thyroid 
hormones. 
Covariates. We selected covariates based on a directed acyclic graph (DAG) and 
subsequently eliminated covariates that did not contribute meaningfully to the model for 
parsimony.181 We identified the following set of potential adjustment factors based on our DAG 
(though it is important to note that the biological relationships between the following factors 
and the exposure and outcome remain unclear): maternal self-reported ADHD, diabetes before 
or during pregnancy, history of major depression, dietary iodine intake, dietary selenium intake, 
smoking during pregnancy, age, education, and child sex. Maternal iodine and selenium intake 
were estimated from the food frequency questionnaire (22 weeks’ gestation). Maternal 
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depression was measured at 17 weeks’ gestation using 8 self-reported symptoms in line with 
DSM-III criteria.205 In the MoBa questionnaire completed when their children were three years 
old, mothers’ symptoms of ADHD were ascertained using six items from the Adult ADHD Self-
Report Scale, based on DSM-IV criteria.206 Maternal smoking, maternal age, maternal diabetes, 
maternal pre-pregnancy body mass index (BMI), and child sex were based on both self-report 
and on MBRN records. The final covariate adjustment set included: maternal smoking, age, 
history of major depression, maternal self-reported ADHD, and child sex. 
Statistical modeling. We assessed the main effect of each thyroid function biomarker 
on the odds of ADHD using logistic regression, with the thyroid function biomarker modeled 
using tertile categories. For each SNP, we tested Hardy-Weinberg equilibrium for mothers and 
children among sub-cohort members. We additionally assessed the main effect of each maternal 
and child SNP on child ADHD.  
To assess effect measure modification, we used augmented product term models, in 
which the model included an interaction term between each covariate in the model and the 
potential effect measure modifier (as well as all main effects).207 This method allows for 
covariate variation across strata of the potential effect measure modifier. A cutoff of p < 0.10 
was used as the criterion for statistically significant effect measure modification. We assessed 
the following potential genetic effect measure modifiers: 2 maternal SNPs (DIO1: rs2235544; 
DIO2: T92A) and 1 child SNPs (DIO2: T92A). For maternal SNPs, we considered the interaction 
between DIO1 and DIO2 and TT3, fT3, TT4, and fT4. For child SNPs, we considered the 
interaction between DIO2 and TT4 and fT4 only (since mostly maternal T4 crosses to the fetus). 
SNPs were modeled additively with the most common homozygote as the referent level. Because 
a priori power analyses indicated lower power to detect interaction effects between genetic 
variants and thyroid hormone levels (~30%), tests of effect measure modification were 
considered exploratory.  
To address missing data, all analyses were conducted using multiple imputation with 
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m=20 imputed datasets and combined using Rubin’s rules using the aregImpute and 
fit.mult.impute functions of the Hmsic R package.208 In separate sensitivity analyses, we 
restricted the analyses to women who were euthyroid, additionally adjusted for maternal pre-
pregnancy BMI, restricted the case group to only those whose symptoms met DSM-IV-TR 
criteria for ADHD (N = 114), and dropped self-reported maternal symptoms of ADHD from the 
adjustment set. The current analysis is based on version 9 of the quality assured MoBa data. 
This study was approved by Regional Committee for Medical Research Ethics (REK) in Norway 
and was reviewed and determined to be exempt from further review by the office of Human 
Research Ethics at the University of North Carolina at Chapel Hill.  
 
5.4 Results 
Compared to mothers of children in the case group, mothers of children in the control 
group reported more symptoms of ADHD themselves, were more likely to report depression 
symptoms, and were more likely to have smoked during pregnancy (Table 18). Children with 
ADHD were more often male than female (Table 18). Women in our study sample were mostly 
classified as having normal thyroid function (499 mothers of controls and 227 mothers of cases 
were euthyroid, Table 19). All genotype frequencies were within Hardy-Weinberg Equilibrium 
(Tables 22 and 23).  
Estimated associations between each thyroid function biomarker and ADHD were 
mostly near-null and relatively imprecise, as shown in Table 20. These effect estimates were 
consistent when we additionally adjusted for pre-pregnancy BMI (Table 24), and when we 
restricted the population to euthyroid individuals (Table 25). Results were similar when we used 
complete-case analysis, when the case group was restricted to those whose symptoms met DSM-
IV-TR criteria for ADHD, and when self-reported maternal ADHD was excluded from the model 
(results not shown).  
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We did not find direct associations between maternal or child SNPs and preschool 
ADHD (Table 20), nor did we find evidence of effect measure modification by maternal or child 
SNPs (Table 21).  
 
5.5 Discussion 
In this case-cohort study of MoBa, we examined the association between maternal 
thyroid function biomarkers at mid-gestation and preschool ADHD. We also investigated 
potential modification by maternal and child SNPs in deiodinase-encoding genes DIO1 and 
DIO2, which encode deiodinase types 1 and 2. We found no significant associations between 
maternal thyroid function biomarkers at mid-pregnancy and offspring preschool ADHD within a 
euthyroid population. Nor did we find significant effect measure modification by maternal or 
child SNPs; however, given our low a priori power to detect modification effects, the role of 
deiodinase-encoding genes remains unclear. 
Although there has been research on the association between maternal thyroid function 
and child symptoms of ADHD, to our knowledge no study has taken into account the role of 
thyroid hormone conversion, which is important in determining biological impact.83,93,94 
Deiodinase activity affects the intracellular concentrations of thyroid hormones, which is where 
thyroid hormones influence the expression and regulation of genes.93 Thus, considering the role 
of maternal and fetal deiodinases—even indirectly through the measurement of key variants that 
influence the expression of these genes—may provide insights into the link between maternal 
thyroid function and fetal neurodevelopment. 
The A allele of rs2235544 in DIO1 has been associated with a less active deiodinase type 1 
(i.e. converts less T4 to T3) and with higher circulating T4 levels.129–133 Both animal and human 
research indicate that deiodinase type 1 contributes to thyroid hormone homeostasis. In iodine 
deficient states, the activity of deiodinase type 1 increases, contributing to the maintenance of 
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normal T3 levels in blood.101,209 In states of normal thyroid function; however, research with 
deiodinase type 1-deficient mice suggest that deiodinase type 1 is not absolutely critical: 
although DIO1 knockout mice have elevated circulating T4 levels, their T3 and TSH levels 
remain relatively unchanged.137,209,210 In our study, maternal SNP rs2235544 in DIO1 did not 
modify the association between maternal thyroid hormones and preschool ADHD. This null 
finding could be because maternal DIO1 affects circulating maternal thyroid hormones but not 
the maternal-fetal transfer of thyroid hormones, or possibly because most women in this study 
had normal thyroid function (thus the activity of DIO1 was less crucial). Alternatively, the low a 
priori power of the effect measure modification analyses may have hindered our ability to detect 
an effect.  
The maternal SNP in DIO2 (T92A) also did not modify the association between maternal 
thyroid hormones and ADHD. Because DIO2 is expressed in the maternal portion of the 
placenta, maternal T92A might alter the supply of maternal thyroid hormones to fetus, thereby 
modifying the relationship between circulating thyroid hormone levels in maternal blood and 
fetal neurodevelopment. That being said, literature on the association between DIO2 and 
circulating thyroid hormone levels has been mixed: previous studies have not found an 
association between variants in DIO2 (including T92A) and T4 or T3 levels or the T3/T4 
ratio.133,139,140 As summarized by Panicker and colleagues, deiodinase type 2 may play less of a 
role in regulating circulating T3 than deiodinase type 1.133  
Deiodinase type 2 is present in the fetal central nervous system as early as 7 weeks’ 
gestation, as well as in the placenta.86,87,193 This deiodinase, particularly in the fetal central 
nervous system, is crucial for producing T3 from maternal T4 to support healthy 
neurodevelopment.83,84 The expression of deiodinase type 2 in the fetal brain increases when 
circulating T4 concentration is low; however, this increased deiodinase type 2 expression has 
not been associated with a corresponding change in thyroid hormone action in the brain.94,101,211 
In other words, changes in fetal deiodinase type 2 activity may not alter the association between 
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maternal thyroid hormone levels and fetal neurodevelopment. In line with this interpretation, 
child SNP T92A in DIO2 did not modify the association between maternal thyroid hormone 
levels and preschool ADHD in our study. However, given the biological importance of fetal 
thyroid hormone conversion for neurodevelopment, as well as our low power to detect effects, 
the role of fetal deiodinases in neurodevelopment remains an important research question.  
Our study has a number of limitations. First, we had only a single measurement of 
maternal thyroid function at 17 weeks’ gestation, although this time point is within a window 
during which the mother is supplying a significant amount of thyroid hormone to the fetus. 
Second, the extent to which symptoms of ADHD in the preschool period arise from the same 
underlying disorder or causes as later childhood ADHD is unclear.31–33,212,213 Thus, our 
classification of cases (which included those who met DSM-IV-TR criteria for ADHD as well as 
those with subthreshold symptoms) might have lower specificity than a later childhood 
assessment of ADHD, potentially reducing statistical power to detect effects. However, 
restricting the case group to only those who met DSM-IV-TR criteria did not change the results 
of our study. Third, our power to detect significant hormone by gene interactions was limited, 
and conducting a large number of tests of interaction increased the probability of spurious 
findings. Fourth, our study included mostly euthyroid women, which might limit our ability to 
detect effects. Limitations aside, null findings are somewhat consistent with past studies of 
maternal thyroid function and ADHD: nearly half of the previous studies reported null or mixed 
effects.59,113,114,214,215 
Our study also had several strengths. It is the first study, to our knowledge, that 
investigated maternal and child genetic variants as potential effect measure modifiers of the 
association between maternal thyroid function and child ADHD. Furthermore, our study used 
high-quality exposure and outcome assessments: maternal thyroid function was based on 
prenatally collected specimen with validated handling, storage, and estimation methods, and 
ADHD was classified by a uniformly administered diagnostic interview with a psychologist 
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following DSM-IV-TR criteria. Finally, we considered a number of important confounders, 
including maternal ADHD, which has not been considered in most previous studies of maternal 
thyroid function and child ADHD.    
Conclusions. This novel investigation examined whether maternal and child variants 
in deiodinase-encoding genes modify the association between maternal prenatal thyroid 
function and preschool ADHD. Studies of maternal thyroid function and child ADHD have 
yielded inconsistent results. Conversion of thyroid hormones by maternal and fetal deiodinases 
may be important modifiers of the effect of maternal thyroid function on fetal 
neurodevelopment. Although we did not find convincing evidence for or against the role of 
thyroid hormone conversion in the development of ADHD, our study is the first step for future 
research considering the role of deiodination in the etiology of neurodevelopmental disorders.  
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5.6 Tables for Paper 1 
 
Table 18. Characteristics of women and children who participated in the ADHD case-cohort study 
nested within the Norwegian Mother and Child Cohort (MoBa), 2004–2008. 
    Cases   Controls   
Characteristic    
Mean (SD) or 
Frequency (%) 
(N = 260)   
Mean (SD) or 
Frequency (%) 
(N = 549)   
Maternal Age at Delivery (years)  30 (4.1)  30.9 (4.2)  
Maternal Pre-Pregnancy BMI (kg/m2) 24.3 (4.7)  23.5 (4)  
Adult ADHD Self-Report Scale Score1  1.7 (1.5)  0.9 (1.2)  
History of Major Depression2 8.7 (2.1)  7.8 (1.9)  
Maternal Smoking During the First Trimester    
 No  197 (76.1)  467 (86.0)  
 Yes   62 (23.9)  76 (14.0)  
 Missing  1  6  
Self-Reported Pre-Existing Thyroid Condition    
 No  250 (96.2)  535 (97.4)  
 Yes  10 (3.8)  14 (2.6)  
 Missing  0  0  
Thyroid Disorder based on Measured Biomarkers3   
 Hyperthyroxinemia  7 (3.1)  15 (3)  
 Hypothyroxinemia  13 (5.8)  14 (2.8)  
 None and not missing TSH, fT4i, or 
 TPOAb 202 (89.4)  459 (92.5)  
 Overt Hyperthyroidism  0 (0)  0 (0)  
 Overt Hypothyroidism  1 (0.4)  0 (0)  
 Subclinical Hyperthyroidism 1 (0.4)  2 (0.4)  
 Subclinical Hypothyroidism  2 (0.9)  6 (1.2)  
 Missing (i.e. missing biomarkers) 34  53  
Thyroid Medication during Pregnancy    
 Yes  9 (3.5)  10 (1.8)  
 No  251 (96.5)  539 (98.2)  
Preeclampsia      
 No   249 (95.8)  531 (96.7)  
 Yes   11 (4.2)  18 (3.3)  
 Missing  0  0  
Low Birth Weight      
 No   249 (95.8)  536 (98.0)  
 Yes  11 (4.2)  11 (2.0)  
 Missing  0  2  
Child Sex      
 Male  145 (55.8)  275 (50.1)  
 Female  115 (44.2)  274 (49.9)  
 Missing   0   0   
1 Computed by summing the number of questions that were indicative of adult ADHD based on the Adult 
ADHD Self-Report Scale206. Higher scores indicate more self-reported symptoms of ADHD.  
2 Computed by summing select responses indicating depression on The Life Time History of Major 
Depression scale.205 Higher scores indicate more self-reported symptoms of depression. 
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3 Clinical definitions based on the following criteria in accordance with Lazarus et al216: overt 
hypothyroidism included individuals with TSH above the reference range, and FT4i below the reference 
range; subclinical hypothyroidism included individuals with TSH above the reference range, FT4i within 
the reference range, and TPO-Ab above 9 IU/mL; hypothyroxinemia included individuals with TSH in the 
reference range and FT4i below the reference range; overt hyperthyroidism included individuals with TSH 
below the reference range and FT4i above the reference range; subclinical hyperthyroidism included 
individuals with TSH below the reference range and FT4i in the reference range; and hyperthyroxinemia 
included individuals with TSH in the reference range, and FT4i above the reference range. 
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Table 19. Distribution of thyroid function biomarkers at 17-18 weeks' gestation among women who participated in the ADHD case-cohort 










    0 20 40 50 60 80 100 
TSH (mu/L)              
 Cases  253  1.8 (1.1) 1.6 (1.7)  0.1 1.1 1.5 1.6 1.8 2.4 8.0 
 Controls  540  1.8 (0.9) 1.6 (1.7)  0.0 1.1 1.5 1.7 1.9 2.4 5.9 
TT3 (ng/dL)              
 Cases  254  170.5 (28.5) 168.2 (1.2)  105.0 147.0 162.2 168.0 173.8 191.4 284.0 
 Controls  540  165.3 (26.5) 163.2 (1.2)  104.0 142.0 158.0 163.0 169.4 186.0 283.0 
TT4 (ug/dL)              
 Cases  255  10.6 (1.8) 10.4 (1.2)  6.7 9.1 10.0 10.5 11.0 11.9 18.1 
 Controls  540  10.6 (1.6) 10.4 (1.2)  6.9 9.2 10.0 10.4 10.8 11.8 17.8 
fT3i               
 Cases  252  167.8 (24.6) 166.1 (1.2)  112.5 148.0 161.2 165.9 170.2 185.8 263.7 
 Controls  536  164.1 (23.8) 162.5 (1.2)  109.0 144.6 157.2 162.0 168.8 182.1 285.6 
fT4i              
 Cases  252  10.5 (1.9) 10.3 (1.2)  6.6 8.9 9.9 10.2 10.7 11.9 19.3 
 Controls  536  10.5 (1.8) 10.4 (1.2)  6.3 9.1 9.9 10.3 10.7 11.8 21.7 
TPOAb (IU/mL)              
 Cases  232  11.8 (70.7) 1.1 (4.4)  0.3 0.4 0.6 0.7 0.8 1.9 947.0 
 Controls  503  12.4 (74.2) 1.2 (4.6)  0.3 0.4 0.6 0.7 0.9 2.1 
1278.
0 
Abbreviations: Attention Deficit Hyperactivity Disorder (ADHD), Norwegian Mother and Child Birth Cohort (MoBa), thyroid stimulating hormone 
(TSH), total triiodothyronine (TT3), total thyroxine (TT4), free triiodothyronine index (fT3i), free thyroxine index (fT4i). 
1 Cases included 114 preschool-aged children who met DSM-IV-TR criteria for ADHD plus 146 preschool-aged children who had sub-threshold 
symptoms of ADHD using the Preschool Age Psychiatric Assessment (PAPA). Controls included a random sample of 549 children who were 
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Table 20. Odds ratios for offspring ADHD1 according to category of thyroid function and SNPs in 
the ADHD case-cohort study nested within the Norwegian Mother and Child Cohort (MoBa), 2004–
2008. 
Exposure2 
Odds Ratio of 
ADHD  
Overall Effect  
(95% CI)3 χ2 (p-value)4 
Maternal Thyroid Function     
 TSH (mu/L)   
  0.04-1.31 0.98 (0.67, 1.43) 1.4 (0.51) 
  1.31-2.01 1  
  2.01-8.01 0.81 (0.55, 1.2)  
 TT3 (ng/dL)   
  104-154 0.91 (0.62, 1.34) 0.3 (0.87) 
  154-176 1  
  176-284 0.92 (0.62, 1.35)  
 fT3i   
  109-155 0.78 (0.53, 1.15) 2.2 (0.34) 
  155-173 1  
  173-286 0.78 (0.53, 1.15)  
 TT4 (ug/dL)   
  6.69-9.8 1.15 (0.78, 1.7) 0.5 (0.78) 
  9.8-11.2 1  
  11.2-18.1 1.06 (0.72, 1.57)  
 fT4i   
  6.29-9.64 1.17 (0.79, 1.74) 0.7 (0.69) 
  9.64-11.1 1  
  11.1-21.7 1.14 (0.77, 1.69)  
 TPOAb (IU/mL)  
 
  < 9 1 0.6 (0.45) 
  ≥ 9 1.22 (0.72, 2.06)  
Genetic Variants  
 
 Maternal rs2235544 (DIO1, A/C)  
 
  Per C allele (additive model) 1.14 (0.92, 1.42) 1.4 (0.24) 
 Maternal rs225014 (T92A, DIO2, C/T)  
 
  Per C allele (additive model) 1.04 (0.83, 1.29) 0.1 (0.74) 
 Child rs225014 (T92A, DIO2, C/T)  
 
  Per C allele (additive model) 0.94 (0.73, 1.2) 0.3 (0.61) 
Abbreviations: Attention Deficit Hyperactivity Disorder (ADHD), Norwegian Mother and Child Birth 
Cohort (MoBa), confidence interval (CI), single nucleotide polymorphism (SNP), thyroid stimulating 
hormone (TSH), total triiodothyronine (TT3), total thyroxine (TT4), free triiodothyronine index (fT3i), free 
thyroxine index (fT4i).  
1 Cases included 114 preschool-aged children who met DSM-IV-TR criteria for ADHD plus 146 preschool-
aged children who had sub-threshold symptoms of ADHD using the Preschool Age Psychiatric 
Assessment (PAPA). Controls included a random sample of 549 children who were eligible for the ADHD 
sub-study.   
2 TSH, TT3, TT4, fT3i, and fT4i were modelled using tertile categories. TPOAb was modelled using a 
dichotomous cut-off at 9 IU/mL. SNPs were modelled using an additive model with the most common 
homozygote as the referent. The presented odds ratios are per each added allele of the less common 
allele.  
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3 Odds ratio of ADHD with the middle tertile of each thyroid function biomarker as the referent, or with the 
heterozygous genotype as the referent. Adjustment factors in the models estimating the effect of maternal 
thyroid function included: maternal smoking during pregnancy, maternal age, maternal self-reported 
history of depression, maternal self-reported symptoms of ADHD, and child sex. There were no 
adjustment factors in the models estimating the effects of maternal SNPs. The model estimating the effect 
of the child SNP including maternal rs225014 as an adjustment factor. All analyses were conducted using 
multiple imputation with m=20 imputed datasets and combined using Rubin’s rules using the aregImpute 
and fit.mult.impute functions of the Hmsic R package.208 
4 The χ2 (p) are the test of the overall effect of the exposure on odds of ADHD.  
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Table 21. Maternal and child SNP-stratified estimates of association between maternal thyroid function biomarkers and offspring ADHD1 
in the case-cohort study nested within the Norwegian Mother and Child Cohort (MoBa), 2003-2008.   
Thyroid 







Odds Ratio  
(95% CI)4 
Interaction 
Effect χ2 (p 
value)5 
TT3 Maternal rs2235544 (DIO1) AA 1 54/22 1.07 (0.52, 2.17) 1.68 (0.43) 
   2 39/13 1  
    3 41/22 1.38 (0.68, 2.8)  
  CA 1 99/31 0.94 (0.64, 1.4)  
   2 89/49 1  
    3 82/40 0.96 (0.65, 1.41)  
  CC 1 36/20 0.84 (0.42, 1.69)  
   2 36/24 1  
     3 45/20 0.66 (0.33, 1.31)   
 Maternal rs225014 (DIO2) TT 1 69/30 1.07 (0.59, 1.91) 0.56 (0.76) 
   2 76/38 1  
    3 75/34 0.96 (0.55, 1.68)  
  CT 1 93/34 0.87 (0.57, 1.33)  
   2 70/39 1  
    3 72/35 0.94 (0.62, 1.44)  
  CC 1 25/10 0.71 (0.3, 1.67)  
   2 18/9 1  
      3 21/14 0.93 (0.4, 2.14)   
fT3i Maternal rs2235544 (DIO1) AA 1 53/21 1.03 (0.52, 2.05) 1.76 (0.41) 
   2 42/19 1  
    3 39/16 1.12 (0.56, 2.25)  
  CA 1 101/33 0.79 (0.53, 1.18)  
   2 83/42 1  
    3 84/44 0.77 (0.52, 1.15)  
  CC 1 38/18 0.61 (0.3, 1.23)  
   2 31/28 1  
     3 46/18 0.53 (0.27, 1.06)   
 Maternal rs225014 (DIO2) TT 1 70/30 1.08 (0.6, 1.93) 1.78 (0.41) 
   2 79/41 1  
    3 71/30 0.98 (0.56, 1.72)  
  CT 1 97/32 0.73 (0.48, 1.12)  
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    3 74/37 0.75 (0. 49, 1.15)  
  CC 1 23/11 0.49 (0.21, 1.16)  
   2 16/11 1  
      3 24/11 0.57 (0.24, 1.33)   
TT4 Maternal rs2235544 (DIO1) AA 1 37/24 1.52 (0.76, 3.05) 0.97 (0.62) 
   2 49/14 1  
    3 49/20 1.23 (0.6, 2.5)  
  CA 1 92/31 1.15 (0.77, 1.7)  
   2 86/41 1  
    3 92/48 1.07 (0.72, 1.6)  
  CC 1 45/29 0.87 (0.44, 1.7)  
   2 41/19 1  
     3 31/16 0.94 (0.46, 1.93)   
 Maternal rs225014 (DIO2) TT 1 73/41 1.07 (0.61, 1.88) 1.51 (0.47) 
   2 74/34 1  
    3 74/27 0.81 (0.45, 1.46)  
  CT 1 76/30 1.15 (0.75, 1.76)  
   2 84/32 1  
    3 75/46 1.15 (0.75, 1.77)  
  CC 1 25/14 1.23 (0.53, 2.87)  
   2 18/8 1  
     3 21/11 1.63 (0.69, 3.84)   
 Child rs225014 (DIO2) TT 1 59/34 1.14 (0.64, 2.01) 0.6 (0.74) 
   2 51/26 1  
    3 60/23 0.89 (0.5, 1.6)  
  CT 1 69/26 1.13 (0.74, 1.75)  
   2 56/32 1  
    3 56/29 1.09 (0.71, 1.67)  
  CC 1 18/8 1.13 (0.48, 2.71)  
   2 20/7 1  
      3 20/11 1.33 (0.56, 3.15)   
fT4i Maternal rs2235544 (DIO1) AA 1 36/25 1.61 (0.79, 3.27) 1.22 (0.54) 
   2 48/11 1  
    3 50/20 1.34 (0.65, 2.74)  
  CA 1 85/29 1.17 (0.79, 1.73)  
   2 95/45 1  
    3 89/45 1.14 (0.77, 1.7)  
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   2 36/16 1  
     3 32/19 0.97 (0.48, 1.98)   
 Maternal rs225014 (DIO2) TT 1 67/42 1.31 (0.74, 2.32) 0.95 (0.62) 
   2 78/30 1  
    3 74/29 1.03 (0.57, 1.85)  
  CT 1 75/28 1.13 (0.73, 1.73)  
   2 83/34   
    3 75/45 1.17 (0.76, 1.8)  
  CC 1 25/15 0.96 (0.41, 2.25)  
   2 17/8 1  
     3 21/10 1.33 (0.55, 3.19)   
 Child rs225014 (DIO2) TT 1 56/31 1.39 (0.77, 2.49) 0.69 (0.71) 
   2 50/24 1  
    3 63/27 1.13 (0.63, 2.02)  
  CT 1 64/29 1.12 (0.73, 1.72)  
   2 62/31 1  
    3 55/28 1.14 (0.74, 1.74)  
  CC 1 19/7 0.91 (0.38, 2.14)  
   2 19/9 1  
      3 18/10 1.15 (0.49, 2.67)   
Abbreviations: Attention Deficit Hyperactivity Disorder (ADHD), Norwegian Mother and Child Birth Cohort (MoBa), confidence interval (CI), single 
nucleotide polymorphism (SNP), thyroid stimulating hormone (TSH), total triiodothyronine (TT3), total thyroxine (TT4), free triiodothyronine index 
(fT3i), free thyroxine index (fT4i).  
1 Cases included 114 preschool-aged children who met DSM-IV-TR criteria for ADHD plus 146 preschool-aged children who had sub-threshold 
symptoms of ADHD using the Preschool Age Psychiatric Assessment (PAPA). Controls included a random sample of 549 children who were 
eligible for the ADHD sub-study.   
2 TSH, TT3, TT4, fT3i, and fT4i were modelled using tertile categories. TPOAb was modelled using a dichotomous cut-off at 9 IU/mL.  
3 SNPs were modelled using an additive model with the most common heterozygote as the referent; stratified estimates were produced from 
model contrasts.  
4 Odds ratio of ADHD with the middle tertile of each thyroid function biomarker as the referent, stratified by genotype from a model with SNPs 
coded additively. Adjustment factors in the models included: maternal smoking during pregnancy, maternal age, maternal self-reported history of 
depression, maternal self-reported symptoms of ADHD, and child sex. All analyses were conducted using multiple imputation with m=20 imputed 
datasets and combined using Rubin’s rules using the aregImpute and fit.mult.impute functions of the Hmsic R package.208 
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5.7 Figure for Paper 1 
 
 
Figure 8. Summary of selection into the study sample. Those who screened negative but were invited to 
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5.8 Supplement for Paper 1  
 
Table 22. Frequency of genotypes of select maternal and child SNPs among women and their children in 
the ADHD case-cohort study nested within the Norwegian Mother and Child Cohort (MoBa), 2003-2008, 
broken down by child ADHD status (ADHD case and control). 
      Cases (N = 260)   Controls (N = 549)   

















DIO2 rs225014 CC 35 (14.1)  27 (13.4)  66 (12.5)  59 (14.1)  
 
 CT 112 (45.0)  91 (45.3)  239 (45.2)  185 (44.4)  
 
 TT 102 (41.0)  83 (41.3)  224 (42.3)  173 (41.5)  
DIO1 rs2235544 AA 59 (23.9)   44 (21.8)   137 (25.8)   114 (27.0)   
    CA 121 (49.0)   101 (50.0)   275 (51.8)   196 (46.4)   
    CC 67 (27.1)   57 (28.2)   119 (22.4)   112 (26.5)   
Abbreviations: Attention Deficit Hyperactivity Disorder (ADHD), Norwegian Mother and Child Birth 
Cohort (MoBa), single nucleotide polymorphism (SNP).  
 
Table 23. Tests of Hardy-Weinberg Equilibrium (HWE) for select maternal and child SNPs among women 
and their children in the ADHD case-cohort study nested within the Norwegian Mother and Child Cohort 
(MoBa), 2003-2008, among controls only.  
Sample SNP (Gene) 
Test of HWE 
χ2 (p value) 
Mother rs2235544 (DIO1) 0.6 (0.43) 
 rs225014 (DIO2) 0 (0.91) 
Child rs2235544 (DIO1) 1.9 (0.17) 
  rs225014 (DIO2) 0.6 (0.45) 
Abbreviations: Attention Deficit Hyperactivity Disorder (ADHD), Norwegian Mother and Child Birth 




 79  
  
Table 24. Tests of main effects of maternal thyroid function biomarkers on offspring ADHD in the ADHD 
case-cohort study nested within the Norwegian Mother and Child Cohort (MoBa), 2003–2008, additionally 
adjusting for maternal pre-pregnancy BMI.  
Thyroid Function Biomarker1 
Odds Ratio of ADHD  
(95% CI)2 
Overall Effect  
χ2 (p-value)3 
Maternal Thyroid Function Biomarkers  
 TSH (units)   
  0.04-1.31 0.95 (0.65, 1.39) 1.8 (0.42) 
  1.31-2.01 1  
  2.01-8.01 0.78 (0.52, 1.15)  
 TT3   
  104-154 0.97 (0.66, 1.43) 1.4 (0.49) 
  154-176 1  
  176-284 0.79 (0.53, 1.19)  
 TT4   
  6.69-9.8 1.17 (0.79, 1.73) 0.6 (0.73) 
  9.8-11.2 1  
  11.2-18.1 1.07 (0.72, 1.58)  
 fT3i   
  109-155 0.82 (0.56, 1.22) 3.2 (0.20) 
  155-173 1  
  173-286 0.7 (0.47, 1.04)  
 fT4i   
  6.29-9.64 1.15 (0.77, 1.70) 0.6 (0.74) 
  9.64-11.1 1  
  11.1-21.7 1.14 (0.77, 1.69)  
 TPOAb   
  < 9 1 0.5 (0.49) 
  ≥ 9 1.2 (0.71, 2.03)  
Abbreviations: Attention Deficit Hyperactivity Disorder (ADHD), body mass index (BMI), Norwegian 
Mother and Child Birth Cohort (MoBa), confidence interval (CI), thyroid stimulating hormone (TSH), total 
triiodothyronine (TT3), total thyroxine (TT4), free triiodothyronine index (fT3i), free thyroxine index (fT4i).  
1 TSH, TT3, TT4, fT3i, and fT4i were modelled using tertile categories. TPOAb was modelled using a 
dichotomous cut-off at 9 IU/mL.  
2 Odds ratio of ADHD with the middle tertile of each thyroid function biomarker as the referent. Adjustment 
factors in the models estimating the effect of maternal thyroid function included: maternal smoking during 
pregnancy, maternal age, maternal self-reported history of depression, maternal self-reported symptoms 
of ADHD, child sex, and maternal pre-pregnancy body mass index (BMI). Analyses were aggregated 
across 20 datasets with multiply-imputed missing values (though findings were similar in complete-case 
analyses). 
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Table 25. Tests of main effects of maternal thyroid function biomarkers and maternal and child SNPs on 
offspring ADHD in the ADHD case-cohort study nested within the Norwegian Mother and Child Cohort 
(MoBa), 2003–2008, restricting to euthyroid women1 and their children.  
Thyroid Function Biomarker2 
Odds Ratio of 
ADHD (95% CI)3 
Overall Effect  
χ2 (p-value)4 
Maternal Thyroid Function Biomarkers 
 TSH (units)   
  0.04-1.31 0.97 (0.64, 1.45) 0.7 (0.72) 
  1.31-2.01 1  
  2.01-8.01 0.85 (0.56, 1.28)  
 TT3   
  104-154 0.91 (0.60, 1.38) 0.3 (0.88) 
  154-176 1  
  176-284 0.91 (0.61, 1.38)  
 TT4   
  6.69-9.8 1.06 (0.7, 1.6) 0.1 (0.94) 
  9.8-11.2 1  
  11.2-18.1 1.07 (0.71, 1.61)  
 fT3i   
  109-155 0.81 (0.54, 1.23) 1.4 (0.48) 
  155-173 1  
  173-286 0.8 (0.53, 1.21)  
 fT4i   
  6.29-9.64 1.09 (0.72, 1.65) 0.4 (0.81) 
  9.64-11.1 1  
  11.1-21.7 1.14 (0.76, 1.72)  
 TPOAb   
  < 9 1 0.1 (0.82) 
  ≥ 9 1.08 (0.58, 2.0)  
Genetic Variants 
 Maternal rs2235544 (DIO1, A/C) 
  Per C allele (additive model) 1.19 (0.95, 1.49) 2.2 (0.14) 
 Maternal rs225014 (DIO2, C/T) 
  Per C allele (additive model) 1.04 (0.82, 1.31) 0.1 (0.75) 
 Child rs225014 (DIO2, C/T)  
  Per C allele (additive model) 1.02 (0.8, 1.32) 0.0 (0.85) 
Abbreviations: Attention Deficit Hyperactivity Disorder (ADHD), Norwegian Mother and Child Birth 
Cohort (MoBa), Medical Birth Registry of Norway (MBRN), confidence interval (CI), single nucleotide 
polymorphism (SNP), thyroid stimulating hormone (TSH), total triiodothyronine (TT3), total thyroxine 
(TT4), free triiodothyronine index (fT3i), free thyroxine index (fT4i).  
1 The euthyroid sample included those with no self-reported or MBRN registered preexisting maternal 
thyroid condition, no thyroid conditions based on measured biomarkers and reference ranges, and no 
self-reported thyroid medications (see Table 1). Of the 809 mother/child pairs with outcome assessment, 
726 were included in the euthyroid analysis. 
2 TSH, TT3, TT4, fT3i, and fT4i were modelled using tertile categories. TPOAb was modelled using a 
dichotomous cut-off at 9 IU/mL. SNPs were modelled using an additive model with the most common 
homozygote as the referent. The presented odds ratios are per each added allele of the less common 
allele. 
3 Odds ratio of ADHD with the middle tertile of each thyroid function biomarker as the referent, or with the 
heterozygous genotype as the referent. Adjustment factors in the models estimating the effect of maternal 
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thyroid function included: maternal smoking during pregnancy, maternal age, maternal self-reported 
history of depression, maternal self-reported symptoms of ADHD, and child sex. There were no 
adjustment factors in the models estimating the effects of maternal SNPs. The model estimating the effect 
of the child SNP including maternal rs225014 as an adjustment factor. Analyses were aggregated across 
20 datasets with multiply-imputed missing values (though findings were similar in complete-case 
analyses). 











CHAPTER 6. ANALYSES SUPPORTING PAPER 1 
6.1 Allelic Correlation (Linkage Disequilibrium) between SNPs from DIO2 
The DIO2 SNPs were highly linked among control children and among mothers of 
children without ADHD (Tables 26, 27). Unsurprisingly, when I analyzed effect measure 
modification by each of DIO2 SNPs, the results were very similar. I therefore decided to focus 
analyses on the DIO2 SNP with the most supporting literature: rs225014. For this reason, I do 
not present effect measure modification results by the other two DIO2 SNPs (rs225011, 
rs225012).  
 
Table 26. Allelic correlations (linkage disequilibrium) for maternal SNPs in DIO2 among women whose 
children were in the ADHD case-cohort study nested within the Norwegian Mother and Child Cohort 
(MoBa), 2003-2008. Linkage disequilibrium was tested among controls only (women of children without 
ADHD). 
 rs225011 rs225012 rs225014 
rs225011   0.98786 0.62198 
rs225012     0.62865 
rs225014       
Abbreviations: Attention Deficit Hyperactivity Disorder (ADHD), Norwegian Mother and Child Birth 
Cohort (MoBa), single nucleotide polymorphism (SNP).  
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Table 27. Allelic correlations (linkage disequilibrium) for maternal SNPs in DIO2 among control children in 
the ADHD case-cohort study nested within the Norwegian Mother and Child Cohort (MoBa), 2003-2008. 
 rs225011 rs225012 rs225014 
rs225011   0.98485 0.58811 
rs225012     0.59307 
rs225014       
Abbreviations: Attention Deficit Hyperactivity Disorder (ADHD), Norwegian Mother and Child Birth 
Cohort (MoBa), single nucleotide polymorphism (SNP).  
 
6.2. Thyroid Function Biomarker Levels Stratified by Genotype  
Crude tests of association revealed that the maternal SNP rs12101255 in TSHR was 
associated with maternal TT4 and fT4i levels: the CC genotype was associated with lower levels 
of TT4 and fT4i and the TT genotype was associated with higher levels of TT4 and fT4i (Table 
28). Additionally, the maternal SNP rs2235544 in DIO1 was associated with fT4i levels: CC was 
associated with lower levels of fT4i and AA was associated with higher levels of fT4i. There was a 
similar pattern of association between rs2235544 and TT4. Table 28 presents genotype-
stratified means of maternal thyroid function biomarkers. Interpretations of these findings are 
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Table 28. Mean maternal thyroid function biomarker levels by maternal genotype of select SNPs, with tests to assess whether means differed by 















F (p value) 
 TSH (mu/L) 
rs2235544 
(DIO1) AA 135 1.64 (1.74) 1.85 (0.88) 0.04-5.55 0.9 (0.63) 0.2 (0.84) 
    CA 270 1.57 (1.73) 1.79 (0.91) 0.09-5.79     
    CC 117 1.62 (1.68) 1.83 (0.96) 0.28-5.92     
  
rs225011 
(DIO2) CC 93 1.74 (1.7) 1.98 (1.01) 0.37-5.23 3.7 (0.16) 2.0 (0.13) 
    CT 247 1.57 (1.65) 1.76 (0.88) 0.22-5.79     
    TT 182 1.56 (1.83) 1.8 (0.91) 0.04-5.92     
  
rs225012 
(DIO2) AA 181 1.56 (1.84) 1.8 (0.91) 0.04-5.92 3.0 (0.22) 1.7 (0.18) 
    GA 246 1.57 (1.65) 1.76 (0.88) 0.22-5.79     
    GG 95 1.73 (1.69) 1.97 (1) 0.37-5.23     
  
rs225014 
(DIO2) CC 64 1.57 (1.84) 1.85 (1.06) 0.26-5.23 0.3 (0.84) 0.1 (0.92) 
    CT 235 1.64 (1.6) 1.81 (0.85) 0.22-5.79     
    TT 221 1.56 (1.82) 1.8 (0.94) 0.04-5.92     
 TT3 (ng/dL) 
rs2235544 
(DIO1) AA 135 160.46 (1.17) 162.45 (25.45) 104-230 4.8 (0.09) 2.6 (0.08) 
    CA 270 162.08 (1.17) 164.17 (26.82) 106-283     
    CC 117 167.65 (1.17) 169.67 (26.54) 114-258     
  
rs225011 
(DIO2) CC 93 164 (1.18) 166.33 (28.39) 110-258 2.6 (0.27) 1.0 (0.36) 
    CT 248 161.26 (1.17) 163.18 (25.6) 104-283     
    TT 181 164.47 (1.18) 166.6 (26.7) 106-254     
  
rs225012 
(DIO2) AA 180 164.42 (1.18) 166.56 (26.77) 106-254 2.3 (0.32) 0.9 (0.42) 
    GA 247 161.38 (1.17) 163.3 (25.61) 104-283     
    GG 95 163.65 (1.18) 165.95 (28.21) 110-258     
  
rs225014 
(DIO2) CC 64 163.71 (1.18) 165.91 (27.15) 110-236 1.4 (0.49) 0.3 (0.72) 
    CT 236 161.85 (1.17) 163.94 (26.89) 104-283     
    TT 220 163.89 (1.17) 165.81 (25.37) 106-254     
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(DIO1) 
    CA 270 10.44 (1.16) 10.55 (1.56) 6.94-15.91     
    CC 117 10.22 (1.18) 10.35 (1.71) 7.04-15.48     
  
rs225011 
(DIO2) CC 93 10.54 (1.18) 10.68 (1.79) 7.16-15.48 1.2 (0.55) 0.9 (0.4) 
    CT 247 10.35 (1.15) 10.45 (1.49) 6.94-14.97     
    TT 182 10.49 (1.16) 10.61 (1.62) 7.04-17.83     
  
rs225012 
(DIO2) AA 181 10.5 (1.16) 10.62 (1.62) 7.04-17.83 0.9 (0.65) 0.7 (0.5) 
    GA 246 10.36 (1.15) 10.47 (1.49) 6.94-14.97     
    GG 95 10.51 (1.18) 10.66 (1.79) 7.16-15.48     
  
rs225014 
(DIO2) CC 64 10.28 (1.19) 10.43 (1.78) 7.22-14.41 0.7 (0.72) 0.3 (0.71) 
    CT 235 10.42 (1.16) 10.53 (1.54) 6.94-15.48     
    TT 221 10.5 (1.16) 10.61 (1.59) 7.04-17.83     
 fT3i 
rs2235544 
(DIO1) AA 134 159.68 (1.15) 161.22 (22.34) 115.14-216.14 4.0 (0.13) 2.3 (0.1) 
    CA 269 161.79 (1.16) 163.5 (24.04) 109-252.68     
    CC 115 165.99 (1.15) 167.66 (24.44) 124.29-285.64     
  
rs225011 
(DIO2) CC 92 164.32 (1.17) 166.29 (26.59) 117.86-285.64 4.0 (0.13) 2.2 (0.11) 
    CT 245 160.12 (1.14) 161.58 (21.95) 109-252.68     
    TT 181 163.95 (1.16) 165.72 (24.45) 113.57-240     
  
rs225012 
(DIO2) AA 180 163.84 (1.16) 165.61 (24.48) 113.57-240 3.5 (0.17) 1.9 (0.14) 
    GA 244 160.2 (1.14) 161.65 (21.95) 109-252.68     
    GG 94 164.07 (1.17) 166.02 (26.43) 117.86-285.64     
  
rs225014 
(DIO2) CC 63 163.67 (1.16) 165.34 (23.66) 117.86-222.5 2.5 (0.28) 0.6 (0.57) 
    CT 233 160.95 (1.16) 162.7 (24.62) 109-285.64     
    TT 220 163.25 (1.15) 164.78 (22.67) 113.57-240     
 fT4i 
rs2235544 
(DIO1) AA 134 10.6 (1.17) 10.73 (1.79) 6.67-21.65 7.1 (0.03) 2.4 (0.09) 
    CA 269 10.4 (1.16) 10.52 (1.63) 7.03-16.48     
    CC 115 10.1 (1.19) 10.25 (1.83) 6.29-17.14     
  
rs225011 
(DIO2) CC 92 10.55 (1.19) 10.71 (1.87) 6.9-17.14 1.9 (0.39) 1.5 (0.22) 
    CT 245 10.26 (1.16) 10.38 (1. 55) 6.67-14.81     
    TT 181 10.44 (1.18) 10.59 (1.87) 6.29-21.65     
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(DIO2) 
    GA 244 10.28 (1.16) 10.39 (1.55) 6.67-14.81     
    GG 94 10.54 (1.19) 10.7 (1.89) 6.9-17.14     
  
rs225014 
(DIO2) CC 63 10.27 (1.19) 10.43 (1.83) 6.96-14.56 0.6 (0.76) 0.3 (0.74) 
    CT 233 10.35 (1.17) 10.48 (1.64) 6.67-17.14     
    TT 220 10.44 (1.18) 10.58 (1.79) 6.29-21.65     
TPOAb (iu/mL) 
rs2235544 
(DIO1) AA 125 1.26 (5.46) 18.54 (115.96) 0.3-1278 0.4 (0.82) 1.0 (0.37) 
    CA 251 1.13 (4.2) 8.16 (32.67) 0.3-364.1     
    CC 110 1.26 (4.94) 16.75 (86.5) 0.3-813.9     
  
rs225011 
(DIO2) CC 87 1.23 (3.98) 5.62 (15.26) 0.3-74.1 2.6 (0.28) 1.5 (0.23) 
    CT 227 1.16 (5.16) 18.96 (107.49) 0.3-1278     
    TT 172 1.2 (4.44) 8.21 (25.75) 0.3-174.4     
  
rs225012 
(DIO2) AA 171 1.19 (4.41) 8.17 (25.82) 0.3-174.4 1.9 (0.38) 1.5 (0.22) 
    GA 226 1.16 (5.16) 19.05 (107.72) 0.3-1278     
    GG 89 1.2 (3.95) 5.51 (15.11) 0.3-74.1     
  rs225014 
(DIO2) CC 60 1.12 (3.55) 4.54 (13.72) 0.3-74.1 1.1 (0.59) 1.2 (0.3) 
    CT 217 1.14 (4.63) 9.43 (36.45) 0.3-364.1     
    TT 207 1.27 (5.12) 18.77 (109.03) 0.3-1278     
Abbreviations: Attention Deficit Hyperactivity Disorder (ADHD), Norwegian Mother and Child Birth Cohort (MoBa), confidence interval (CI), single 
nucleotide polymorphism (SNP), thyroid stimulating hormone (TSH), total triiodothyronine (TT3), total thyroxine (TT4), free triiodothyronine index 
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6.3. Effect Measure Modification by Maternal Dietary Selenium and Iodine 
Intake 
Neither maternal dietary iodine intake nor maternal dietary selenium intake were effect 
measure modifiers of the association between maternal thyroid function and odds of ADHD 
(Tables 29, 30). Stratified odds ratio estimates are presented in Tables 29 and 30. Using total 
iodine intake (supplement plus dietary iodine) as opposed to only dietary iodine did not 
meaningfully affect results. In both cases, a cutoff of 150 ug/day was used. Total iodine intake 
had more missing data. The analyses presented here used dietary iodine intake. 
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Table 29. Maternal iodine-stratified estimates of association between maternal thyroid function 
biomarkers and offspring ADHD in the case-cohort study nested within the Norwegian Mother and Child 
Cohort (MoBa), 2003-2008.  
  
High Iodine  
(≥150 ug/day) 
N=2311 
Low Iodine  
(<150 ug/day)  
N=5671   
Thyroid Function 
Biomarker2 
Odds Ratio of 
ADHD (95% CI)3 
Odds Ratio of 
ADHD (95% CI)3 
Interaction Effect χ2 (p-
value)4 
TSH (mu/L)       
 0.04-1.31 1.0 (0.48, 2.11) 0.97 (0.62, 1.52) 0.47 (0.79) 
 1.31-2.01 1 1   
 2.01-8.01 0.99 (0.47, 2.11) 0.74 (0.46, 1.18)   
TT3 (ng/dL)       
 104-154 0.70 (0.32, 1.53) 1.01 (0.65, 1.59) 2.12 (0.35) 
 154-176 1 1   
 176-284 1.17 (0.55, 2.45) 0.86 (0.54, 1.36)   
fT3i       
 109-155 0.63 (0.29, 1.34) 0.86 (0.54, 1.35) 2.04 (0.36) 
 155-173 1 1   
 173-286 0.47 (0.22, 1.03) 0.92 (0.58, 1.46)   
TT4 (ug/dL)       
 6.69-9.8 1.11 (0.52, 2.4) 1.11 (0.71, 1.76) 0.06 (0.97) 
 9.8-11.2 1 1   
 11.2-18.1 1.11 (0.51, 2.41) 1 (0.63, 1.59)   
fT4i       
 6.29-9.64 1.01 (0.46, 2.21) 1.21 (0.76, 1.92) 0.61 (0.74) 
 9.64-11.1 1 1   
 11.1-21.7 0.86 (0.4, 1.87) 1.24 (0.78, 1.97)   
TPOAb (IU/mL)       
 < 9 1 1 2.38 (0.12) 
 ≥ 9 0.56 (0.17, 1.84) 1.62 (0.88, 2.98)   
Abbreviations: Attention Deficit Hyperactivity Disorder (ADHD), Norwegian Mother and Child Birth 
Cohort (MoBa), confidence interval (CI), single nucleotide polymorphism (SNP), thyroid stimulating 
hormone (TSH), total triiodothyronine (TT3), total thyroxine (TT4), free triiodothyronine index (fT3i), free 
thyroxine index (fT4i).  
1 These are the numbers of complete-case observations for high and low iodine; the distribution of high 
and low iodine may differ across multiple imputations. 
2 TSH, TT3, TT4, fT3i, and fT4i were modelled using tertile categories. TPOAb was modelled using a 
dichotomous cut-off at 9 IU/mL.  
3 Odds ratio of ADHD with the middle tertile of each thyroid function biomarker as the referent. Adjustment 
factors in the models estimating the effect of maternal thyroid function included: maternal smoking during 
pregnancy, maternal age, maternal self-reported history of depression, maternal self-reported symptoms 
of ADHD, and child sex. All analyses were conducted using multiple imputation with m=20 imputed 
datasets and combined using Rubin’s rules using the aregImpute and fit.mult.impute functions of the 
Hmsic R package.208 
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Table 30. Maternal selenium-stratified estimates of association between maternal thyroid function 
biomarkers and offspring ADHD in the case-cohort study nested within the Norwegian Mother and Child 
Cohort (MoBa), 2003-2008.  
  
High Selenium 




N=5521   
Thyroid Function 
Biomarker2 
Odds Ratio of 
ADHD (95% CI)3 
Odds Ratio of 
ADHD (95% CI)3 
Interaction Effect χ2 (p-
value)4 
TSH (mu/L)       
 0.04-1.31 1.28 (0.62, 2.65) 0.89 (0.56, 1.4) 1.48 (0.48) 
 1.31-2.01 1 1   
 2.01-8.01 0.7 (0.33, 1.5) 0.84 (0.53, 1.34)   
TT3 (ng/dL)       
 104-154 0.93 (0.44, 1.95) 0.96 (0.61, 1.52) 0.6 (0.74) 
 154-176 1 1   
 176-284 1.16 (0.53, 2.53) 0.86 (0.55, 1.35)   
fT3i       
 109-155 0.52 (0.25, 1.09) 0.93 (0.59, 1.48) 2.82 (0.24) 
 155-173 1 1   
 173-286 0.47 (0.21, 1.01) 0.95 (0.6, 1.5)   
TT4 (ug/dL)       
 6.69-9.8 0.81 (0.38, 1.71) 1.31 (0.83, 2.08) 1.51 (0.47) 
 9.8-11.2 1 1   
 11.2-18.1 0.73 (0.33, 1.6) 1.2 (0.76, 1.9)   
fT4i       
 6.29-9.64 0.89 (0.42, 1.9) 1.34 (0.84, 2.13) 1.04 (0.59) 
 9.64-11.1 1 1   
 11.1-21.7 0.85 (0.39, 1.86) 1.28 (0.81, 2.03)  
TPOAb (IU/mL)       
 < 9 1 1 1.2 (0.27)  
 ≥ 9 0.75 (0.25, 2.21) 1.5 (0.82, 2.77)   
Abbreviations: Attention Deficit Hyperactivity Disorder (ADHD), Norwegian Mother and Child Birth 
Cohort (MoBa), confidence interval (CI), single nucleotide polymorphism (SNP), thyroid stimulating 
hormone (TSH), total triiodothyronine (TT3), total thyroxine (TT4), free triiodothyronine index (fT3i), free 
thyroxine index (fT4i).  
1 These are the numbers of complete-case observations for high and low selenium; the distribution of high 
and low selenium may differ across multiple imputations. 
2 TSH, TT3, TT4, fT3i, and fT4i were modelled using tertile categories. TPOAb was modelled using a 
dichotomous cut-off at 9 IU/mL.  
3 Odds ratio of ADHD with the middle tertile of each thyroid function biomarker as the referent. Adjustment 
factors in the models estimating the effect of maternal thyroid function included: maternal smoking during 
pregnancy, maternal age, maternal self-reported history of depression, maternal self-reported symptoms 
of ADHD, and child sex. All analyses were conducted using multiple imputation with m=20 imputed 
datasets and combined using Rubin’s rules using the aregImpute and fit.mult.impute functions of the 
Hmsic R package.208 
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6.4 Effect Measure Modification by Child Sex 
Child sex was not an effect measure modifier of the association between maternal 
thyroid function and odds of ADHD (Table 31). 
Table 31. Child sex-stratified estimates of association between maternal thyroid function biomarkers and 
offspring ADHD in the case-cohort study nested within the Norwegian Mother and Child Cohort (MoBa), 
2003-2008.  
  Male N=4201 Femaile N=3891  
Thyroid Function 
Biomarker2 
Odds Ratio of 
ADHD (95% CI)3 




TSH (mu/L)    
 0.04-1.31 0.87 (0.52, 1.45) 1.13 (0.63, 2.02) 0.94 (0.62) 
 1.31-2.01 1 1  
 2.01-8.01 0.67 (0.4, 1.15) 0.98 (0.55, 1.76)  
TT3 (ng/dL)    
 104-154 0.86 (0.51, 1.46) 0.98 (0.55, 1.76) 0.11 (0.94) 
 154-176 1 1  
 176-284 0.88 (0.52, 1.5) 0.97 (0.55, 1.71)  
fT3i    
 109-155 0.71 (0.41, 1.21) 0.87 (0.49, 1.55) 0.42 (0.81) 
 155-173 1 1  
 173-286 0.8 (0.47, 1.36) 0.76 (0.43, 1.34)  
TT4 (ug/dL)    
 6.69-9.8 1.28 (0.75, 2.18) 1 (0.56, 1.78) 1.38 (0.5) 
 9.8-11.2 1 1  
 11.2-18.1 0.96 (0.56, 1.64) 1.19 (0.67, 2.12)  
fT4i    
 6.29-9.64 1.46 (0.85, 2.5) 0.87 (0.48, 1.57) 2.41 (0.3) 
 9.64-11.1 1 1  
 11.1-21.7 1.11 (0.65, 1.89) 1.17 (0.65, 2.08)  
TPOAb (IU/mL)    
 < 9 1 1 0.95 (0.33) 
 ≥ 9 0.75 (0.25, 2.21) 0.75 (0.25, 2.21)  
Abbreviations: Attention Deficit Hyperactivity Disorder (ADHD), Norwegian Mother and Child Birth 
Cohort (MoBa), confidence interval (CI), single nucleotide polymorphism (SNP), thyroid stimulating 
hormone (TSH), total triiodothyronine (TT3), total thyroxine (TT4), free triiodothyronine index (fT3i), free 
thyroxine index (fT4i).  
1 There were no missing child sex values, so all imputed sets had the same male/female distribution.  
2 TSH, TT3, TT4, fT3i, and fT4i were modelled using tertile categories. TPOAb was modelled using a 
dichotomous cut-off at 9 IU/mL.  
3 Odds ratio of ADHD with the middle tertile of each thyroid function biomarker as the referent. Adjustment 
factors in the models estimating the effect of maternal thyroid function included: maternal smoking during 
pregnancy, maternal age, maternal self-reported history of depression, and maternal self-reported 
symptoms of ADHD. All analyses were conducted using multiple imputation with m=20 imputed datasets 
and combined using Rubin’s rules using the aregImpute and fit.mult.impute functions of the Hmsic R 
package.208 
4 The χ2 (p) are the test of the overall interaction effect between the thyroid hormone and the SNP.  
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6.5 Analyses Restricting the Case Group to Clinical ADHD 
In Paper 1 (Chapter 5), the case group included 114 clinical cases of ADHD and 146 
subclinical cases of ADHD (for a total of 260 ADHD cases). It is possible that the inclusion of 
subclinical ADHD cases attenuated effect estimates. To investigate this possibility, I estimated 
the main effects of maternal thyroid function, maternal SNPs, and child SNPs on the odds of 
ADHD, restricting the case group to clinical ADHD only (N=114). Due to the smaller sample size 
of cases, I did not assess effect measure modification using the restricted case group; many 
interaction cells included fewer than 5 observations. Effect estimates in this restricted analysis 
(Table 32) did not meaningfully differ from effect estimates using the full case group (Table 20).  
 
 
 92  
Table 32. Tests of main effects of maternal thyroid function biomarkers and maternal and child SNPs on 
offspring ADHD in the ADHD case-cohort study nested within the Norwegian Mother and Child Cohort 
(MoBa), 2003–2008, excluding subclinical cases of ADHD. 
Exposure1 
Odds Ratio of 
ADHD (95% CI)2 
Overall Effect  
χ2 (p-value)3 
Maternal Thyroid 
Function     
 TSH (mu/L) 0.98 (0.59, 1.62) 4.3 (0.12) 
  0.04-1.31 1   
  1.31-2.01 0.59 (0.34, 1.02) 4.3 (0.12) 
  2.01-8.01     
 TT3 (ng/dL) 0.91 (0.53, 1.58) 0.1 (0.94) 
  104-154 1   
  154-176 0.98 (0.58, 1.65) 0.1 (0.94) 
  176-284     
 fT3i 0.83 (0.49, 1.42) 0.7 (0.72) 
  109-155 1   
  155-173 0.82 (0.49, 1.39) 0.7 (0.72) 
  173-286     
 TT4 (ug/dL) 1.08 (0.64, 1.82) 0.2 (0.92) 
  6.69-9.8 1   
  9.8-11.2 0.97 (0.56, 1.66) 0.2 (0.92) 
  11.2-18.1     
 fT4i 1.21 (0.71, 2.08) 0.5 (0.78) 
  6.29-9.64 1   
  9.64-11.1 1.08 (0.63, 1.86) 0.5 (0.78) 
  11.1-21.7     
 TPOAb (IU/mL) 1 0.4 (0.51) 
  < 9 0.76 (0.34, 1.72)   
  ≥ 9     
Abbreviations: Attention Deficit Hyperactivity Disorder (ADHD), Norwegian Mother and Child Birth 
Cohort (MoBa), confidence interval (CI), single nucleotide polymorphism (SNP), thyroid stimulating 
hormone (TSH), total triiodothyronine (TT3), total thyroxine (TT4), free triiodothyronine index (fT3i), free 
thyroxine index (fT4i).  
1 TSH, TT3, TT4, fT3i, and fT4i were modelled using tertile categories. TPOAb was modelled using a 
dichotomous cut-off at 9 IU/mL. SNPs were modelled using a genotypic model with the heterozygous 
genotype as the referent.  
2 Odds ratio of ADHD with the middle tertile of each thyroid function biomarker as the referent. ADHD 
cases included only the clinical cases (N=114) and controls included the represenative sample (N=549). 
Adjustment factors in the models estimating the effect of maternal thyroid function included: maternal 
smoking during pregnancy, maternal age, maternal self-reported history of depression, maternal self-
reported symptoms of ADHD, and child sex. There were no adjustment factors in the models estimating 
the effects of maternal SNPs. The model estimating the effect of the child SNP including maternal 
rs225014 as an adjustment factor. All analyses were conducted using multiple imputation with m=20 
imputed datasets and combined using Rubin’s rules using the aregImpute and fit.mult.impute functions of 
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6.6 Select stratified plot  
 Figure 9 presents effect estimates stratified by the maternal SNP rs2235544 (DIO1), just 
as a demonstration of the effect. 
‘  
Figure 9. Maternal SNP rs2235544 (DIO1)-stratified effect estimates of the 
association between maternal T4 biomarkers (TT4 and fT4i) and the odds of ADHD, 
using an additive model of genotype. TT4 and fT4i were modelled using tertile 
categories with the middle tertile as the referent. Adjustment factors in the models 
estimating the effect of maternal thyroid function included: maternal smoking during 
pregnancy, maternal age, maternal self-reported history of depression, maternal self-
reported symptoms of ADHD, and child sex. Overall interaction effect between fT4i 
and maternal rs2235544 was χ2 = 7.94 (p = 0.09), and the overall interaction effect 
between TT4 and maternal rs2235544 was χ2 = 8.61 (p = 0.07). Analyses were 
aggregated across 20 datasets with multiply-imputed missing values (though findings 
were similar in complete-case analyses). 
Abbreviations: Attention Deficit Hyperactivity Disorder (ADHD), Norwegian Mother 
and Child Birth Cohort (MoBa), confidence interval (CI), single nucleotide 
polymorphism (SNP), total thyroxine (TT4), free thyroxine index (fT4i).  
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6.7 Bounds Sensitivity Analysis for Missing Covariate Data 
 Among the variables included in the regression models used to estimate the association 
between maternal thyroid function biomarkers and preschool ADHD, maternal history of 
depression is missing the largest number of observations (Nmissing=43, 5.3%), whereas the rest of 
the variables are missing fewer than 5% of the observations.  
To estimate the bounds of the main effect estimates, I conducted single imputation 
according to two extreme scenarios of non-random missingness (whereby the unobserved values 
of maternal history of depression were differential by preschool ADHD case classification). In 
the first scenario, all preschool ADHD cases with missing maternal history of depression were 
assigned the lowest observed maternal history of depression score (6), and all controls with 
missing maternal history of depression were assigned the highest observed maternal history of 
depression score (12). The second scenario was the reverse of the first: all preschool ADHD 
cases with missing maternal history of depression were assigned the highest observed maternal 
history of depression score (12), and all the controls with missing maternal history of depression 
were assigned the lowest observed maternal history of depression score (6).  
As can be seen in Table 33, the bounds created by the aforementioned two extreme 
scenarios of non-random missingness are quite narrow. These narrow bounds suggest that the 
estimated associations between maternal thyroid function biomarkers and preschool ADHD are 
robust to extreme cases of non-differential (with respect to outcome) unobserved values of 
maternal history of depression.   
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Table 33. Bounds on odds ratios for offspring ADHD1 according to category of thyroid function, based on 
extreme scenarios of non-random missingness of maternal history of depression. Data were from the 
ADHD case-cohort study nested within the Norwegian Mother and Child Cohort (MoBa), 2004–2008. 
Exposure2 
Odds Ratio of ADHD 
Bounds3 
Maternal Thyroid Function   
 TSH (mu/L)  
  0.04-1.31 1.002-1.005 
  1.31-2.01 1 
  2.01-8.01 0.803-0.806 
 TT3 (ng/dL)  
  104-154 0.901-0.937 
  154-176 1 
  176-284 0.973-0.98 
 fT3i  
  109-155 0.748-0.808 
  155-173 1 
  173-286 0.781-0.793 
 TT4 (ug/dL)  
  6.69-9.8 1.142-1.231 
  9.8-11.2 1 
  11.2-18.1 1.081-1.12 
 fT4i  
  6.29-9.64 1.162-1.197 
  9.64-11.1 1 
  11.1-21.7 1.152-1.165 
Abbreviations: Attention Deficit Hyperactivity Disorder (ADHD), Norwegian Mother and Child Birth 
Cohort (MoBa), thyroid stimulating hormone (TSH), total triiodothyronine (TT3), total thyroxine (TT4), free 
triiodothyronine index (fT3i), free thyroxine index (fT4i).  
1 Cases included 114 preschool-aged children who met DSM-IV-TR criteria for ADHD plus 146 preschool-
aged children who had sub-threshold symptoms of ADHD using the Preschool Age Psychiatric 
Assessment (PAPA). Controls included a random sample of 549 children who were eligible for the ADHD 
sub-study.   
2 TSH, TT3, TT4, fT3i, and fT4i were modelled using tertile categories.  
3 Odds ratio of ADHD with the middle tertile of each thyroid function biomarker as the referent, or with the 
heterozygous genotype as the referent. Adjustment factors in the models estimating the effect of maternal 
thyroid function included: maternal smoking during pregnancy, maternal age, maternal self-reported 
history of depression, maternal self-reported symptoms of ADHD, and child sex. Bounds were based on 
two extreme scenarios of non-random missingness of maternal self-reported history of depression, where 
the unobserved values of maternal self-reported history of depression were differential with respect to 
preschool ADHD case classification. Odds ratios are estimated to the third decimal place to make 









CHAPTER 7. PAPER 2: MATERNAL THYROID FUNCTION AND CHILD 
EXECUTIVE FUNCTION: EFFECT MEASURE MODIFICATION BY 
VARIANTS IN DEIODINASE-ENCODING GENES 
 
Note: Tables and figures for this chapter are in sections 7.6-7.8. 
 
7.1 Chapter 7 Overview 
 
Maternal thyroid function is a crucial support for fetal neurodevelopment; however, the 
epidemiological evidence for associations with child executive function is mixed. Prior studies 
did not consider the role of activating maternal and child deiodinases, which may alter the 
availability of thyroid hormones to the fetus, independent of maternal circulating levels.  
We estimated the association between maternal thyroid function biomarkers at 17 weeks’ 
gestation and multiple measures of child executive function at 3.5 years. We also assessed 
whether two maternal SNPs in deiodinase-encoding genes DIO1 and DIO2 (rs2235544 and 
rs225014 or T92A, respectively) and one child SNP in DIO2 (rs225014, or T92A) modified 
associations. We utilized a nested sub-study of preschool ADHD within the Norwegian Mother 
and Child Cohort (MoBa) (N = 342). 
A one-standard deviation increase in maternal free thyroxine index (fT4i) was associated 
with a 0.10 standard deviation unit increase in parent-rated inhibition (95%CI: 0.01, 0.19), a 
0.13 standard deviation unit increase in teacher-rated inhibition (95%CI: 0.01, 0.24), and a 0.13 
standard deviation unit increase in parent-rated working memory (95%CI: 0.04, 0.22). We did 
not detect effect measure modification by maternal variants in DIO1 or DIO2, nor by the child 




  Maternal thyroxine may be uniquely important for fetal neurodevelopment; however, 
more research on the role for deiodinases in the association between maternal thyroid function 
and fetal neurodevelopment is needed.  
7.2 Introduction 
Executive function refers to a set of cognitive capacities that enable goal-directed and 
self-regulatory behavior.35 Key components of executive function include planning, attentional 
flexibility, impulse control, and working memory (the ability to hold and manipulate 
information in mind when it is no longer perceptually available).36,37 These processes undergo 
substantial development during the preschool years.36,42 Impairments in executive function have 
been associated with an increased risk of addiction, conduct disorder, difficulties maintaining 
employment, and poor physical health (e.g., overeating and obesity).38–41   
Executive function is fundamental for everyday cognitive functioning, yet the underlying 
mechanisms supporting its development and use are unknown. Some predictors of executive 
function include family socioeconomic status, maternal marital status, smoking during 
pregnancy, anxiety during pregnancy, maternal executive function, and birth weight.47–54 One 
potential etiologic contributor to executive function development is maternal thyroid function. 
Recent systematic reviews have found some, albeit mixed, evidence for an association between 
maternal thyroid dysfunction during pregnancy and child executive function, with the 
association between maternal hypothyroxinemia and executive function impairments having the 
most support.57–59,190  
The thyroid hormone triiodothyronine (T3) is required to support fetal 
neurodevelopment. T3 binds to receptors in the nuclei of cells, regulating the expression of 
genes that influence neurodevelopmental processes.88 One such process is myelination—
aberrant myelination (i.e. white matter abnormalities) has been associated with executive 




support their needs until mid-gestation, maternally-supplied thyroid hormones are essential to 
fetal development.83,84 Maternal thyroxine (T4) crosses to the fetus more readily than T3.85 
Maternally-supplied T4 can then be converted to the more biologically active T3 in the fetal 
cerebral cortex by deiodinase type 2, which is present as early as 7 weeks’ gestation.86,87 Fetal 
deiodinase type 2 may thus alter the association between maternal thyroid function and 
executive function, as it influences fetal T3 availability separately from circulating maternal 
thyroid hormone concentrations.    
Maternal activating deiodinases may also play a role in modifying the association 
between maternal thyroid function and fetal neurodevelopment. Maternal deiodinase type 2 is 
expressed in the decidual cells of the uterine lining, which form the maternal portion of the 
placenta.92 As a result, maternal placental deiodinase type 2 may affect the supply of maternal 
T4 to the fetus, independent from maternal circulating thyroid hormone levels. Maternal 
deiodinase type 1, which also converts T4 to T3, may also modify the local fetal supply of 
maternal T4, though its presence in the placenta is debated.95 
Deiodinase type 1 and deiodinase type 2 are encoded by the genes DIO1 and DIO2, 
respectively. Among adults, genetic variants in both genes have been associated with circulating 
thyroid hormone concentrations as well as the fT3/fT4 ratio.129–133 Among children, the SNP 
rs225014 (T92A) in DIO2 has been associated with intellectual disability in iodine-deficient 
regions.195 To our knowledge, no studies have investigated how maternal variants in deiodinase-
encoding genes affect fetal neurodevelopment, or whether child variants in these genes alters 
the association between maternal thyroid function and fetal neurodevelopment.  
Our aims were to examine the association between maternal thyroid function at 17 
weeks’ gestation and child executive function at approximately 3.5 years. Because executive 
function processes show divergent neural and behavioral developmental trajectories,43,44 we 
assessed multiple domains including inhibition, working memory, and emotional control, and 




reflect distinct constructs.46 We also interrogated the potentially modifying effect of maternal 
and fetal conversion of thyroid hormones by deiodinase types 1 and 2, by measuring maternal or 
fetal variants in DIO1 and DIO2. To address these questions, we used data collected as part of a 
nested sub-study of preschool ADHD within the population-based prospective Norwegian 
Mother and Child Cohort (MoBa).  
 
7.3 Methods 
Study sample. The Norwegian Mother and Child Cohort Study (MoBa) is an ongoing 
prospective population-based cohort study of Norwegian-speaking women that is conducted by 
the Norwegian Institute of Public Health (41% participation rate).196 The current paper is from a 
clinical sub-study of ADHD oversampling of children with high scores on ADHD symptoms, 
using data from the MoBa questionnaire that was administered to mothers at child age 3 
years.197 The questionnaire included 11 items about ADHD, including six items from the Child 
Behavior Checklist/1.5-5198 and five items from the DSM-IV-TR criteria for ADHD.185 Children 
with scores  90th percentile on these 11 items (n = 2798) were invited to participate, along with 
randomly selected children (n = 654) (Figure 10). In total, about 35% agreed to participate in the 
ADHD sub-study, and from 2007 to 2011, 1195 children (mean age: 3.5 years, age range: 3.1 – 
3.8 years) took part in a 1-day clinical assessment including diagnostic interviews with parents 
(with few exceptions, mothers) (Figure 10).  
Because the present study investigated maternal thyroid function biomarkers measured 
in maternal plasma samples, the sample was restricted to the 870 children whose mothers had 
available biospecimen (Figure 10). Of the 870 children, those who were classified as having 
ADHD according to DSM-IV-TR criteria or as having subthreshold symptoms of ADHD 
(diagnostic procedure described below) were included in this study (n = 260) (Figure 1). This 




questionnaire and who were not classified as having ADHD, subthreshold symptoms of ADHD, 
or any other disorder at the clinical assessment (n = 82) (Figure 10). Clinical assessment details 
are described in further detail by Overgaard and colleagues.217 
Maternal Thyroid Function. At their first ultrasound appointment (17 weeks’ 
gestation), women provided a blood sample. Two 7ml ethylenediamine tetraacetic acid (EDTA) 
tubes (Becton-Dickinson (BD), Plymouth, UK) of blood were drawn, one of which was spun to 
pull off plasma, and then was shipped overnight at room temperature to a central biospecimen 
processing lab.199 Most samples arrived at the biobank the day after collection, and were stored 
in 1ml cryovials at -80°C.199 
For thyroid function biomarker analysis, the samples were shipped frozen on dry ice to 
ARUP Laboratories in Salt Lake City, Utah. TSH, total T3 (TT3), and total T4 (TT4) were 
estimated using a quantitative chemiluminescent immunassay on a Roche Cobas e602 blood 
analyzer. 201 We computed an index measure of free T4 (fT4i) and fT3 (fT3i) using T3-uptake 
and TT4 or TT3, respectively.76 Our thyroid function measurements and their sensitivity to 
biospecimen handling procedures within the MoBa population have been validated.76 
Outcome Measures. During the on-site clinical assessment, working memory was 
assessed using subtasks of the Stanford-Binet Intelligence Scales, Fifth Edition (SB5).218 In the 
SB5 delayed response task, children keep track of objects under plastic cups, which the examiner 
rotated and briefly obscured from the child’s view.218 In the SB5 block span task, children copy 
the sequence of an experimenter’s block taps.218 In the SB5 verbal working memory for 
sentences task, children repeat increasingly complex sentences. These tests yielded verbal 
(sentence task) and nonverbal (block span + delayed response tasks) working memory scores as 
well as an overall working memory index. Inhibition and impulsivity were assessed using the 
cookie delay task and the NEPSY (A Developmental NEuroPSYchological Assessment) statue 
task. In the cookie delay task, the child chooses between a smaller, immediate reward (one 




statue task requires children to stand still with their eyes closed while an experimenter makes 
distracting sounds.158,219 In our analyses, all performance-based measures (SB5, NEPSY, and 
cookie delay task) were standardized to a mean of 0 and a standard deviation of 1, with higher 
scores indicating better executive function. 
In addition, parents and teachers completed the Behavior Rating Inventory of Executive 
Function-Preschool (BRIEF-P) when children were 3 years old. BRIEF-P involves rating the 
frequency with which particular child behaviors have been a problem (“Never”, “Sometimes”, or 
“Often”).154 This questionnaire yields 5 non-overlapping clinical scales, of which we used three: 
inhibition, emotional control, and working memory. Like the performance-based measures, we 
standardized the raw BRIEF-P scores to a mean of 0 and a standard deviation of 1. Higher 
scores on the BRIEF-P indicated better executive function (scores were reverse coded in these 
analyses, so that all executive function measures were in the same direction).  
Genotyping. DNA was extracted from maternal blood samples collected at 17 weeks’ 
gestation and from infant cord blood (or 3-4 days after birth at the time of phenylketonuria 
screening if cord blood was unavailable) using FlexiGene. Candidate SNPs were measured using 
Sequenom Iplex. We considered 2 maternal SNPs (rs2235544 in DIO1 and rs225014 or T92A in 
DIO2) and 1 child SNP (rs225014 or T92A in DIO2). Child SNPs in DIO1 were not considered 
because there is little evidence that fetal DIO1 is expressed early in gestation.   
Covariates. We identified a set of potential adjustment factors using a directed acyclic 
graph (DAG): maternal self-reported ADHD, diabetes before or during pregnancy, history of 
major depression, dietary iodine intake, dietary selenium intake, smoking during the first 
trimester, age at delivery, maternal education, and child sex. From this set, we eliminated 
covariates that did not contribute meaningfully to the model,181 leading to the final adjustment 
set: maternal smoking, maternal age, history of major depression, and maternal self-reported 
ADHD, and child sex. Maternal smoking was self-reported and maternal age came from the 




gestation using 8 items from the Lifetime History of Major Depression Scale (a self-report scale 
that assesses symptoms in line with DSM-III criteria).205 Self-reported maternal symptoms of 
ADHD were measured using six items from the Adult ADHD Self-Report Scale, based on DSM-
IV criteria.206  
Statistical methods. We used linear regression weighted by inverse probability of 
being a preschool ADHD case. Thyroid function biomarkers were standardized and modeled 
linearly or modeled using tertile categories, depending on tests of nonlinearity. Nonlinearity was 
tested by comparing thyroid function biomarkers modeled linearly to thyroid function 
biomarkers non-linearly with a decision criterion of p<.05. To compare the linear to non-linear 
models, pseudo-likelihoods (resembling the binomial likelihoods applied to weighted counts 
instead of sample counts) from the R function svyglm() were compared using a pseudo-
likelihood ratio test with the R function anova().220 SNPs were modelled additively, with the AA 
genotype as the referent for the DIO1 SNP (maternal rs2235544) and the TT genotype as the 
referent for the DIO2 SNPs (maternal and child T92A). To assess non-additivity of the main 
effects of SNPs on executive function, we used pseudo-likelihood ratio tests (described above220) 
to compare models with the SNP genotypes coded genotypically versus additively (both with the 
same referent).  
 As noted above, executive function outcomes were also standardized (to a mean of 0 
and a standard deviation of 1). Before standardization, the cookie delay task scores were 
reflected, log-transformed, and then reflected back to the original scale direction. For all 
performance-based tasks (SB5 working memory, NEPSY statue task, and cookie delay task), 
higher scores indicated better executive function. In contrast, higher scores on the BRIEF-P 
subscales indicated worse executive function. Each thyroid function biomarker by executive 
function outcome combination were modeled in a separate model, adjusting for maternal 
smoking, age, history of major depression, and maternal self-reported ADHD and child sex, and 




weights down-weighted preschool ADHD cases (weight=0.1652) and up-weighted controls 
(weight=3.6469) in order to weight the case-cohort study to match the prevalence of those who 
screened positive for ADHD in the eligible cohort (12.6%, which is comparable with the 
prevalence of preschool ADHD: 10.5%221). The statistical criterion for a significant main effect 
was p<.05.  
We tested effect measure modification using augmented product term models, in which 
an interaction term between the modifier and all other predictors in the model were included in 
addition to all main effect terms.207 We investigated the interaction between maternal DIO1 and 
DIO2 SNPs and maternal thyroid function biomarkers TT3, fT3i, TT4, and fT4i and the 
interaction between the child DIO2 SNP and maternal TT4 and fT4i. SNPs were modelled 
additively (described above). Effect measure modification was deemed statistically significant if 
the interaction term between the modifier and the thyroid function biomarker had an effect on 
the outcome with p<.01. This more stringent criterion was established to avoid the over-
interpreting small differences in association across strata given the large number of interactions 
tested. We considered the overall consistency and pattern of modification effects when 
interpreting results. Because a priori power analyses indicated lower power (<45%) to detect 
interaction effects between genetic variants and thyroid hormone levels, tests of effect measure 
modification were considered exploratory. 
 
7.4 Results 
On average, women were 30 years old at delivery, and most (77%) did not smoke during 
pregnancy. Most children were boys (56%) (Table 34). The distribution of key covariates, 
including maternal age, smoking during pregnancy, self-reported symptoms of depression and 
ADHD, and child sex, did not meaningfully change when the sample was restricted to women 




probability of ADHD case status (Table 34). Because most women were euthyroid (unweighted 
N=295 out of 342), it is not surprising that thyroid hormones largely fell within reference ranges 
and within the ranges observed in other samples of pregnant women from the general 
population (Table 35).70,80  
Weighting the distributions of outcome scores by the inverse probability of preschool 
ADHD status did not meaningfully change most distributions, with the possible exception of the 
parent-completed emotional control and inhibition BRIEF-P subscales (Figure 11).  
SNPs were in Hardy-Weinberg equilibrium among children without preschool ADHD 
and their mothers (Tables 38, 39), as well as in the larger representative sample (N=549) of 
those eligible for the preschool ADHD sub-study (Table 40). Tests of non-additivity of the main 
effects of the SNPs on executive function outcomes were not consistently significant, so SNPs 
were modeled additively in all tests of association.  
We present the estimated main effects of thyroid function biomarkers on performance 
(Table 36) or inventory-based measures of executive function (Table 37) as standardized 
regression coefficients and 95% confidence intervals. Tests of nonlinearity did not reveal any 
consistent nonlinear effects; hence thyroid function biomarkers were standardized (to a mean of 
0 and a standard deviation of 1) and modelled linearly. For maternal thyroid function 
biomarkers, the regression coefficient represents the change in standard deviation units in the 
outcome associated with a one-standard deviation increase in the biomarker. For SNPs, the beta 
coefficients represent the change in standard deviation units in the outcome associated with 
each additional copy of the index allele. We observed few associations between maternal thyroid 
function biomarkers, maternal genetic variants in DIO1 or DIO2, or child genetic variant in 
DIO2 and performance-based (Table 36) and parent/teacher reported (Table 37) measures of 
executive function. A one-standard deviation increase in maternal free thyroxine index (fT4i) 
was associated a 0.10 standard deviation unit increase in parent-rated inhibition (95%CI: 0.01, 




and a 0.13 standard deviation unit increase in parent-rated working memory (95%CI: 0.04, 
0.22) (Table 37).  
We also observed associations between maternal SNPs in deiodinase-encoding genes and 
executive function. Specifically, each additional C allele in maternal SNP T92A (DIO2) was 
associated with a 0.40 standard deviation unit increase in SB5 verbal working memory (95%CI: 
0.11, 0.70) (Table 36). Each additional C allele of maternal SNP rs2235544 (DIO1) was 
associated with a 0.26 standard deviation unit increase in teacher-rated inhibition (95%CI: 
0.03, 0.49) (Table 37).  
We did not observe any patterns of effect measure modification by maternal or child 
SNPs for the associations between any maternal thyroid hormone and any of the executive 
function outcomes.  
7.5 Discussion 
Using data collected from participants within the Norwegian Mother and Child Cohort 
(MoBa), we investigated the association between maternal thyroid function at 17 weeks’ 
gestation and executive function in 3.5 year old children. We found that higher maternal fT4i 
was associated with better parent- and teacher-rated executive function, but that other maternal 
thyroid function biomarkers (TSH, TT4, TT3, fT3i) were not strongly associated with either 
performance-based or inventory measures of executive function. Of note, our study is the first to 
investigate effect measure modification by maternal variants in deiodinase-encoding genes DIO1 
and DIO2 and by a child variant in DIO2. Although we did not find evidence for modification by 
these gene variants, future studies better powered to detect interaction effects should consider 
these biologically relevant potential modifiers. 
Maternal T4 is the main thyroid hormone that is supplied to the fetus,85 which may 
explain the unique importance of maternal T4 to fetal neurodevelopment, and thus to executive 




homeostasis, it may be less relevant to the fetus’ separate and distinct thyroid metabolism 
requirements. In a recent study of the Danish National Birth Cohort, Andersen and colleagues 
found that maternal thyroid dysfunction in early pregnancy was associated with worse teacher-
rated (but not parent-rated) executive function on the BRIEF.117 The authors reported that this 
association was largely due to maternal hypothyroxinemia, a condition characterized by low fT4 
and normal TSH.117 Similarly, we found that lower maternal fT4i was associated with worse 
teacher- and parent-rated inhibition, and worse parent-rated working memory on the BRIEF-P. 
The literature on the association between maternal thyroid function and child executive function 
comprises a small number of studies with inconsistent findings.57,113,119,120,125,127  
To further investigate the association between maternal thyroid function and child 
executive function, we considered the role of activating deiodinases that convert T4 to T3. 
Deiodinases affect the biological impact of thyroid hormones by altering the relative 
intracellular concentrations of T4 and T3, independent of circulating concentrations.83,93,94 
Specifically, deiodinase type 2 in the maternal placental cells92  as well as in the fetal cerebral 
cortex86,87 may alter the local availability of the biologically active T3 to the fetus. Deiodinase 
type 1 may also play a modifying role, though its presence in the placenta is debated.95  
The CC genotype of the SNP T92A in deiodinase type 2-encoding gene DIO2 has been 
associated with a less active deiodinase (meaning less conversion of T4 to T3).141 This genotype 
has also been associated with adverse outcomes that are frequently comorbid with adult ADHD, 
including heavy alcohol consumption and bipolar disorder.134,135,194 We hypothesized that a less 
active deiodinase type 2 paired with high levels of T4 and fT4 might lead to excess T4, adversely 
affecting fetal neurodevelopment. Accordingly, we expected higher maternal TT4 and fT4i to be 
associated with worse executive function among children with the CC genotype themselves or 
whose mothers had the CC genotype of T92A. However, given our low a priori power to detect 
interactions along with our null modification effects, we found no clear evidence for or against 




Deiodinase type 1, which converts T4 to T3, is important in maintaining thyroid 
hormone homeostasis, particularly in response to hypothyroidism. In hypothyroid states, a 
significant proportion of circulating T3 is produced by deiodinase type 1 conversion of T4 to 
T3.137 This homeostatic mechanism may be slower among those with the A allele of the SNP 
rs2235544 in DIO1: this allele is associated with higher fT4 levels, a lower fT3/fT4 ratio, and 
slower thyroid hormone conversion.129,131,133 Given its role in responding to hypothyroidism, we 
predicted that among women with the AA genotype of the SNP rs2235544, lower maternal fT4i 
or TT4 would be associated with worse child executive function.137 However, we did not detect 
effect measure modification by maternal SNP rs2235544. Nonetheless, because of our low a 
priori power to detect interaction effects, we also do not rule out a possible modifying role.  
The inclusion of performance-based and inventory measures of several executive 
function processes is an important strength of this study. We found that the magnitude of 
estimated effects of maternal thyroid function biomarkers varied across biomarkers and across 
executive function domains. This varied pattern could reflect a true difference in how maternal 
thyroid function influences the domains of executive function. The components of executive 
function follow divergent behavioral and neural developmental trajectories,43,44 which might 
mean that they are differentially sensitive to maternal thyroid function at mid-gestation. It is 
also possible that the variable effects across outcome measures reflect task-level factors. For 
example, response modality and the additional cognitive task demands may affect performance, 
independent of executive function competency.44 Finally, each measure of executive function 
may have different degrees of sensitivity and specificity, contributing to variable results.   
While we observed a main effect of maternal fT4i on inventory measures of executive 
function (the parent and teacher-completed BRIEF-P), we did not observe any consistent effects 
of maternal thyroid function on performance-based measures of executive function (the SB5 
working memory scales, NEPSY statue task, and the cookie delay task). It is debated whether 




review of 20 studies found that the median correlation between inventory and performance-
based measures of executive function was 0.19.46 The median correlation between inventory 
(BRIEF) and performance-based (CDT, SB5 working memory, NEPSY statue task) measures of 
executive function in our study was 0.12. This weak correlation may be because performance-
based measures assess optimal performance in constrained and standardized situations, 
whereas rating measures evaluate typical performance in everyday and less restricted 
situations.46  
The novel hypothesis of effect measure modification by deiodinase-encoding gene 
variants was an important strength of this study. Other strengths of our study include measuring 
multiple maternal thyroid function biomarkers using methods validated in samples collected 
during pregnancy, and the intentional oversampling of preschool ADHD cases, which allowed us 
to investigate a broader range of executive function scores. This study is limited by the single 
measure of maternal thyroid function at 17 weeks’ gestation. However, the fetus is still relying 
on maternal thyroid hormones at 17 weeks, making it a valuable time point to assess.  
In this study of maternal thyroid function at 17 weeks’ gestation and child executive 
function at 3.5 years, we found that increasing maternal fT4i was associated with better 
executive function as rated by parents and teachers on the BRIEF-P (specifically, inhibition and 
working memory). This finding is consistent with an evolving literature linking maternal 
hypothyroidism/hypothyroxinemia with adverse fetal neurodevelopment.  
Although we did not observe effect measure modification by SNPs in deiodinase-encoding genes 
DIO1 (rs2235544) and DIO2 (T92A), the biological relevance of these genes warrants future 
studies elucidating their potential impact on the association between maternal thyroid function 





7.6 Tables for Paper 2 
 
Table 34. Characteristics of the study sample who were clinically evaluated as part of the nested case-
cohort preschool ADHD study within the Norwegian Mother and Child Cohort (MoBa), 2003–2008. 
  
Not Weighted (N = 
342)   Weighted (N = 342)5 
Characteristic Mean (SD) or N (%)   Mean (SD) or N (%) 
Maternal Age (years) 30.2 (4.1)  30.8 (4.2) 
Maternal BMI (kg/m2) 24.3 (4.6)  24.1 (4.1) 
History of Major Depression Sum Score1 8.6 (2.1)  8.3 (2.0) 
Sum Maternal ADHD Symptoms above Cutoff2 1.6 (1.5)  1.3 (1.4) 
Marital Status    
 Single 18 (5.3)  13 (3.9) 
 Cohabitating 165 (48.4)  146 (42.6) 
 Married 158 (46.3)  183 (53.5) 
Maternal Smoking    
 No 262 (77.1)  270 (79.7) 
 Yes 78 (22.9)  69 (20.3) 
Preeclampsia    
 No 325 (95.0)  318 (93.1) 
 Yes 17 (5.0)  24 (6.9) 
Self-reported or MBRN registered preexisting maternal thyroid condition3 
 No 329 (96.2)  329 (96.3) 
 Yes 13 (3.8)  13 (3.7) 
Thyroid Disorder Based on Biomarkers    
 Hyperthyroxinemia 13 (4.3)  23 (7.6) 
 Hypothyroxinemia 16 (5.4)  13 (4.3) 
 None and not missing TSH, fT4i, or TPOAb 264 (88.3)  259 (85.5) 
 Overt Hypothyroidism 1 (0.3)  0 (0.1) 
 Subclinical Hyperthyroidism 2 (0.7)  4 (1.3) 
 Subclinical Hypothyroidism 3 (1.0)  4 (1.3) 
Self-Reported Thyroid Medications during 
Pregnancy    
 No 330 (96.5)  330 (96.5) 
 Yes 12 (3.5)  12 (3.5) 
Euthyroid Status4    
 Thyroid dysfunction (prior/current) or thyroid 
medication 47 (13.7)  57 (16.5) 
 Euthyroid 295 (86.3)   285 (83.5) 
Child Sex    
 Male 190 (55.6)  188 (55.0) 
 Female 152 (44.4)  154 (45.0) 
1 Computed by summing select responses indicating depression on The Life Time History of Major 
Depression scale.205 Higher scores indicate more self-reported symptoms of depression. 
2 Computed by summing the number of questions that were indicative of adult ADHD based on the Adult 
ADHD Self-Report Scale206. Higher scores indicate more self-reported symptoms of ADHD. 
3 Clinical definitions based on the following criteria in accordance with Lazarus et al216: overt 
hypothyroidism included individuals with TSH above the reference range, and FT4i below the reference 




the reference range, and TPO-Ab above 9 IU/mL; hypothyroxinemia included individuals with TSH in the 
reference range and FT4i below the reference range; overt hyperthyroidism included individuals with TSH 
below the reference range and FT4i above the reference range; subclinical hyperthyroidism included 
individuals with TSH below the reference range and FT4i in the reference range; and hyperthyroxinemia 
included individuals with TSH in the reference range, and FT4i above the reference range. 
4 Euthyroid women included those with no self-reported or MBRN registered preexisting maternal thyroid 
condition, no thyroid conditions based on measured biomarkers and reference ranges, and no self-
reported thyroid medications.  
5 Weighted by stabilized inverse probability weights of being a preschool ADHD case, based on the 
prevalence of those who screened positive for ADHD in the eligible cohort (2062 of 16422 screened 
positive). Accordingly, preschool ADHD cases were down-weighted with the weight 0.1652 and controls 





Table 35. Unweighted distribution of thyroid function biomarkers at 17-18 weeks' gestation among women who participated in the nested case-
cohort preschool ADHD study within the Norwegian Mother and Child Cohort (MoBa), 2003–2008. 




mean (SD) 0% 20% 40% 50% 60% 80% 100% 
TSH (mu/L) 334 1.78 (1.02) 1.55 (1.75) 0.04 1.03 1.39 1.58 1.78 2.37 8.01 
TT3 (ng/dL) 335 170.81 (28.84) 168.48 (1.18) 105.00 147.00 162.00 169.00 174.00 192.00 284.00 
TT4 (ug/dL) 336 10.68 (1.83) 10.53 (1.19) 6.69 9.22 10.04 10.50 11.01 12.09 18.05 
fT3i 330 168.49 (25.84) 166.61 (1.16) 112.50 147.54 161.83 166.41 170.87 187.29 282.86 
fT4i 330 10.57 (1.94) 10.4 (1.2) 6.62 8.96 9.88 10.32 10.90 12.09 19.34 
Abbreviations: Attention Deficit Hyperactivity Disorder (ADHD), Norwegian Mother and Child Birth Cohort (MoBa), thyroid stimulating hormone 
(TSH), total triiodothyronine (TT3), total thyroxine (TT4), free triiodothyronine index (fT3i), free thyroxine index (fT4i). 








Table 36. Tests of main effects2 of maternal thyroid function biomarkers and maternal and child SNPs on offspring behavioral executive function 
measures in the preschool ADHD case-cohort study nested within the Norwegian Mother and Child Cohort (MoBa), 2003–2008. 
  Stanford-Binet Working Memory   
Exposure1 
Index  
β per SD 
increase (95% CI) 
Verbal  
β per SD 
increase (95% CI) 
Non-Verbal 
 β per SD 
increase (95% CI) 
NEPSY Statue 
Task  
β per SD 
increase (95% CI) 
Cookie Delay 
Task  
β per SD 
increase (95% CI) 
Maternal Thyroid Function 
(Standardized)     
 TSH  -0.06 (-0.33, 0.22) 0.07 (-0.21, 0.34) -0.11 (-0.36, 0.14) 0.19 (-0.04, 0.41) -0.01 (-0.12, 0.10) 
 TT3 -0.09 (-0.30, 0.12) -0.14 (-0.34, 0.06) 0.00 (-0.20, 0.21) -0.23 (-0.48, 0.03) 0.11 (-0.13, 0.35) 
 fT3i 0.00 (-0.20, 0.20) -0.07 (-0.23, 0.10) 0.07 (-0.12, 0.26) -0.14 (-0.39, 0.11) 0.10 (-0.12, 0.33) 
 TT4 0.04 (-0.15, 0.23) -0.16 (-0.37, 0.04) 0.09 (-0.11, 0.29) -0.14 (-0.31, 0.03) 0.08 (-0.19, 0.34) 
 fT4i 0.13 (-0.05, 0.31) -0.06 (-0.24, 0.12) 0.14 (-0.05, 0.33) -0.08 (-0.26, 0.11) 0.07 (-0.18, 0.32) 
Genetic Variants      
 Maternal rs2235544 (T92A, 
DIO1, A/C)      
  Per C allele (additive model) 0.04 (-0.31, 0.39) -0.13 (-0.48, 0.21) 0.25 (-0.06, 0.57) 0.02 (-0.26, 0.29) -0.07 (-0.34, 0.21) 
 Maternal rs225014 (T92A, 
DIO2, C/T)      
  Per C allele (additive model) -0.05 (-0.39, 0.29) 0.40 (0.11, 0.70) -0.15 (-0.47, 0.17) 0.02 (-0.31, 0.35) 0.01 (-0.26, 0.29) 
 Child rs225014 (DIO2, C/T)      
  Per C allele (additive model) 0.30 (-0.08, 0.68) -0.16 (-0.59, 0.27) 0.39 (-0.04, 0.81) -0.20 (-0.62, 0.22) 0.13 (-0.20, 0.46) 
Abbreviations: Attention Deficit Hyperactivity Disorder (ADHD), Norwegian Mother and Child Birth Cohort (MoBa), A Developmental 
NEuroPSYchological Assessment (NEPSY), confidence interval (CI), single nucleotide polymorphism (SNP), thyroid stimulating hormone (TSH), 
total triiodothyronine (TT3), total thyroxine (TT4), free triiodothyronine index (fT3i), free thyroxine index (fT4i).  
1 TSH, TT3, TT4, fT3i, and fT4i were standardized and modeled linearly. SNPs were modelled using an additive model.  
2 Main effects are presented as standardized regression coefficients with 95% confidence intervals, representing the change in standard deviation 
units in the outcome associated with a one-standard deviation increase in the exposure. For SNPs, the beta coefficients represent the change in 
standard deviation units in the outcome associated an increase in the number of the index allele. Each exposure by outcome combination was 
modeled using a separate linear regression model. Adjustment factors in the models estimating the effect of maternal thyroid function included: 
maternal smoking during pregnancy, maternal age, maternal self-reported history of depression, maternal self-reported symptoms of ADHD, and 
child sex. There were no adjustment factors in the models estimating the effects of maternal SNPs. The model estimating the effect of the child 







(though findings were similar in complete-case analyses). All models were weighted by the inverse probability of being a preschool ADHD case. 
Bolding indicates that the estimated association was statistically significant at p<.05. Positive regression coefficients indicate that higher scores on 








Table 37. Tests of main effects2 of maternal thyroid function biomarkers and maternal and child SNPs on offspring executive function as 
rated by teachers and parents in the preschool ADHD case-cohort study nested within the Norwegian Mother and Child Cohort (MoBa), 
2003–2008.  
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Abbreviations: Attention Deficit Hyperactivity Disorder (ADHD), Behavior Rating Inventory of Executive Function-Preschool (BRIEF-P), 
Norwegian Mother and Child Birth Cohort (MoBa), confidence interval (CI), single nucleotide polymorphism (SNP), thyroid stimulating hormone 
(TSH), total triiodothyronine (TT3), total thyroxine (TT4), free triiodothyronine index (fT3i), free thyroxine index (fT4i).  








2 Main effects are presented as standardized regression coefficients with 95% confidence intervals, representing the change in standard deviation 
units in the outcome associated with a one-standard deviation increase in the exposure. For SNPs, the beta coefficients represent the change in 
standard deviation units in the outcome associated an increase in the number of the index allele. Each exposure by outcome combination was 
modeled using a separate linear regression model. Adjustment factors in the models estimating the effect of maternal thyroid function included: 
maternal smoking during pregnancy, maternal age, maternal self-reported history of depression, maternal self-reported symptoms of ADHD, and 
child sex. There were no adjustment factors in the models estimating the effects of maternal SNPs. The model estimating the effect of the child 
SNP including maternal rs225014 as an adjustment factor. Analyses were aggregated across 20 datasets with multiply-imputed missing values 
(though findings were similar in complete-case analyses). All models were weighted by the inverse probability of being a preschool case. Bolding 
indicates that the estimated association was statistically significant at p<.05. Positive regression coefficients indicate that higher scores on the 
exposure is associated with better executive function (BRIEF scores were reverse-coded so that lower scores indicated more executive function 







7.7 Figure for Paper 2 
 
 




7.8 Supplement for Paper 2 
 
Table 38. Frequency of genotypes of select maternal and child SNPs among women and their children 
who participated in the clinical evaluation for the preschool ADHD case-cohort study nested within the 
Norwegian Mother and Child Cohort (MoBa), 2003-2008, broken down by child ADHD status (ADHD case 
and control). 








Maternal SNPs    
 rs225014 (DIO2)   
  CC  41 (12.5) 35 (14.1) 6 (7.7) 
  CT  147 (45) 112 (45.0) 35 (44.9) 
  TT  139 (42.5) 102 (41.0) 37 (47.4) 
 rs2235544 (DIO1)   
  AA  72 (22.1) 59 (23.9) 13 (16.5) 
  CA  162 (49.7) 121 (49.0) 41 (51.9) 
  CC  92 (28.2) 67 (27.1) 25 (31.6) 
Child SNPs     
 rs225014 (DIO2)   
  CC  34 (12.9) 27 (13.4) 7 (11.1) 
  CT  124 (47.0) 91 (45.3) 33 (52.4) 
  TT  106 (40.2) 83 (41.3) 23 (36.5) 
Abbreviations: Attention Deficit Hyperactivity Disorder (ADHD), Norwegian Mother and Child Birth 
Cohort (MoBa), single nucleotide polymorphism (SNP).  
 
Table 39. Tests of Hardy-Weinberg Equilibrium (HWE) for select maternal and child SNPs among women 
and their children who participated in the clinical evaluation for the preschool ADHD case-cohort study 







DIO1   
 rs2235544 0.1 (0.70) NA 
DIO2   
 rs225014 0.1 (0.71) 0.6 (0.45) 
Abbreviations: Attention Deficit Hyperactivity Disorder (ADHD), Norwegian Mother and Child Birth 





Table 40. Tests of Hardy-Weinberg Equilibrium (HWE) for select maternal and child SNPs among a 
representative random sample of women and their children who were eligible for the preschool ADHD 
case-cohort study nested within the Norwegian Mother and Child Cohort (MoBa), 2003-2008 (N = 549 







DIO1   
 rs2235544 0.6 (0.43) NA 
DIO2   
 rs225014 0 (0.91) 1.9 (0.17) 
Abbreviations: Attention Deficit Hyperactivity Disorder (ADHD), Norwegian Mother and Child Birth 
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Figure 11. Unweighted (blue) and weighted (red) distributions of raw executive-function measure scores, 
assessed as part of the clinical evaluation in the preschool ADHD case-cohort study nested within the 







CHAPTER 8. ADDITIONAL ANALYSES SUPPORTING PAPER 2 
8.1 Correlations and factor analyses of outcome variables  
This section includes visualizations of the correlations among executive function 





Figure 12. Correlations between executive function outcome variables assessed in 
3.5-year-old children who were clinically evaluated as part of the nested case-cohort 
attention-deficit hyperactivity disorder study within the Norwegian Mother and Child 
Cohort (MoBa), 2003–2008 (N = 342). 
Note: The BRIEF outcome variables were reverse-coded to create this figure so that 
all outcome variables were scored in the same direction, with higher scores indicating 







Figure 13. Factor analysis loadings for all measures of executive function in the 3.5-
year-old children who were clinically evaluated as part of the nested case-cohort 
attention-deficit hyperactivity disorder study within the Norwegian Mother and Child 
Cohort (MoBa), 2003–2008 (N = 342). 
Note: A scree plot of the eigenvalues indicated that three to four factors provided the 







8.2 Teacher versus parent BRIEF-P ratings  
 
 Table 41 prevents the comparison of the raw BRIEF-P scores for parents and teachers.  
 
Table 41. Paired-samples t-tests comparing parent- and teacher-ratings on executive function on the 
BRIEF-P among cases (N=260) and clinical controls (N=82).  


























































8.3 Effect measure modification summary 
 
 Table 42 summarizes the significant effect measure modification results, using a 
criterion of p<.01. Given the large number of tests of effect measure modification, we focused on 
looking at consistent patterns (that is, consistent effects across multiple outcome measures and 
multiple thyroid function biomarkers). There were no clearly consistent effects, though 
selenium’s modification of the association between TSH and two tasks of inhibition is of interest 
(see Figure 14 for stratified estimates).   
Table 43 summarizes significant effect measure modification results among ADHD cases 




results among clinical controls only. Given the small sample size in each group, it is difficult to 
interpret differences in effect measure modification patterns. 
 
 




Table 42. Summary of significant effect measure modification of the association between maternal thyroid 
function biomarkers and offspring executive function in the preschool ADHD case-cohort study nested 
within the Norwegian Mother and Child Cohort (MoBa), 2003–2008. 
 TSH TT3 fT3i TT4 fT4i 
SB5 WM      
 WM Index      
 Verbal WM      
 Non-Verbal WM      





Cookie Delay Task 
 
   
 
BRIEF-Teacher      
 Working Memory   
 
  
 Inhibition      
 Emotional Control      
BRIEF-Parent      
 Working Memory  
 
   
 Inhibition       
 Emotional Control   
 
  
Abbreviations: Attention Deficit Hyperactivity Disorder (ADHD), Behavior Rating Inventory of Executive 
Function-Preschool (BRIEF-P), Norwegian Mother and Child Birth Cohort (MoBa), A Developmental 
NEuroPSYchological Assessment (NEPSY), Stanford-Binet Intelligence Scales, Fifth Edition (SB-5), 
thyroid stimulating hormone (TSH), total triiodothyronine (TT3), total thyroxine (TT4), free triiodothyronine 
index (fT3i), free thyroxine index (fT4i), working memory (WM).  
Note: We tested effect measure modification using augmented product term models, in which an 
interaction term between the modifier and all other predictors in the model are included in addition to all 
main effect terms.207 This method allows for covariate variation across strata of the potential effect 
measure modifier. We investigated the interaction between maternal DIO1 and DIO2 SNPs and maternal 
thyroid function biomarkers TT3, fT3i, TT4, and fT4i and the interaction between child DIO2 SNPs and 
maternal TT4 and fT4i. SNPs were modelled genotypically. TSH, TT3, TT4, fT3i, and fT4i were 
standardized and modeled linearly. Adjustment factors in the models estimating the effect of maternal 
thyroid function included: maternal smoking during pregnancy, maternal age, maternal self-reported 
history of depression, maternal self-reported symptoms of ADHD, and child sex). All models were 
weighted by the inverse probability of being a preschool ADHD case. Only effect measure modification 







 Maternal rs2235544  Maternal rs225014  Maternal iodine intake (Jod)  







Figure 14. Maternal selenium-stratified estimated associations between 
maternal TSH the NEPSY statue task and the cookie delay task. TSH 
were standardized and modelled linearly. Outcome measures were also 
standardized. Adjustment factors included: maternal smoking during 
pregnancy, maternal age, maternal self-reported history of depression, 
maternal self-reported symptoms of ADHD, and child sex. All models 
were weighted by the inverse probability of being a preschool ADHD 
case. Labels inset in the graph are the genotype-specific standardized 
beta coefficient and 95% confidence interval for the association between 
the thyroid hormone and the outcome measure.  
Abbreviations: Attention Deficit Hyperactivity Disorder (ADHD), 
Norwegian Mother and Child Birth Cohort (MoBa), confidence interval 
(CI), single nucleotide polymorphism (SNP), total thyroxine (TT4), free 




Table 43. Summary of significant effect measure modification of the association between maternal thyroid 
function biomarkers and offspring executive function in the preschool ADHD case-cohort study nested 
within the Norwegian Mother and Child Cohort (MoBa), 2003–2008, among cases only (N=260) 
 TSH TT3 fT3i TT4 fT4i 
SB5 WM      
 WM Index      
 Verbal WM      
 Non-Verbal WM    
  
NEPSY Statue Task     
 
Cookie Delay Task      
BRIEF-Teacher      
 Working Memory   
 
  
 Inhibition   
 
  
 Emotional Control      
BRIEF-Parent      
 Working Memory      
 Inhibition       
 Emotional Control    
  
Abbreviations: Attention Deficit Hyperactivity Disorder (ADHD), Behavior Rating Inventory of Executive 
Function-Preschool (BRIEF-P), Norwegian Mother and Child Birth Cohort (MoBa), A Developmental 
NEuroPSYchological Assessment (NEPSY), Stanford-Binet Intelligence Scales, Fifth Edition (SB-5), 
thyroid stimulating hormone (TSH), total triiodothyronine (TT3), total thyroxine (TT4), free triiodothyronine 
index (fT3i), free thyroxine index (fT4i), working memory (WM).  
Note: We tested effect measure modification using augmented product term models, in which an 
interaction term between the modifier and all other predictors in the model are included in addition to all 
main effect terms.207 This method allows for covariate variation across strata of the potential effect 
measure modifier. We investigated the interaction between maternal DIO1 and DIO2 SNPs and maternal 
thyroid function biomarkers TT3, fT3i, TT4, and fT4i and the interaction between child DIO2 SNPs and 
maternal TT4 and fT4i. SNPs were modelled genotypically. TSH, TT3, TT4, fT3i, and fT4i were 
standardized and modeled linearly. Adjustment factors in the models estimating the effect of maternal 
thyroid function included: maternal smoking during pregnancy, maternal age, maternal self-reported 
history of depression, maternal self-reported symptoms of ADHD, and child sex). All models were 
weighted by the inverse probability of being a preschool ADHD case. Only effect measure modification 
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Table 44. Summary of significant effect measure modification of the association between maternal thyroid 
function biomarkers and offspring executive function in the preschool ADHD case-cohort study nested 
within the Norwegian Mother and Child Cohort (MoBa), 2003–2008, among controls only (N=82) 
 TSH TT3 fT3i TT4 fT4i 
SB5 WM      
 WM Index 
   
  




 Non-Verbal WM      









BRIEF-Teacher      
 Working Memory 
 
    
 Inhibition      
 Emotional Control      
BRIEF-Parent      
 Working Memory   
   
 Inhibition      
 
 Emotional Control    
 
 
Abbreviations: Attention Deficit Hyperactivity Disorder (ADHD), Behavior Rating Inventory of Executive 
Function-Preschool (BRIEF-P), Norwegian Mother and Child Birth Cohort (MoBa), A Developmental 
NEuroPSYchological Assessment (NEPSY), Stanford-Binet Intelligence Scales, Fifth Edition (SB-5), 
thyroid stimulating hormone (TSH), total triiodothyronine (TT3), total thyroxine (TT4), free triiodothyronine 




Note: We tested effect measure modification using augmented product term models, in which an 
interaction term between the modifier and all other predictors in the model are included in addition to all 
main effect terms.207 This method allows for covariate variation across strata of the potential effect 
measure modifier. We investigated the interaction between maternal DIO1 and DIO2 SNPs and maternal 
thyroid function biomarkers TT3, fT3i, TT4, and fT4i and the interaction between child DIO2 SNPs and 
maternal TT4 and fT4i. SNPs were modelled genotypically. TSH, TT3, TT4, fT3i, and fT4i were 
standardized and modeled linearly. Adjustment factors in the models estimating the effect of maternal 
thyroid function included: maternal smoking during pregnancy, maternal age, maternal self-reported 
history of depression, maternal self-reported symptoms of ADHD, and child sex). All models were 
weighted by the inverse probability of being a preschool ADHD case. Only effect measure modification 
effects that were statistically significant at p<.01 are presented in this table.  
Legend  Maternal rs2235544  Maternal rs225014  Maternal iodine intake (Jod)  
 Maternal selenium intake  Child rs225014  Child sex (kjonn) 
 
8.4 Bounds Sensitivity Analysis for Missing Outcome Values 
 Among the 342 children who were included in the study of the association between 
maternal thyroid function biomarkers and executive function, there was a relatively substantial 
number of missing observations for the SB5 verbal working memory score (and thus the overall 
SB5 working memory index) (Nmissing = 75, 22%), the NEPSY statue task (Nmissing = 43, 13%), and 
measures from the teacher-completed BRIEF-P (Nmissing = 19, 5.6%).  
 To estimate the bounds of the main effect estimates of maternal thyroid function 
biomarkers, I conducted single imputation according to extreme scenarios of non-random 
missingness (whereby the unobserved outcome values were differential with respect ot the 
exposure, maternal thyroid function biomarker value). In the first scenario, children of mothers 
with below-median values on a given thyroid function biomarker were assigned the lowest 
observed score of the outcome, while children of mothers with above-median values on that 
same thyroid function biomarker were assigned the highest observed score of the outcome. In 
the second scenario, children of mothers with below-median values on a given thyroid function 




with above-median values on that same thyroid function biomarker were assigned the lowest 
observed score of the outcome. These two scenarios were simulated for each maternal thyroid 
function biomarker-outcome combination (restricting to the outcomes with high missingness).  
As can be seen in Tables 45 and 46, the estimated bounds under the aforementioned two 
extreme scenarios of non-random missingness are relatively broad for the SB5 working memory 
measures, narrower for the NEPSY statue task, and narrower still for the teacher-completed 
BRIEF-P measures.  
I additionally estimated the bounds of the main effect estimates of maternal and child 
SNPs, again conducting single imputation according to extreme scenarios of non-random 
missingness (whereby the unobserved outcome values were differential with respect to the 
maternal or child SNP). In the first scenario, children with the referent genotype (or whose 
mother had the referent genotype) of a given SNP were assigned the lowest observed outcome 
score, while children with two copies of the index allele (or whose mother had two copies of the 
index allele) were assigned the highest observed outcome score (those with the heterozygous 
allele were assigned the median value of the outcome score). The second scenario was a reverse 
of the first: children with the referent genotype (or whose mother had the referent genotype) of a 
given SNP were assigned the highest observed outcome score, while children with two copies of 
the index allele (or whose mothers had two copies of the index allele) were assigned the lowest 
observed outcome score (again, those with the heterozygous allele were assigned the median 
value of the outcome score). These two scenarios were simulated for each SNP-outcome 
combination (restricting to the outcomes with high missingness).   
As with the main effects of the thyroid function biomarkers, the estimated bounds under 
the aforementioned extreme scenarios of non-random missingness are relatively broad for the 
SB5 measures of working memory, and somewhat narrower for the NEPSY statue task and the 




Table 45. Bounds on the main effects2 of maternal thyroid function biomarkers and maternal and child 
SNPs on offspring behavioral executive function measures based on extreme scenarios of non-random 
missingness of the outcomes. Data are from the preschool ADHD case-cohort study nested within the 
Norwegian Mother and Child Cohort (MoBa), 2003–2008. 

















β bounds4  β bounds4 β bounds4 
Maternal Thyroid Function   
 TSH  
-0.06 (-0.33, 0.22) 
-0.54, 0.48 
0.07 (-0.21, 0.34) 
-0.25, 0.39 
0.19 (-0.04, 0.41) 
-0.09, 0.43 
 TT3 
-0.09 (-0.30, 0.12) 
-0.45, 0.32 
-0.14 (-0.34, 0.06) 
-0.37, 0.16 
-0.23 (-0.48, 0.03) 
-0.40, 0.05 
 fT3i 
0.00 (-0.20, 0.20) 
-0.29, 0.31 
-0.07 (-0.23, 0.10) 
-0.27, 0.16 
-0.14 (-0.39, 0.11) 
-0.29, 0.05 
 TT4 
0.04 (-0.15, 0.23) 
-0.24, 0.34 
-0.16 (-0.37, 0.04) 
-0.35, 0.02 
-0.14 (-0.31, 0.03) 
-0.28, 0.03 
 fT4i 
0.13 (-0.05, 0.31) 
-0.17, 0.41 
-0.06 (-0.24, 0.12) 
-0.25, 0.11 
-0.08 (-0.26, 0.11) 
-0.21, 0.06 
Genetic Variants    
 Maternal rs2235544 
(DIO1, A/C)    
  Per C allele (additive 
model) 
0.04 (-0.31, 0.39) 
-0.57, 0.64 
-0.13 (-0.48, 0.21) 
-0.5, 0.3 
0.02 (-0.26, 0.29) 
-0.1, 0.16 
 Maternal rs225014 
(DIO2, C/T)    
  Per C allele (additive 
model) 
-0.05 (-0.39, 0.29) 
-0.63, 0.59 
0.40 (0.11, 0.70) 
-0.14, 0.67 
0.02 (-0.31, 0.35) 
-0.24, 0.24 
 Child rs225014 (DIO2, 
C/T)    
  Per C allele (additive 
model) 
0.30 (-0.08, 0.68) 
-0.01, 0.59 
-0.16 (-0.59, 0.27) 
-0.36, -0.01 
-0.20 (-0.62, 0.22) 
-0.41, 0.05 
Abbreviations: Attention Deficit Hyperactivity Disorder (ADHD), Norwegian Mother and Child Birth 
Cohort (MoBa), A Developmental NEuroPSYchological Assessment (NEPSY), confidence interval (CI), 
single nucleotide polymorphism (SNP), thyroid stimulating hormone (TSH), total triiodothyronine (TT3), 
total thyroxine (TT4), free triiodothyronine index (fT3i), free thyroxine index (fT4i).  
1 TSH, TT3, TT4, fT3i, and fT4i were standardized and modeled linearly. SNPs were modelled using an 
additive model.  
2 See Table 36, footnote 2.     
3 As estimated in the main analysis (i.e. the results summarized in Table 36). 
4 Estimated bounds on the coefficient estimate based on extreme scenarios of non-random missingness 






Table 46. Bounds on the main effects2 of maternal thyroid function biomarkers and maternal and child 
SNPs on teacher-completed BRIEF-P measures based on extreme scenarios of non-random missingness 
of the outcomes. Data are from the preschool ADHD case-cohort study nested within the Norwegian 
Mother and Child Cohort (MoBa), 2003–2008. 














Maternal Thyroid Function   
 TSH  
-0.08 (-0.25, 0.09) 
-0.13, 0.00 
-0.03 (-0.20, 0.14) 
-0.07, 0.04 
-0.01 (-0.17, 0.16) 
-0.05, 0.06 
 TT3 
-0.07 (-0.19, 0.05) 
-0.14, -0.02 
0.01 (-0.14, 0.15) 
-0.06, 0.06 
-0.03 (-0.16, 0.10) 
-0.10, 0.02 
 fT3i 
-0.00 (-0.12, 0.11) 
-0.03, 0.08 
0.07 (-0.06, 0.20) 
0.04, 0.14 
0.04 (-0.08, 0.16) 
0.02, 0.11 
 TT4 
-0.05 (-0.18, 0.09) 
-0.16, 0.01 
0.08 (-0.03, 0.20) 
-0.02, 0.13 
-0.01 (-0.13, 0.11) 
-0.11, 0.04 
 fT4i 
0.04 (-0.08, 0.15) 
0.00, 0.09 
0.13 (0.01, 0.24) 
0.09, 0.17 
0.06 (-0.04, 0.16) 
0.02, 0.11 
Genetic Variants    
 Maternal rs2235544 
(DIO1, A/C)    
  Per C allele (additive 
model) 
0.17 (-0.01, 0.36) 
0.06, 0.33 
0.26 (0.03, 0.49) 
0.15, 0.39 
0.15 (-0.04, 0.33) 
0.04, 0.27 
 Maternal rs225014 
(DIO2, C/T)    
  Per C allele (additive 
model) 
0.10 (-0.11, 0.36) 
0.06, 0.25 
-0.04 (-0.30, 0.22) 
-0.08, 0.09 
0.05 (-0.21, 0.32) 
0.01, 0.18 
 Child rs225014 (DIO2, 
C/T)    
  Per C allele (additive 
model) 
0.05 (-0.22, 0.32) 
-0.16, 0.12 
0.13 (-0.21, 0.47) 
-0.06, 0.19 
-0.20 (-0.51, 0.12) 
-0.36, -0.11 
Abbreviations: Attention Deficit Hyperactivity Disorder (ADHD), Behavior Rating Inventory of Executive 
Function-Preschool (BRIEF-P), Norwegian Mother and Child Birth Cohort (MoBa), confidence interval 
(CI), single nucleotide polymorphism (SNP), thyroid stimulating hormone (TSH), total triiodothyronine 
(TT3), total thyroxine (TT4), free triiodothyronine index (fT3i), free thyroxine index (fT4i).  
 
1 TSH, TT3, TT4, fT3i, and fT4i were standardized and modeled linearly. SNPs were modelled using an 
additive model.  
2 See Table 37, footnote 2.     
3 As estimated in the main analysis (i.e. the results summarized in Table 37). 
4 Estimated bounds on the coefficient estimate based on extreme scenarios of non-random missingness 










CHAPTER 9. DISCUSSION 
9.1 Overview of Study  
The overarching aim of this dissertation was to investigate the association between 
maternal thyroid function at 17 weeks’ gestation and preschool neurodevelopment, specifically 
ADHD and executive function. Furthermore, this dissertation investigated effect measure 
modification by maternal and fetal variants in deiodinase-encoding genes (DIO1, DIO2), 
maternal dietary iodine and selenium intake, and child sex. No study of maternal thyroid 
function and offspring neurodevelopment to date has evaluated the potential modifying role of 
variants in deiodinase-encoding genes. By investigating effect measure modification by maternal 
and child variants in deiodinase-encoding genes, our study provides a novel picture of how 
maternal and fetal thyroid conversion might affect the association between maternal thyroid 
function and fetal neurodevelopment. Similarly, no study to date has evaluated how maternal 
nutrient intake (iodine and selenium) might modify the association between maternal thyroid 
function and fetal neurodevelopment. To address these questions, this dissertation used data 
from the ADHD sub-study nested within the Norwegian Mother and Child Cohort (MoBa).  
We did not find associations between maternal thyroid function and preschool ADHD, 
nor was this association modified by deiodinase-encoding gene variants, maternal iodine or 
selenium intake, or child sex. However, higher maternal fT4i was associated with better parent- 
and teacher-rated preschool executive function. Other maternal thyroid function biomarkers 
(TSH, TT3, fT3i, TT4, or TPOAb) were not consistently associated with executive function 
outcomes. Although there was no clear pattern of effect measure modification by any single 




function was inconsistently modified by selenium, iodine, and/or maternal SNP rs2235544. 
9.2 Discussion and Interpretation of Findings 
Main effects of maternal thyroid function. Maternal thyroid function biomarkers 
(TSH, TT3, fT3i, TT4, fT4i, TPOAb) were not associated with ADHD in this dissertation. 
However, higher maternal fT4i was associated with better parent- and teacher-rated inhibition 
as well as better parent-rated working memory on the BRIEF-P. It is noteworthy that the main 
effect we observed was of maternal fT4i: maternal T4 crosses more readily to the fetus than 
maternal T3, and therefore has particular importance for fetal neurodevelopment.85 This finding 
is in line with a recent study of maternal thyroid function and executive function in 5 year old 
children that found that maternal hypothyroxinemia (characterized by low fT4 but normal TSH) 
was associated with worse teacher-rated (but not parent-rated) executive function on the 
BRIEF.222 Generally, however, the extant literature on the association between maternal thyroid 
function and child executive function is comprised of few studies with inconsistent 
findings.57,113,119,120,125,127  
The finding that maternal thyroid function was associated with executive function but 
not ADHD in the same preschool-aged children calls into question the nature of the relationship 
between clinical diagnoses of ADHD and continuous measures of related behaviors during the 
preschool period. This question is further discussed in section 9.4 (specifically, “Diagnostic 
categories versus continuous measures”). A second debate highlighted by these findings is the 
degree to which teacher- and parent-ratings of executive function correspond; section 9.3 
focuses on this question (specifically “Parent versus teacher ratings of executive function”). 
Finally, we found associations between maternal thyroid function and inventory, but not 
performance-based, measures of executive function. This finding contributes to the discussion 




same underlying construct (discussed in section 9.3, “Performance-based versus inventory 
measures of executive function”).    
Effects of variants in DIO1 and DIO2. The genes DIO1 and DIO2 encode the 
activating deiodinase types 1 and 2, respectively. Deiodinase types 1 and 2 both convert T4 to the 
more biologically active T3, affecting the intracellular availability of T3. Variants in DIO2 were 
of interest in this dissertation because deiodinase type 2 is expressed in the fetal cerebral cortex 
early in gestation and in maternal uterine decidual cells that form the maternal part of the 
placenta.92 Thus, fetal and maternal deiodinase type 2 provide a plausible biologic mechanism 
for modifying the association between maternal thyroid function and fetal neurodevelopment. 
By investigating effect measure modification by the maternal and fetal SNP rs225014 in DIO2, 
we hoped to tap into the role of maternal and fetal thyroid hormone conversion in fetal 
neurodevelopment.  
We did not observe clear main effects of maternal or fetal rs225014 (DIO2) or maternal 
rs2235544 (DIO1) on the odds of ADHD or on executive function performance. Although 
estimating the main effects of these SNPs was not a specific aim of this dissertation, no study to 
date has assessed the association between maternal and fetal deiodinase-encoding gene variants 
and child neurodevelopmental outcomes. We may have observed null effects because the study 
population consisted mostly of women who were euthyroid and their children. The variants in 
DIO1 and DIO2, which have been linked to thyroid hormone conversion rates,129–133 may matter 
more when thyroid hormone levels are too low or too high (as would be the case in women with 
clinical thyroid dysfunctions). Deiodinases contribute to thyroid hormone homeostasis;137 
perhaps in states of thyroid hormone stasis, variation in deiodinase activity has less of a 
biological impact. Animal research supports this interpretation: deiodinase type 1 deficiency in 
mice did not jeopardize T3 levels when the thyroid gland was functioning well; however, 
deiodinase type 1 activity was crucial for coping with iodine deficiency, suggesting that it is 




possible that there is no main effect of fetal rs225014 (DIO2) or maternal rs2235544 (DIO1) on 
ADHD or executive function; given that this is the first study of this association, future studies 
are warranted.  
As an exploratory aim, we investigated effect measure modification by the deiodinase-
encoding gene variants. Contrary to our predictions, neither maternal or fetal rs225014 (DIO2) 
nor maternal rs2235544 (DIO1) clearly modified the association between maternal thyroid 
function and ADHD or executive function. The a priori power to detect interaction effects 
between genetic variants and thyroid function biomarkers in this dissertation was low (<45%), 
which may have contributed to our null effects. Given the strong biological motivation 
supporting this interaction analysis (described above and throughout this dissertation), I think 
that this exploratory test of modification is valuable despite the low power, as it acts as a first 
step investigating this important relationship. That being said, it is important to consider 
alternative explanations for our null effects in addition to the low power. 
First, deiodinases are expressed throughout the body (see section 1.6), yet the effect of 
interest in this dissertation was deiodinase activity in maternal placental cells and in the fetal 
cerebral cortex. Variation in one SNP of DIO1 or DIO2 could thus have many effects throughout 
the body, possibly obscuring the specific effects of interest in this dissertation. In addition to 
being expressed throughout different tissues, the regulation of deiodinases in response to 
thyroid hormone variation is tissue-specific. For example, in hypothyroid states, deiodinase type 
1 is down-regulated in the liver and kidney, but up-regulated in the thyroid.78 Thus, a given 
variant in DIO1 may differentially alter the biological impact of thyroid hormone concentrations, 
depending on the tissue. The expression of deiodinases changes over the course of pregnancy as 
well.93,192,193 Thus, modifying effects of maternal SNPs in DIO1 and DIO2 may change across 
gestation. To summarize, assessing whether SNPs in DIO1 and DIO2 modify the association 
between maternal thyroid function and child ADHD or executive function may result in 




important modifying role of deiodinases located in the placenta and fetal cerebral cortex (the 
challenge being the ability to target this specific effect, without also capturing the obscuring 
effects of deiodinases throughout the body).   
Second, previous studies suggest that the activity of fetal deiodinases might not 
sufficiently adapt to maternal thyroid hormone abnormalities.83,94 It is therefore possible that 
variants in the child DIO2 gene would not alter the association between maternal thyroid 
function and fetal neurodevelopment. Third, in line with the discussion of the main effects of the 
genetic variants, the modifying effect of SNPs in the deiodinase-encoding genes may be more 
apparent in the context of maternal thyroid dysfunction. Because the study sample comprised 
mostly women who were euthyroid and their children, the impact of deiodinase-encoding gene 
variants on the association between maternal thyroid function and fetal neurodevelopment 
might have been minimal.  
Although it is important to consider these alternative explanations for the null 
modification findings, it is also important to recognize how young this avenue of research is. 
Accordingly, these alternative explanations are not meant to discount the possibility that the 
deiodinase-encoding gene variants are important modifiers of the association between maternal 
thyroid function and fetal neurodevelopment: there is simply not enough research on their 
potential modifying role. Future studies investigating whether maternal and fetal deiodinase-
encoding gene variants modify the association between maternal thyroid function and fetal 
neurodevelopment would be valuable steps in understanding the mechanisms affecting ADHD 
and executive function.  
Modifying Effects of Maternal Dietary Nutrients Selenium and Iodine. Iodine 
and selenium are both crucial for healthy thyroid hormone synthesis and conversion, and 
requirements for both nutrients are increased during pregnancy.69,103 Iodine deficiency during 
pregnancy has been associated with cognitive impairments in offspring, including impairments 




positively associated with child language and psychomotor development in a prospective 
study.103 Despite their important role in supporting thyroid function and their associations with 
child development, neither iodine nor selenium have been investigated as effect measure 
modifiers of the association between maternal thyroid function and child neurodevelopment. In 
this dissertation, iodine was not a consistent effect measure modifier of the association between 
maternal thyroid function and ADHD or maternal thyroid function and executive function. 
However, maternal selenium intake was a modifier of the association between maternal TSH 
and performance-based inhibition (as measured by the NEPSY statute task and the cookie delay 
task).  
We found that among children of women with low selenium (<60mug/day), the 
association between maternal TSH and performance-based inhibition was null, whereas among 
children of women with high selenium, higher maternal TSH was associated with better 
inhibition. Selenium is a key constituent for the deiodinase enzymes, and higher levels of 
selenium are associated with more active deiodinases, and consequently, higher T3 levels.107 For 
maternal deiodinase type 2 in the placenta, higher selenium would lead to more T4 conversion 
to T3, possibly resulting in higher T3 availability to the fetus. Because selenium is readily 
transferred from the mother to the fetus,223 higher maternal selenium may also result in more 
active deiodinase type 2 in the fetal cerebral cortex, again leading to a higher local availability of 
fetal T3. In summary, higher levels of selenium may amplify the fetal availability of T3, 
supporting healthy neurodevelopment and thus better executive function.  
However, there are a number of qualifications to the interpretation that higher levels of 
selenium may support fetal neurodevelopment. First and foremost, we observed an interaction 
between maternal TSH and selenium, with no complementary interactions between maternal 
TT4/fT4i or TT3/fT3i and selenium. Yet, deiodinases act on T4 and T3, not on TSH; thus, it 
seems odd to observe an interaction with TSH only. Second, selenium was an effect measure 




function. Meanwhile, despite having more than twice the sample size of the executive function 
analyses, the analyses with ADHD as the outcome did not detect effect measure modification by 
selenium. It is possible that the performance-based measures of inhibition were more sensitive 
to the specific modifying effects of selenium; alternatively, it is also possible that the significant 
selenium interaction effects were spurious findings resulting from the large number of 
interaction tests. Given that this is the first investigation of selenium as an effect measure 
modifier of the association between maternal thyroid function and fetal neurodevelopment, 
further studies are needed. 
Iodine levels also affect deiodinase activity; however, this effect may be more limited 
than that of selenium. In the state of iodine deficiency, the expression of deiodinase type 2 is up-
regulated (and deiodinase type 3 is downregulated) in the central nervous system.102 Thus, 
iodine deficiency may not affect thyroid hormone conversion in maternal placental cells, though 
it may affect thyroid hormone conversion in the fetal cerebral cortex (since some maternal 
iodine is transferred to the fetus).69 
Modifying effects of child sex. Previous studies that have investigated whether child 
sex modifies the association between maternal thyroid function and ADHD or executive function 
have reported mixed findings.117,120,127 For example, one study of maternal TSH found that it was 
more strongly associated with attention in boys than in girls at 2-5 years,120 whereas another 
study found that maternal TSH was more strongly associated with inattention and hyperactivity 
in 5 year-old girls than in boys.127 Another recent study found that maternal hypothyroxinemia 
was more strongly associated with ADHD in 8 year old girls than in boys.117 In this dissertation, 
child sex did not clearly modify the association between maternal thyroid function and ADHD or 
executive function in children aged 3.5 years. The inconsistency of sex-interaction effects may 
have a number of possible explanations.  
First, the interaction effect of sex and maternal thyroid function on neurodevelopment 




neuroimaging study of individuals aged 3 to 27 years, and found that neurodevelopmental 
trajectories for many structures demonstrated strong sex effects. In most cases, female 
neurodevelopmental trajectories reached maturity earlier than male trajectories, which were 
more protracted.224 The authors suggest that these age-dependent sex differences in brain 
development may help explain inconsistent sex differences. Given that previous studies of 
maternal thyroid function and ADHD or executive function have investigated sex modification 
among children ranging in age from 2 to 8 years, it is possible that the inconsistent results are in 
part due to age-dependent sex differences in neurodevelopment.  
Second, ADHD presents differently in male and female children, and the timeline of 
ADHD symptom emergence and waning differs by sex. ADHD in females is more frequently 
characterized by symptoms of inattention, whereas ADHD in males is more likely to manifest as 
hyperactive or impulsive behaviors.225 This difference is important because inhibition and 
attention processes develop at different rates,43 and furthermore, impairments in inhibition and 
attention become apparent at different ages.225 As Mahone and colleagues summarize, 
symptoms of inattention begin to be problematic once children are required to independently 
plan and accomplish tasks, as in middle school and high school. By contrast, hyperactivity may 
be more impairing or evident in preschool-aged children.225 Thus, sex differences in ADHD or 
executive function likely depend not only on age, but also on the specific domains assessed (e.g. 
inattention, hyperactivity, ADHD diagnosis, etc.).  
Pattern of modification across multiple modifiers. The association between 
multiple maternal thyroid function biomarkers and both performance-based measures of 
inhibition (NEPSY statue task and the cookie delay task) was modified by selenium, iodine, 
and/pr maternal SNP rs2235544 (see Table 41). Specifically, maternal selenium intake modified 
the association between maternal TSH and both performance-based inhibition measures as well 
as the association between maternal fT4i and the cookie delay task. Maternal iodine intake 




maternal TT4 and the statue task. Finally, maternal SNP rs2235544 in DIO1 modified the 
association between maternal TT3 and the statue task. Given that selenium, iodine, and 
maternal deiodinase type 1 are all part of maternal thyroid function, it is possible that this 
pattern of modification reflects an underlying, common modifier affecting the association 
between maternal thyroid function and fetal neurodevelopment. It is possible that these factors 
(selenium, iodine, and deiodinase activity) themselves interact to affect thyroid function’s role in 
fetal neurodevelopment; however, this dissertation is not powered to assess higher-order 
interactions. Alternatively, these results could be spurious, the result of increased chance of type 
I error with the high number of tests of interaction.  
9.3 Measurement of Executive Function 
Parent versus teacher ratings of executive function. In this dissertation, both 
teachers and parents rated the executive function of the children using the BRIEF-P inventory. 
Parent- and teacher-ratings of child executive function are expected to differ: parents and 
teachers observe children in different environments with different sets of expectations and 
behavioral norms. Parent- and teacher-completed BRIEF-P scores show moderate or weak 
correlations, with parents rating their children as having more problems on average than 
teachers.154 In this dissertation, I compared parent- and teacher-ratings of child working 
memory, inhibition, and emotional control using raw BRIEF-P scores (I.e. those unadjusted for 
rater and for child sex). Among children with ADHD, parents rated their child as having 
significantly more problems on all three dimensions than did teachers. Among children without 
ADHD, parents rated their child as having significantly more problems with working memory 
and inhibition than did teachers; ratings of emotional control did not differ.  
However, differences in parent- and teacher-ratings of executive function do not 
necessarily mean that associations between maternal thyroid function and executive function 




question. Andersen and colleagues found that maternal thyroid dysfunction was associated with 
parent-rated executive function but not teacher-rated executive function;222 in contrast, 
Oostenbroek and colleagues found that hypothyroxinemia was associated with teacher-rated, 
but not parent-rated, hyperactivity/inattention.125 In this dissertation, associations between 
maternal thyroid function and child executive function did not meaningfully differ by rater.  
Domain-specific versus task-specific. At face-value, different measures of 
inhibition (for example) would be expected to be related. However, in this dissertation, inter-
correlations and an exploratory factor analysis of executive function measures in this 
dissertation demonstrated that tasks correlated more highly with other tasks from the same 
measure than with tasks assessing the same executive function process. For example, teacher-
rated inhibition on the BRIEF-P correlated more strongly with other teacher-rated BRIEF-P 
measures than with parent-rated inhibition or performance-based measures of inhibition (e.g. 
the NEPSY statue task and the cookie delay task). This measure-specific rather than process-
specific correlation pattern may be due in part to what Miyake and colleagues describe as the 
impurity problem.45,226 The impurity problem is that a measure of an executive function process 
places demands not only on that specific process, but also on other unrelated cognitive 
functions, and possibly on other executive function components.44–46,226 This impurity problem 
may be exacerbated in preschool-aged children, for whom unrelated task-level factors (e.g. 
response modality and language demands) may be a larger performance barrier, obscuring 
underlying executive function competence.  
Performance-based versus inventory measures of executive function. It is 
unclear whether performance-based and questionnaire measures of executive function tap into 
the same construct. In a review of 20 studies that assessed the association between 
performance-based and inventory/rating measures, Toplak and colleagues found that the 
median correlation was 0.19.46 The authors point out that this is likely an over-estimation of the 




of the file-drawer problem.46 Other studies have similarly reported minimal associations 
between performance-based and rating measures of executive function.227,228 The dissociation 
between these tasks may be because performance-based measures assess optimal performance 
in constrained and standardized situations, whereas rating measures evaluate typical 
performance in everyday and less restricted situations.46 In this dissertation, I found 
associations between maternal thyroid function and inventory measures of executive function 
(the teacher- and parent-completed BRIEF-P), but not between maternal thyroid function and 
performance-based measures of executive function. Given that most effect estimates were small 
and relatively imprecise, it is possible that the effect of maternal thyroid function variation 
within the euthyroid range is not strongly associated with ADHD or executive function 
outcomes.  
9.4 Clinical Implications  
Universal versus case-finding thyroid hormone screening. The women included 
in the ADHD sub-study of the MoBa cohort were mostly euthyroid: most women were not taking 
thyroid medications, did not have a pre-existing thyroid disorder, and had measured thyroid 
function biomarkers within normal reference ranges. Furthermore, on average, the women 
included in the ADHD sub-study would not be classified as at high risk of a thyroid disorder.229 
As a result, according to the current case-finding approach for thyroid dysfunction during 
pregnancy, most women included in this dissertation would not be screened for thyroid 
dysfunction during pregnancy. 
The current thyroid hormone screening guidelines during pregnancy is that only those 
who are at high risk or those who demonstrate symptoms of thyroid dysfunction should be 
screened.230 Those at high risk include women over 30 years, women with clinical symptoms of 
hypothyroidism, and women with a history of thyroid disorders, among other factors.231 The 




pregnant women, specifically focusing on the question of whether the prevalence adverse birth 
or neonatal outcomes differ under each approach. The case-finding approach is effective in 
identifying the more severe cases of thyroid dysfunction; however, it misses approximately one 
third of pregnant women with hypothyroidism. Although the case-finding approach increases 
the chance of false negatives, another study found that the number of adverse obstetrical or 
neonatal outcomes was not associated with the screening method (universal versus case-
finding).232 The lack of difference between the case-finding and universal screening approaches 
may be because by the time pregnant women are screened for thyroid function, damage from 
existing thyroid dysfunctions have already occurred. Fetal neurodevelopment—and thus the 
fetus’ need for maternal thyroid hormones—begins well before screening for thyroid function 
would typically take place (and indeed potentially even before pregnancy awareness).  
In our study of mostly euthyroid women, there were minimal associations between 
maternal thyroid function and ADHD or executive function. Universally screening (and 
appropriately treating) the women in the ADHD sub-study for thyroid dysfunction would not 
likely have affected the odds of their children having ADHD or executive function impairments. 
Indeed, when analyses were restricted to euthyroid women (those who would not be treated 
based on current thyroid hormone reference ranges), results were comparable. With respect to 
child ADHD and executive function specifically, the results of this dissertation do not indicate a 
need for universal maternal thyroid function screening.  
Diagnostic categories versus continuous measures. ADHD is characterized by 
executive function impairments, however the specific executive function domains that are 
impaired in those with ADHD vary,61,63 underscoring the heterogeneity of the disorder. For 
example, a meta-analysis found that children with ADHD demonstrated worse executive 
function on 13 different measures compared to typically developing children, yet less than half 
of the children showed impairment on any given executive function measure.61 The most 




memory.61,63,227 A paper that also used the ADHD sub-study (the same study population used for 
this dissertation) found that parent-rated inhibition and working memory subscales of the 
BRIEF-P were most associated with ADHD symptoms among 3.5 year old children.227  
Although ADHD and executive function are related and clearly share some overlapping 
etiology, they are still distinct and thus have some non-overlapping causes. For example, 
parenting behaviors (e.g. directing their child’s attention) has been associated with executive 
function.48,233 However, there is little evidence that parenting behaviors affect the development 
of ADHD.48 Multiple pathways may lead to, or contribute to, the development of ADHD; the 
underlying mechanisms supporting executive function are neither sufficient nor necessary to 
account for ADHD.61 This is all to say that continuous measures of executive function and 
diagnostic classifications of ADHD provide distinct information about neurodevelopment. 
The Research Domain Criteria (RDoC) is an approach to clinical research that focuses on 
the mechanisms contributing to clinical symptoms rather than focusing on the clinical 
symptoms or syndromes themselves.234–236 This approach is contrasted with diagnostic 
guidelines like DSM or ICD, which categorize disorders according to symptoms with often times 
relatively arbitrary cutoffs. Whereas the DSM or ICD favour categorical classifications (e.g. 
clinical ADHD versus no ADHD), RDoC would favour continuous measures that tap into 
underlying processes or mechanisms. Currently, RDoC is touted not as a replacement to DSM or 
ICD criteria, but rather as a method of organizing and directing clinical research such that it will 
better contribute to defining clinical disorders.236  
This dissertation examined the association between maternal thyroid function and a 
clinical categorical outcome (DSM-IV ADHD diagnoses) as well as between maternal thyroid 
function and multiple continuous measures of cognitive processes that may contribute to the 
clinical outcome (executive function). In this way, this dissertation speaks to both the RDoC 
approach and the diagnostic categorical approaches. Maternal thyroid function was not 




(specifically fT4i) was associated with parent- and teacher-rated executive function. One 
possible reason for this dissociation is that ADHD diagnostic criteria in the DSM-IV is better 
suited for children 4 years and up (the recommended earliest age of diagnosis2). In contrast, 
because executive function develops rapidly during the preschool years,36,42 there are a number 
of well-validated measures of executive function for preschool-aged children. In this way, 
continuous measures of executive function in preschoolers may be more valuable for research 
than current ADHD diagnostic guidelines.  
However, in a paper using the same ADHD sub-study as this dissertation, Skogan and 
colleagues found that parent-rated working memory and inhibition in the BRIEF-P collectively 
explained 38.5% of the variance in ADHD clinical symptoms.227 Thus, measures of executive 
function in preschoolers are associated with ADHD symptoms according to the DSM-IV. 
Whether preschool ADHD reflects the same underlying construct as ADHD in older children 
remains to be answered.  
9.5 Methodological Considerations and Limitations 
The socio-economic context of the cookie delay task. The cookie delay task, 
which was used in this dissertation as a performance-based measure of inhibition, mimics the 
marshmallow task. The value of the marshmallow task in predicting long-term outcomes like 
academic achievement has been called into question. A recent study found that much of the 
variability in the delayed gratification task can be accounted for by family background factors 
such as socioeconomic status.237 When we additionally adjusted for maternal education (as a 
proxy for socioeconomic status) in tests of association between maternal thyroid function and 
cookie delay task performance, results did not change. That being said, the socioeconomic 
background of women included in this study was relatively homogeneous.  
Limitations of the weighting scheme. Because the second paper of this dissertation 




distribution of outcome scores theoretically are biased by the intentional oversampling of 
preschool children with symptoms indicative of ADHD. To address the potential bias imposed 
by this selection scheme, I weighted regression models by the inverse probability of preschool 
ADHD status. The purpose of these weights was to re-distribute the relative proportion of 
preschool ADHD cases and controls in the N=342 clinical sample to match the relative 
proportion of those who screened positive and negative for ADHD in the 3-year questionnaire 
among those eligible for the ADHD sub-study (include numbers here). The prevalence of those 
screening positive for ADHD symptoms was 12.6% in the eligible population, which is 
comparable with the estimated prevalence of preschool ADHD (10%).221 
This weighting scheme has some limitations. First, it implicitly assumes that screening 
positive for ADHD is equivalent to testing positive for ADHD. We are weighting by clinically-
evaluated ADHD status; however, selection into the sub-study was actually based on scores on a 
parent-completed screening inventory. That being said, Overgaard and colleagues, who also 
used the ADHD sub-study, argued that: “Our sample may resemble a primary health care unit, 
where concerned parents ask whether their active preschool child might have ADHD.”217 Thus, 
the sampling structure of the ADHD sub-study can be said to have some ecological validity.     
A second limitation is that the weights do not reflect the fact that exclusion from these analyses 
differed based on screening status and test results. Specifically, among those who screened 
negative, those who tested negative for ADHD were included, whereas among those who 
screened positive, those who tested negative for ADHD were excluded.  
 One-time measure of maternal thyroid function. Maternal thyroid function was 
measured only once: at 17 weeks’ gestation. Because maternal thyroid hormone levels change 
during pregnancy, this may be considered a limitation of this dissertation. However, of all the 
potential measurement time points, this particular timing of measurement may be 
advantageous for several reasons. First, 17 weeks falls within the first half of gestation, during 




neurodevelopment.83,84 Second, a recent systematic review of animal and human studies of the 
association between maternal thyroid function and fetal neurodevelopment indicate that 
maternal thyroid function earlier in gestation has a greater impact on neurodevelopment than 
later.68 However, maternal thyroid hormones change the most during the first trimester, and 
begin to level off thereafter.69 Thus, it would be valuable to additionally measure thyroid 
function in the first trimester.    
Limitations in the directed acyclic graph (DAG). A challenge in creating the DAG 
underlying this dissertation project is that the biological mechanisms linking many of the 
relevant variables are not well characterized. One example of this limitation is the biological role 
of maternal pre-pregnancy BMI. There is some evidence that BMI causally influences thyroid 
hormone levels,238 though the mechanism is unclear and the effect may be restricted to clinical 
thyroid hormone disorders and/or BMI levels outside of the healthy range.171,172 Similarly, there 
is some evidence that maternal BMI influences offspring ADHD and cognitive 
development;173,174,239 however, it is possible that this effect is due to unmeasured confounding 
by familial factors.240 In this dissertation, I addressed these limitations by conducting sensitivity 
analyses investigating the effect of additionally adjusting for BMI. Results did not change when 
maternal pre-pregnancy BMI was added to the model. That being said, the results of this single 
investigation cannot speak to the underlying biological mechanisms linking BMI, maternal 
thyroid function, and child neurodevelopment: these mechanisms remain to be illuminated.  
Missing performance-based executive function data. Children were only 3.5 
years of age when they took part in the performance-based measures of executive function 
(including the working memory subscales of the SB5 battery, the NEPSY statue task, and the 
cookie delay task). Remaining on task, across multiple tasks, could be difficult for children of 
this age due to factors related to executive function (e.g. attention, inhibition) as well as factors 
that are not directly related to executive function (e.g. fatigue or energy level, hunger). Potential 




the SB5 verbal working memory (and consequently the working memory index), and more than 
10% of observations were missing for the NEPSY statue task. Our sensitivity analysis suggested 
that, in extreme scenarios where the unobserved outcome values were differential with respect 
to the exposure, the bounds on the estimated main effects on the SB5 verbal working memory 
(and working memory index) and the NEPSY statue task are relatively broad. That being said, 
we did not observe clear patterns of main effects; thus, our interpretations remain unchanged by 
these sensitivity analyses. These sensitivity analyses do, however, highlight the importance of 
considering how children’s ability to complete performance-based measures of executive 
function could potentially affect estimated associations.  
9.6 Strengths 
 An important novel contribution and strength of this dissertation project was the 
evaluation of effect measure modification by variants in maternal and child deiodinase-encoding 
genes. No study to date has assessed genetic modification of the association between maternal 
thyroid function and fetal neurodevelopment. Another strength of this project was the multiple 
measures of executive function, which included performance-based and inventory measures. 
Combined with the clinical measurement of ADHD, this dissertation could address questions 
about how these different measurements relate to preschool ADHD. The validated index 
measure of free thyroid hormones constituted another strength of this project: most previous 
studies of maternal thyroid function during pregnancy and offspring neurodevelopment have 
used immunoassay for fT4 measurement, which is inaccurate during pregnancy. Finally, the rich 
covariate data (e.g. validated measures of maternal depression and executive function 





9.7 Summary and Next Steps 
 Summary. This dissertation examined the association between maternal thyroid 
function at 17 weeks’ gestation and neurodevelopmental outcomes in preschool-aged children, 
including ADHD and executive function. Furthermore, it assessed effect measure modification 
by maternal and child variants in deiodinase-encoding genes, maternal iodine and selenium 
intake, and by child sex. We investigated these questions using a sub-study of ADHD nested 
within the Norwegian Mother and Child Cohort (MoBa). 
We observed that higher levels of maternal free thyroxine index were associated with 
better parent-rated and teacher-rated executive function. This finding highlights the importance 
of maternal thyroxine—which is the main thyroid hormone transferred to the fetus—in fetal 
neurodevelopment. The fact that the effect was observed for inventory measures of executive 
function, but not performance-based measures of executive function contributes to the debate of 
whether these two types of measures evaluate the same underlying construct.  
Despite observing an association between maternal thyroid function and executive 
function, maternal thyroid function was not associated with preschool ADHD. This dissociation 
may be due to the fact that current DSM guidelines for diagnosing ADHD are not well suited for 
preschool-aged children, or it may reflect a meaningful etiologic difference between preschool 
ADHD and ADHD later in childhood. These findings also contribute to the discussion of the 
Research Domain Criteria approach, which focuses on continuous measures of mechanisms 
contributing to disorders rather than focusing on symptoms (as current diagnostic classification 
systems do).  
Considering the results of this dissertation project in the context of past studies (see 
section 2.2), I would hypothesize that maternal thyroid function does indeed affect the 
development of ADHD and executive function via the thyroid hormones’ influence on the 




observed in this study as well as previous studies (see Tables 5, 6), the contribution of maternal 
thyroid function to child ADHD and executive function is likely small. The best-supported 
association is between maternal hypothyroxinemia and ADHD or related symptoms, which is 
consistent with our finding that low maternal T4 was associated with worse executive function. 
As the causes of ADHD remain largely unknown, identifying a modifiable causal factor with 
even a small effect is of substantial importance, and could contribute to preventative efforts.  
Our mostly near-null effect measure modification estimates do not preclude an 
important role for maternal or fetal deiodinase-encoding gene variants, maternal iodine or 
selenium intake, or child sex. The biological importance of deiodinases, iodine, and selenium for 
thyroid function is well-documented (see sections 1.6 and 2.3). Furthermore, animal research 
suggests that these factors can modify the biological impact of circulating thyroid hormones, 
lending support for their modifying role in the association between maternal thyroid function 
and child ADHD or executive function (sections 1.6 and 2.3). The studies in this dissertation 
were the first to investigate effect measure modification by maternal iodine and selenium intake, 
and by maternal and child variants in deiodinase-encoding genes. The sample size in this 
dissertation resulted in low a priori power to detect interaction effects, but there is a strong 
biological motivation to further investigate the potential modifying role of maternal iodine and 
selenium intake, maternal and child deiodinase-encoding gene variants, and child sex. 
Understanding the modifying role of these factors can help characterize the underlying 
mechanism linking maternal thyroid function to ADHD and executive function.  
Next Steps. Because this dissertation was the first to investigate whether the 
association between maternal thyroid function and ADHD or executive function is modified by 
maternal nutrient intake and by maternal and child variants in deiodinase-encoding genes, 




First, it is possible that the modifying effect of iodine, selenium, and deiodinases is more 
relevant in states of maternal thyroid dysfunction. Future studies might incorporate a larger 
number of women with thyroid dysfunctions during pregnancy and their children. Second, it 
would be valuable to consider how interactions among iodine, selenium, and deiodinase-
encoding gene variants influence the association between maternal thyroid function and 
neurodevelopment. Iodine and selenium deficiency are associated with changes in the activity of 
deiodinases, which then in turn may alter the association between maternal circulating thyroid 
hormones and fetal neurodevelopment. Considering the interdependency of these potential 
modifiers in future studies (with larger sample sizes) may contribute to a better understanding 
of how thyroid function mechanisms affect neurodevelopment.  
Third, future studies might include longitudinal follow-up of children to assess how the 
association between maternal thyroid function and ADHD or executive function changes from 
the preschool period into childhood. Specifically, assessing how profiles of maternal thyroid 
function (classified by multiple maternal thyroid function biomarkers) are associated with 
development trajectories of ADHD and executive function would provide insight into the 
etiologic relation between preschool and child ADHD and executive function.  
Conclusion. ADHD is a heterogeneous disorder with likely many causes, both genetic 
and environmental. Similarly, executive function consists of a number of related, and sometimes 
overlapping, cognitive processes whose development is likely influenced by a variety of 
environmental and genetic factors. As a result of the complexity and heterogeneity of the 
constructs of ADHD and executive function, it is difficult to statistically detect the etiologic 
contribution of a single factor (in this case, maternal thyroid function). Nonetheless, the value in 
identifying etiologic mechanisms underlying ADHD and supporting executive function 
development is highlighted by the personal and societal impact of ADHD and by the 
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